<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005060.pub3" GROUP_ID="ENDOC" ID="371903042811200762" MERGED_FROM="" MODIFIED="2012-04-05 17:15:37 +0200" MODIFIED_BY="Bernd Richter" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-04-05 17:15:37 +0200" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2011-07-27 12:38:48 +0200" MODIFIED_BY="[Empty name]">Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin</TITLE>
<CONTACT MODIFIED="2012-04-05 17:15:37 +0200" MODIFIED_BY="Bernd Richter"><PERSON ID="EAB4E7E782E26AA20125F76B99EA0CA4" ROLE="AUTHOR"><FIRST_NAME>Uriëll</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Malanda</LAST_NAME><EMAIL_1>u.malanda@gmail.com</EMAIL_1><EMAIL_2>uriell.malanda@rivm.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of General Practice, EMGO Institute for Health and Care Research</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>PO Box 7057</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1007 MB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 8395</PHONE_1><FAX_1>+31 20 444 8361</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-04-05 17:15:37 +0200" MODIFIED_BY="Bernd Richter"><PERSON ID="EAB4E7E782E26AA20125F76B99EA0CA4" ROLE="AUTHOR"><FIRST_NAME>Uriëll</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Malanda</LAST_NAME><EMAIL_1>u.malanda@gmail.com</EMAIL_1><EMAIL_2>uriell.malanda@rivm.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of General Practice, EMGO Institute for Health and Care Research</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>PO Box 7057</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1007 MB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 8395</PHONE_1><FAX_1>+31 20 444 8361</FAX_1></ADDRESS></PERSON><PERSON ID="19662" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Laura</FIRST_NAME><MIDDLE_INITIALS>MC</MIDDLE_INITIALS><LAST_NAME>Welschen</LAST_NAME><POSITION>MSc</POSITION><EMAIL_1>l.welschen@vumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice, EMGO Institute for Health and Care Research</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>PO Box 7057</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1007 MB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 5263</PHONE_1><FAX_1>+31 20 444 8181</FAX_1></ADDRESS></PERSON><PERSON ID="15430" ROLE="AUTHOR"><FIRST_NAME>Ingrid</FIRST_NAME><MIDDLE_INITIALS>I</MIDDLE_INITIALS><LAST_NAME>Riphagen</LAST_NAME><SUFFIX>MSc</SUFFIX><EMAIL_1>ingrid.i.riphagen@ntnu.no</EMAIL_1><ADDRESS><DEPARTMENT>Unit for Applied Clinical Research, Faculty of Medicine</DEPARTMENT><ORGANISATION>Norwegian University of Science and Technology</ORGANISATION><CITY>Trondheim</CITY><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 72575422</PHONE_1></ADDRESS></PERSON><PERSON ID="17392" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Jacqueline</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Dekker</LAST_NAME><POSITION>PhD</POSITION><EMAIL_1>jm.dekker@vumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Departments of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>PO Box 7057</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1007 MB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 8173</PHONE_1></ADDRESS></PERSON><PERSON ID="17391" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giel</FIRST_NAME><LAST_NAME>Nijpels</LAST_NAME><POSITION>MD, PhD</POSITION><EMAIL_1>g.nijpels@vumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice, EMGO Institute for Health and Care Research</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>PO Box 7057</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1007 MB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 9659</PHONE_1></ADDRESS></PERSON><PERSON ID="C2902AEB82E26AA2008044A2B52EB3E3" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><MIDDLE_INITIALS>DM</MIDDLE_INITIALS><LAST_NAME>Bot</LAST_NAME><POSITION>Postdoctoral fellow</POSITION><EMAIL_1>s.bot@vumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice, EMGO Institute for Health and Care Research</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>PO Box 7057</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1007 MB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 8169</PHONE_1><FAX_1>+31 20 444 8361</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-04-05 16:24:33 +0200" MODIFIED_BY="Bernd Richter">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="7" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2012-04-05 16:28:35 +0200" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-04-05 16:28:35 +0200" MODIFIED_BY="Bernd Richter">
<DATE DAY="5" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>New feedback received on 6 March 2012, authors replied on 12 March 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-04-05 16:26:55 +0200" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-04-05 16:26:50 +0200" MODIFIED_BY="Bernd Richter">
<DATE DAY="8" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Updated with six new trials (Barnett 2008; DiGEM trial 2007; Durán 2010; Franciosi 2011; Kleefstra 2010; O'Kane 2008).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-04-05 16:26:55 +0200" MODIFIED_BY="Bernd Richter">
<DATE DAY="8" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Conclusions were changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-02-04 17:07:08 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Review has been updated with 5 new trials. Conclusions have been changed. Four authors have left the team and three others have joined.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-21 11:52:14 +0200" MODIFIED_BY="Gudrun Paletta">
<DATE DAY="1" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>Uriëll Malanda, Sandra Bot and Ingrid Riphagen has joined the review team</P>
<P>Evelien Bloemendal, Robert Jan Heine, Wim Stalman and Lex Bouter have left the team.</P>
<P>Uriëll Malanda is the new contact person: u.malanda@vumc.nl</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-12-03 13:55:27 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-12-03 13:55:27 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-12-03 13:55:27 +0100" MODIFIED_BY="[Empty name]">
<NAME>EMGO Institute for Health and Care Research</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-30 16:08:45 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2011-11-30 16:03:10 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-10-19 16:26:06 +0200" MODIFIED_BY="[Empty name]">Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-30 16:03:10 +0100" MODIFIED_BY="[Empty name]">
<P>Self-monitoring of blood glucose has been found to be effective as a tool in the self-management of patients' glucose levels in people with type 1 diabetes and people with type 2 diabetes using insulin therapy. Patients can use the glucose values to adjust their insulin doses. It is hypothesized that patients with type 2 diabetes who are not using insulin might use the glucose values to adjust their diet and 'lifestyle'. However, there is no consensus on the effect of self-monitoring of blood glucose for type 2 diabetes patients not using insulin. In this systematic review update six new randomised controlled trials were added to the six trials that had been included in the original review. For the comparison of the effect of self-monitoring versus no self-monitoring in patients with a diabetes duration of one year or more 2324 patients with a six months follow-up and 493 patients with a 12 months follow-up were available. Pooled results of studies including patients diagnosed with type 2 diabetes for at least one year show that self-monitoring of blood glucose has a minimal effect in improving glucose control at six months, which disappears after 12 months follow-up. The clinical benefit resulting from this effect is limited. </P>
<P>Two studies reported costs of self-monitoring: One study compared the costs of self-monitoring of blood glucose with self-monitoring of urine glucose based on nine measurements per week and with the prices in US dollars for self-monitoring in 1990. They concluded that total costs in the first year of self-monitoring of blood glucose, with the purchase of a reflectance meter were 12 times more expensive than self-monitoring of urine glucose ($481 or 361 EURO [11/2011 conversion] versus $40 or 30 EURO [11/2011 conversion]). Another study reported a full economical evaluation of the costs and effects of self-monitoring. At the end of the trial, costs for the intervention were £89 (104 EURO [11/2011 conversion]) for standardized usual care (control group), £181 (212 EURO [11/2011 conversion]) for the less intensive self-monitoring group and £173 (203 EURO [11/2011 conversion]) for the more intensive self-monitoring group.</P>
<P>We did not find good evidence for an effect on general health-related quality of life, general well-being, patient satisfaction, or on the decrease of the number of hypoglycaemic episodes. However, hypoglycaemic episodes were more often reported in the self-monitoring blood glucose groups than in the control groups (four studies). Because patients in the self-monitoring blood glucose groups can use their device to confirm both periods of asymptomatic and symptomatic hypoglycaemic episodes, this is according to expectations.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-30 16:08:45 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-10-07 16:50:27 +0200" MODIFIED_BY="[Empty name]">
<P>Self-monitoring of blood glucose (SMBG) has been found to be effective for patients with type 1 diabetes and for patients with type 2 diabetes using insulin. There is much debate on the effectiveness of SMBG as a tool in the self-management for patients with type 2 diabetes who are not using insulin.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-11-08 22:42:28 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of SMBG in patients with type 2 diabetes mellitus who are not using insulin.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-11-09 20:39:30 +0100" MODIFIED_BY="[Empty name]">
<P>Multiple electronic bibliographic and ongoing trial databases were searched supplemented with handsearches of references of retrieved articles (date of last search: 07 July 2011).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-08 09:38:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised controlled trials investigating the effects of SMBG compared with usual care, self-monitoring of urine glucose (SMUG) or both in patients with type 2 diabetes who where not using insulin. Studies that used glycosylated haemoglobin A<SUB>1c</SUB> (HbA<SUB>1c</SUB>) as primary outcome were eligible for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-29 16:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data from included studies and evaluated the studies' risk of bias. Data from the studies were compared to decide whether they were sufficiently homogeneous to pool in a meta-analysis. Primary outcomes were HbA<SUB>1c</SUB>, health-related quality of life, well-being and patient satisfaction. Secondary outcomes were fasting plasma glucose level, hypoglycaemic episodes, morbidity, adverse effects and costs.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-30 16:08:45 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve randomised controlled trials were included and evaluated outcomes in 3259 randomised patients. Intervention duration ranged from 6 months (26 weeks) to 12 months (52 weeks). Nine trials compared SMBG with usual care without monitoring, one study compared SMBG with SMUG, one study was a three-armed trial comparing SMBG and SMUG with usual care and one study was a three-armed trial comparing less intensive SMBG and more intensive SMBG with a control group.<B> </B>Seven out of 11 studies had a low risk of bias for most indicators. Meta-analysis of studies including patients with a diabetes duration of one year or more showed a statistically significant SMBG induced decrease in HbA<SUB>1c</SUB> at up to six months follow-up (-0.3; 95% confidence interval (CI) -0.4 to -0.1; 2324 participants, nine trials), yet an overall statistically non-significant SMBG induced decrease was seen at 12 month follow-up (-0.1; 95% CI -0.3 to 0.04; 493 participants, two trials). Qualitative analysis of the effect of SMBG on well-being and quality of life showed no effect on patient satisfaction, general well-being or general health-related quality of life. Two trials reported costs of self-monitoring: One trial compared the costs of self-monitoring of blood glucose with self-monitoring of urine glucose based on nine measurements per week and with the prices in US dollars for self-monitoring in 1990. Authors concluded that total costs in the first year of self-monitoring of blood glucose, with the purchase of a reflectance meter were 12 times more expensive than self-monitoring of urine glucose ($481 or 361 EURO [11/2011 conversion] versus $40 or 30 EURO [11/2011 conversion]). Another trial reported a full economical evaluation of the costs and effects of self-monitoring. At the end of the trial, costs for the intervention were £89 (104 EURO [11/2011 conversion]) for standardized usual care (control group), £181 (212 EURO [11/2011 conversion]) for the less intensive self-monitoring group and £173 (203 EURO [11/2011 conversion]) for the more intensive self-monitoring group. Higher losses to follow-up in the more intensive self-monitoring group were responsible for the difference in costs, compared to the less intensive self-monitoring group.</P>
<P>There were few data on the effects on other outcomes and these effects were not statistically significant. None of the studies reported data on morbidity.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-30 15:57:01 +0100" MODIFIED_BY="[Empty name]">
<P>From this review, we conclude that when diabetes duration is over one year, the overall effect of self-monitoring of blood glucose on glycaemic control in patients with type 2 diabetes who are not using insulin is small up to six months after initiation and subsides after 12 months. Furthermore, based on a best-evidence synthesis, there is no evidence that SMBG affects patient satisfaction, general well-being or general health-related quality of life. More research is needed to explore the psychological impact of SMBG and its impact on diabetes specific quality of life and well-being, as well as the impact of SMBG on hypoglycaemia and diabetic complications.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-30 16:04:48 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2011-11-09 20:48:32 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a previous Cochrane review (<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>) investigating the effects of self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes who are not using insulin.</P>
<CONDITION MODIFIED="2011-02-03 15:57:18 +0100" MODIFIED_BY="[Empty name]">
<P>"Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy and neuropathy. The risk of cardiovascular disease and cancer is increased. For a detailed overview of diabetes mellitus, please <I>see</I> under 'Additional information' in the information on the Metabolic and Endocrine Disorders Group in <I>The Cochrane Library </I>(<I>see</I> 'About', 'Cochrane Review Groups (CRGs)'). For an explanation of methodological terms, <I>see</I> the main Glossary in <I>The Cochrane Library</I>."</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-11-09 20:48:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diabetes care is complex and requires patients to take an active role in the management of their disease. Currently, adequate and continuing medical care aiming at preventing acute complications, diminishing risk of long-term complications as well as patient self-management education are considered standard in the care for type 2 diabetes patients (<LINK REF="REF-ADA-2010" TYPE="REFERENCE">ADA 2010</LINK>). Patients who improve their skills and confidence to manage their diabetes and who take a central role in the management of their disease improve their outcomes (<LINK REF="REF-Olivarius-2001" TYPE="REFERENCE">Olivarius 2001</LINK>;<B> </B>
<LINK REF="REF-Piatt-2006" TYPE="REFERENCE">Piatt 2006</LINK>;<B> </B>
<LINK REF="REF-Rothman-2005" TYPE="REFERENCE">Rothman 2005</LINK>;<B> </B>
<LINK REF="REF-Wagner-2001" TYPE="REFERENCE">Wagner 2001</LINK>).<B> </B>
</P>
<P>Hence, self-management skills have an important role in optimal diabetes control. They  enable patients to control their glucose level by recognizing, understanding and act on symptoms related to type 2 diabetes. Self-monitoring of blood glucose levels (SMBG) is presented as such a self-management skill and is therefore recommended as an element in self-management education (<LINK REF="REF-ADA-2010" TYPE="REFERENCE">ADA 2010</LINK>). The hypothesis that self-monitoring of glucose empowers the patient by its feedback, is based on the principles of the self-regulation theory (<LINK REF="REF-Leventhal-1980" TYPE="REFERENCE">Leventhal 1980</LINK>; <LINK REF="REF-Leventhal-1997" TYPE="REFERENCE">Leventhal 1997</LINK>). This model proposes that individuals construct schematic perceptions of illness and health-threatening conditions according to their available sources of information. These illness perceptions determine how patients respond to their illness or related threats and are mediators in the willingness and ability to take action. Feedback on the illness condition allows adaptation of illness perceptions, which eventually may lead to changes in 'lifestyle', quality of life and subsequently glycaemic control. Furthermore, it is assumed that SMBG may improve adherence to pharmacological treatment and motivate patients to make appropriate lifestyle changes (<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>; <LINK REF="REF-Karter-2001" TYPE="REFERENCE">Karter 2001</LINK>). Collecting data of glucose levels on different time points and its feedback allows the timely identification of high and low blood glucose levels and might help patients to a better understanding of day to day variation in glucose levels. Provided that the patient is informed how to interpret the results and what actions to take, self-monitoring information can help in making adjustments in direct interacting medication (insulin dosages) and 'lifestyle'. SMBG has been found to be effective for patients with type 1 diabetes (<LINK REF="REF-Bode-1999" TYPE="REFERENCE">Bode 1999</LINK>;<B> </B>
<LINK REF="REF-DCCT-1993" TYPE="REFERENCE">DCCT 1993</LINK>
<B> </B>) and patients with type 2 diabetes who are using insulin (<LINK REF="REF-Karter-2001" TYPE="REFERENCE">Karter 2001</LINK>; <LINK REF="REF-Nathan-1996" TYPE="REFERENCE">Nathan 1996</LINK>). However, consensus on the effectiveness of SMBG for the self-management of patients with non-insulin treated type 2 diabetes still remains inconclusive (<LINK REF="REF-Davidson-2010" TYPE="REFERENCE">Davidson 2010</LINK>;<B> </B>
<LINK REF="REF-Kempf-2008" TYPE="REFERENCE">Kempf 2008</LINK>;<B> </B>
<LINK REF="REF-Klonoff-2008" TYPE="REFERENCE">Klonoff 2008</LINK>;<B> </B>
<LINK REF="REF-Kolb-2010" TYPE="REFERENCE">Kolb 2010</LINK>;<B> </B>
<LINK REF="REF-O_x0027_Kane-2009" TYPE="REFERENCE">O'Kane 2009</LINK>). This can be attributed to a lack of comparability between published trials. Moreover, methodological limitations and poor quality of several performed trials investigating SMBG might have had an impact on the observed effectiveness of SMBG<B> </B>(<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2011-11-08 22:42:28 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Previous reviews and meta-analyses</HEADING>
<P>The present review is an update of the Cochrane review performed by Welschen et al in 2005 (<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>). In this review, substantial clinical heterogeneity between included trials was noted. Consequently, qualitative analyses were performed and it was concluded that self-monitoring of blood glucose might be effective in improving glycaemic control in patients with type 2 diabetes who are not using insulin. The same systematic review has been published in <I>Diabetes Care</I> with the addition of a meta-analysis, on request of the editor (<LINK REF="REF-Davidson-2005a" TYPE="REFERENCE">Davidson 2005a</LINK>; <LINK REF="REF-Kleefstra-2005" TYPE="REFERENCE">Kleefstra 2005</LINK>; <LINK REF="REF-Welschen-2005b" TYPE="REFERENCE">Welschen 2005b</LINK>). In the meta-analysis, the overall effect of SMBG was a statistically significant and clinically relevant decrease of 0.39% in HbA<SUB>1c</SUB> in favour of SMBG compared with control groups. Since then, 11 other reviews on the effect of SMBG in patients with type 2 diabetes not using insulin have been published. Nine reviews included RCT&#8217;s only (<LINK REF="REF-Allemann-2009" TYPE="REFERENCE">Allemann 2009</LINK>; <LINK REF="REF-Clar-2010" TYPE="REFERENCE">Clar 2010</LINK>; <LINK REF="REF-Jansen-2006" TYPE="REFERENCE">Jansen 2006</LINK>;<B> </B>
<LINK REF="REF-Kleefstra-2009" TYPE="REFERENCE">Kleefstra 2009</LINK>; <LINK REF="REF-McIntosh-2010" TYPE="REFERENCE">McIntosh 2010</LINK>; <LINK REF="REF-Poolsup-2008" TYPE="REFERENCE">Poolsup 2008</LINK>; <LINK REF="REF-Poolsup-2009" TYPE="REFERENCE">Poolsup 2009</LINK>;<B> </B>
<LINK REF="REF-Sarol-2005" TYPE="REFERENCE">Sarol 2005</LINK>; <LINK REF="REF-Towfigh-2008" TYPE="REFERENCE">Towfigh 2008</LINK>),  one included cross-sectional, longitudinal and (non)randomised trials (<LINK REF="REF-McAndrew-2007" TYPE="REFERENCE">McAndrew 2007</LINK>) and two combined observational studies and RCT&#8217;s (<LINK REF="REF-McGeoch-2007" TYPE="REFERENCE">McGeoch 2007</LINK>;<B> </B>
<LINK REF="REF-St-John-2010" TYPE="REFERENCE">St John 2010</LINK>). In all reviews, change in HbA<SUB>1c</SUB> was the primary outcome measure. Seven reviews performed a meta-analysis (<LINK REF="REF-Allemann-2009" TYPE="REFERENCE">Allemann 2009</LINK>; <LINK REF="REF-Clar-2010" TYPE="REFERENCE">Clar 2010</LINK>; <LINK REF="REF-Jansen-2006" TYPE="REFERENCE">Jansen 2006</LINK>;<B> </B>
<LINK REF="REF-McIntosh-2010" TYPE="REFERENCE">McIntosh 2010</LINK>; <LINK REF="REF-Poolsup-2008" TYPE="REFERENCE">Poolsup 2008</LINK>; <LINK REF="REF-Poolsup-2009" TYPE="REFERENCE">Poolsup 2009</LINK>;<B> </B>
<LINK REF="REF-Sarol-2005" TYPE="REFERENCE">Sarol 2005</LINK>; <LINK REF="REF-St-John-2010" TYPE="REFERENCE">St John 2010</LINK>; <LINK REF="REF-Towfigh-2008" TYPE="REFERENCE">Towfigh 2008</LINK>) with  HbA<SUB>1c</SUB> varying from -0.42% to -0.16% in favour of SMBG versus no-SMBG. Three reviews performed qualitative analyses only and concluded similar to Welschen et al (<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>) that SMBG might be effective in glycaemic control but that the heterogeneity in design and quality between trials complicated drawing an overall conclusion on the effectiveness of SMBG (<LINK REF="REF-Kleefstra-2009" TYPE="REFERENCE">Kleefstra 2009</LINK>; <LINK REF="REF-McAndrew-2007" TYPE="REFERENCE">McAndrew 2007</LINK>; <LINK REF="REF-McGeoch-2007" TYPE="REFERENCE">McGeoch 2007</LINK>).</P>
<P>Since the publication of our first review new studies have been published, possibly with good or improved methodological quality and design. We performed this update in order to explore if these new trials provide new evidence of the effect of SMBG on glycaemic control in patients not requiring insulin. In addition, if possible, an estimation of the effect of SMBG on glycaemic control in patients with type 2 diabetes not requiring insulin will be obtained. Furthermore, assessment of risk of bias of included trials illustrate limitations or enhance strengths of the studies.</P>
</SUBSECTION>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-08 22:42:28 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-30 12:58:06 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-30 12:50:57 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-11-30 12:50:20 +0100" MODIFIED_BY="[Empty name]">
<P>Published and unpublished randomised controlled clinical trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-11-08 22:43:37 +0100" MODIFIED_BY="[Empty name]">
<P>Patients diagnosed with type 2 diabetes and who are not using insulin therapy. To be consistent with changes in classification and diagnostic criteria of diabetes mellitus through the years, the diagnosis should be established using the standard criteria valid at the time of the beginning of the trial (for example <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-ADA-2008" TYPE="REFERENCE">ADA 2008</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). Ideally, diagnostic criteria should have been described. If necessary, we used authors' definition of (type 2) diabetes.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-11-08 21:33:32 +0100" MODIFIED_BY="[Empty name]">
<P>Studies describing self-monitoring of blood glucose (SMBG) as primary intervention compared to control are investigated. Studies concerning the comparison between SMBG and self-monitoring of urine glucose (SMUG) were included as well (SMUG as control group).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-30 12:50:57 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-11-30 12:50:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>glycaemic control measured by glycated haemoglobin concentration A1c (HbA<SUB>1c</SUB>-level);</LI>
<LI>health-related quality of life, well-being (e.g. by using the SF 36 (<LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>) or the well-being questionnaire (<LINK REF="REF-Bradley-1994a" TYPE="REFERENCE">Bradley 1994a</LINK>));</LI>
<LI>patient satisfaction (e.g. by using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) (<LINK REF="REF-Bradley-1994b" TYPE="REFERENCE">Bradley 1994b</LINK>)).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-11-30 12:50:57 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>fasting plasma glucose level;</LI>
<LI>hypoglycaemic episodes;</LI>
<LI>morbidity;</LI>
<LI>adverse effects;</LI>
<LI>costs.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Co-variates thought to be effect modifiers</HEADING>
<UL>
<LI>baseline glycaemic control;</LI>
<LI>change in hypoglycaemic medications;</LI>
<LI>duration of diabetes at baseline;</LI>
<LI>age;</LI>
<LI>compliance to the intervention.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome assessment</HEADING>
<UL>
<LI>short-term: up to six months of follow-up;</LI>
<LI>medium-term: between six and twelve months of follow-up;</LI>
<LI>long-term: twelve months or more after start of follow-up.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-08 22:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>
<BR/>
</B>
</I>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-11-08 22:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>Electronic search strategies were used to identify relevant RCT&#8217;s and reviews or meta-analyses (for identification of additional eligible trials).</P>
<P>We used the following sources for the identification of trials:</P>
<UL>
<LI>
<I>The Cochrane Library (i</I>ssue 3, 2011);</LI>
<LI>MEDLINE (until July 2011);</LI>
<LI>EMBASE (until July 2011);</LI>
<LI>PsycINFO (until July 2011).</LI>
</UL>
<P>We also searched databases of ongoing trials: 'Current Controlled Trials' (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A> - with links to other databases of ongoing trials).</P>
<P>For detailed search strategies please see under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.    </P>
<P>Additional key words of relevance could have been detected during any of the electronic or other searches. If this was the case, we would have modified the electronic search strategies to incorporate these terms. Studies published in any language were included.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-02-07 12:15:22 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We tried to identify additional studies by searching the reference lists of included trials and (systematic) reviews, meta-analyses and health technology assessment reports noticed.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-30 12:58:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-11-30 12:51:55 +0100" MODIFIED_BY="[Empty name]">
<P>The search for publications were performed by one of the review authors (IR) supported by the Cochrane Metabolic and Endocrine Disorders' trials search coordinator. The MeSH terms and search strategy used were agreed upon and tested by two review authors (IR, UM).</P>
<P>Studies were selected for full text reading in three steps:</P>
<SUBSECTION>
<HEADING LEVEL="4">Step 1          </HEADING>
<P>Two review authors (UM, LW) independently made a selection of the titles of the identified references that corresponded with the criteria for inclusion in this review stated above. If the title did not provide enough information to decide whether or not to include the trial in the selection, or no consensus could be made based on the title alone it was selected as well.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Step 2</HEADING>
<P>All abstracts of selected titles were independently read (UM, LW). Full-text articles were retrieved from all abstracts potentially eligible for inclusion. In addition, if there was no abstract available the full article was retrieved.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Step 3</HEADING>
<P>All selected full-text articles were read and selected if they met the criteria for including studies in the review.</P>
<P>Studies were excluded (step 2 and 3) if both review authors (UM, LW) agreed that the study did not meet the criteria for including studies in the review. A third party resolved possible differences in opinion (SB). An adapted PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow-chart of study selection (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) is attached (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>). Interrater agreement for selection of potentially relevant studies was measured using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). In the case of duplicate publications and subsequent papers of a primary study, we tried to maximise yield of information by simultaneous evaluation of all available data. In cases of doubt, the original publication (usually the oldest version) obtained priority.</P>
</SUBSECTION>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-11-30 12:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>We used data concerning details of study design, intervention and outcomes employing a standardized extraction form and included the following items.</P>
<UL>
<LI>
<B>General information</B> (authors, title, details of journal, year of publication).</LI>
</UL>
<UL>
<LI>
<B>Trial characteristics</B> (study duration, design, methods, geographical region, temporal setting, sequence generation, allocation concealment, randomisation).</LI>
<LI>
<B>Participants</B> (total number per group, baseline characteristics).</LI>
<LI>
<B>Interventions</B> (specific details of intervention/control group).</LI>
<LI>
<B>Outcomes</B> (primary and secondary outcomes, timing of the outcome assessment).</LI>
<LI>
<B>Results</B> (number of participants analysed per group, dropouts/missing participants, summary data for each group, all available results on outcomes).</LI>
<LI>
<B>Notes</B> (any information reported that can be important; e.g. conflicts of interests).</LI>
</UL>
<P>A pilot test, using two trials excluded from the review preceded the data extraction of the selected RCT's. This test was likely to identify data that were not needed or missing to optimise the data extraction sheet.</P>
<P>Data extraction and data entry was performed independently by two review authors (UM, LW). Any discrepancies between authors were resolved by discussion. If necessary a third review author (SB) was consulted for the final decision. We sought any relevant missing information on the trial from the original author(s) of the article, if required.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-11-30 12:53:46 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (UM, LW) assessed each trial independently. Possible disagreement were resolved by consensus, or with consultation of a third party in case of disagreement. Interrater agreement for key bias indicators (e.g. allocation concealment, incomplete outcome data) was calculated using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). In cases of disagreement, the rest of the group was consulted and a judgement was made based on consensus. A pilot, using two trials excluded from the review, preceded the assessment of risk of bias of the RCTs.</P>
<P>The results and the rationale for the decision are presented in a methodological quality graph, summary and table. No trials were excluded based on the assessment of risk of bias.</P>
<P>The risk of bias in included studies and the internal validity of included studies was assessed with the Cochrane Collaboration's recommended 'Risk of bias' tool (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). With this tool, a study&#8217;s risk on selection-, performance-, attrition-, detection-, and reporting bias can be critically evaluated and judged.</P>
<P>We used the following criteria:</P>
<UL>
<LI>sequence generation (was the allocation sequence adequately generated?);</LI>
<LI>allocation concealment (was the allocation adequately concealed?);</LI>
<LI>blinding of participants, personnel and outcome assessors (was knowledge of the allocated intervention adequately prevented during the study?);</LI>
<LI>incomplete outcome data (were incomplete outcome data adequately addressed?);</LI>
<LI>selective outcome reporting (were reports of the study free of suggestion of selective outcome reporting?);</LI>
<LI>other sources of bias (was the study apparently free of other problems that could put it at a high risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-02-07 12:27:31 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Dichotomous data were expressed as odds ratio (OR) or risk ratio (RR) with 95% confidence intervals (CI). Continuous were expressed as differences in means (MD) with 95% CI.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-02-07 12:27:40 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We took into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials and multiple observations for the same outcome.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-10-29 11:39:13 +0200" MODIFIED_BY="[Empty name]">
<P>We obtained relevant missing data from authors, if feasible and carefully performed evaluation of important numerical data such as screened, eligible and randomised patients as well as intention-to-treat (ITT) and per-protocol (PP) population. We investigated attrition rates such as drop-outs, losses to follow-up and withdrawn study participants.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-11-08 22:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>In the event of substantial clinical-, methodological-, or statistical heterogeneity, study results were not reported as meta-analytically pooled effect estimates. We identified heterogeneity by visual inspection of the forest plots, by using a standard Chi<SUP>2 </SUP>test and a significance level of &#945; = 0.1, in view of the low power of this test. We specifically examined heterogeneity with the I<SUP>2</SUP> statistic quantifying inconsistency across studies to assess the impact of heterogeneity on the meta-analysis (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), where an I<SUP>2</SUP> statistic of 75% and more indicates a considerable level of inconsistency (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>When heterogeneity was found, we attempted to determine potential reasons for it by examining individual study and subgroup characteristics.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-11-30 12:55:14 +0100" MODIFIED_BY="Bernd Richter">
<P>We planned to use funnel plots to assess for the potential existence of small study bias. There are a number of explanations for the asymmetry of a funnel plot (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). Therefore, we carefully interpreted results (<LINK REF="REF-Lau-2006" TYPE="REFERENCE">Lau 2006</LINK>). Due to small number of included studies we did not employ funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-11-30 12:56:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Quantitative analyses</B>
</P>
<P>We summarised data statistically if they were available, sufficiently similar and of sufficient quality. We performed statistical analyses according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>Meta-analyses were conducted using a random-effects model . The results of each RCT were plotted as point estimates with corresponding 95% confidence intervals. Statistical heterogeneity was tested using the Z score and the Chi<SUP>2</SUP> statistic with significance being set at P &lt; 0.10. Quantification of the effect of heterogeneity was assessed by means of I<SUP>2</SUP>, ranging from 0% to 100% including its 95% confidence interval (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). The I<SUP>2</SUP> statistic demonstrates the percentage of total variation across studies due to heterogeneity and was used to judge the consistency of evidence. If the evidence of statistical heterogeneity would be substantial (I<SUP>2 </SUP>greater than 50%), the potential sources of variation between the RCTs would be investigated using subgroup analyses.</P>
<P>
<B>Qualitative analyses </B>(<B>best-evidence synthesis</B>)</P>
<P>When severe clinical or statistical heterogeneity was found, a qualitative analysis (best-evidence synthesis) was performed to summarize the results of the included studies in terms of strength of the scientific evidence. Findings were considered consistent if more than one of the studies reported the same direction of the effect on the outcome measure.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-11-30 12:57:20 +0100" MODIFIED_BY="[Empty name]">
<P>If the data permitted, we planned to perform subgroup analyses to determine whether there were any systematic differences between groups of patients. We mainly carried out subgroup analyses if one of the primary outcome parameters demonstrated statistically significant differences between intervention groups. In any other case subgroup analyses were planned to be clearly marked as a hypothesis generating exercise.</P>
<P>A priori defined subgroup analyses were:</P>
<UL>
<LI>HbA<SUB>1c</SUB> level at baseline (subdividing into three groups of low (less than 7.0%), medium (between 7.0% and 11.0%) and high level (11.0% or higher) - based on data);</LI>
<LI>diabetes duration (up to one year past diagnosis vs duration over one year);</LI>
<LI>duration of intervention (short-term (up to six months follow-up), medium-term (between 6 and 12 months follow-up), long term (12 months follow-up or more)).</LI>
<LI>age groups (below 60 years, over 60 years);</LI>
<LI>gender;</LI>
<LI>presence of complications (e.g. diabetic complications);</LI>
<LI>different comparison interventions;</LI>
<LI>type of treatment: oral hypoglycaemic agents, diet, exercise, no treatment;</LI>
<LI>weight (normal (body mass index - BMI: women less than 25, men less than 27), overweight (BMI: women 25 to 30, men 27 to 30) obese (BMI more than 30)).</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-11-30 12:58:06 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to perform sensitivity analyses in order to explore the influence of the following factors on effect size:<BR/>
</P>
<UL>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis taking account of risk of bias:</LI>
<LI>repeating the analysis excluding very long or large studies to establish how much they dominate the results;</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>We also planned to test the robustness of the results by repeating the analysis using different measures of effect size (relative risk, odds ratio etc.) and different statistical models (fixed-effect model and random-effects model).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-30 16:04:48 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_DESCRIPTION MODIFIED="2011-11-30 11:32:17 +0100" MODIFIED_BY="Gudrun Paletta">
<SEARCH_RESULTS MODIFIED="2011-11-29 17:50:32 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic database search identified a total of 1138 citations (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After excluding titles and abstracts clearly not related to the objective of our review, 36<B> </B>full text publications were retrieved for further examination. Screening of references resulted in another 15 citations. One trial (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>) had multiple publications which displayed the design of the trial (<LINK REF="REF-Farmer-2005" TYPE="REFERENCE">Farmer 2005</LINK>)<B>,</B> set out different outcome measures (<LINK REF="REF-Farmer-2007" TYPE="REFERENCE">Farmer 2007</LINK>; <LINK REF="REF-French-2008" TYPE="REFERENCE">French 2008</LINK>;<B> </B>
<LINK REF="REF-Simon-2008" TYPE="REFERENCE">Simon 2008</LINK>) and one overall publication (<LINK REF="REF-Farmer-2009" TYPE="REFERENCE">Farmer 2009</LINK>). One retrieved publication of Siebolds et al (<LINK REF="REF-Siebolds-2006" TYPE="REFERENCE">Siebolds 2006</LINK>) described additional results of the trial of Schwedes et al (<LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK>), a trial that was included in the original review. Results from that publication were used to supplement the trial of Schwedes et al, now referred to as <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>. The search identified one letter to the editor and four abstracts submitted to international conferences all describing a randomised controlled trial. Three of the abstracts had already been published and identified as an eligible trial (<LINK REF="STD-Davidson-2004" TYPE="STUDY">Davidson 2004</LINK>; <LINK REF="STD-Drouin-2002" TYPE="STUDY">Drouin 2002</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2006" TYPE="STUDY">O'Kane 2006</LINK>). Detailed trial information on the letter to the editor (<LINK REF="STD-Shiraiwa-2010" TYPE="STUDY">Shiraiwa 2010</LINK>) and the fourth abstract (<LINK REF="STD-Atsumi-1997" TYPE="STUDY">Atsumi 1997</LINK>) could not be retrieved and were therefore excluded (<LINK REF="STD-Atsumi-1997" TYPE="STUDY">Atsumi 1997</LINK>). One trial stopped following the control group after three months (<LINK REF="STD-Chidum-2011" TYPE="STUDY">Chidum 2011</LINK>). We unsuccessfully requested additional data on the control group from the corresponding author. Therefore, we excluded this study as well (<LINK REF="STD-Chidum-2011" TYPE="STUDY">Chidum 2011</LINK>).</P>
<P>Searching the database of ongoing trials identified five registered trials related to our objective. Two trials were completed and had already been published and identified as an eligible trial (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>) and three trials were still ongoing (<LINK REF="STD-Bergenstal-2005" TYPE="STUDY">Bergenstal 2005</LINK>; <LINK REF="STD-Malanda-2009" TYPE="STUDY">Malanda 2009</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>). The authors of these trials were contacted and asked to provide (published or unpublished) data for the review. Only one author provided the requested data (<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>).</P>
<P>Finally, six eligible RCTs met all inclusion criteria and were added to the six trials included in our previous review. In total, 12 trials were included in this review.</P>
<P>We asked the corresponding authors of the <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>, <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>, <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK> and <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK> to provide short-term follow-up data if available. They were asked if they could calculate changes in HbA<SUB>1c</SUB> for short-term follow-up and to provide this in terms of means (SD). All authors responded and provided the additional data as requested.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-11-30 11:32:17 +0100" MODIFIED_BY="Gudrun Paletta">
<P>See:<B> </B>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for an overview of study populations and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for baseline characteristics of included studies.</P>
<P>Nine trials compared self monitoring of blood glucose (SMBG) with usual care without monitoring (<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
<B>; </B>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
<B>; </B>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
<B>; </B>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
<B>; </B>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>
<B>; </B>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
<B>; </B>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
<B>; </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
<B>; </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
<B>),</B> one study compared SMBG with self-monitoring of urine glucose (SMUG) <B>(</B>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
<B>)</B>, one study was a three-armed trial comparing SMBG and SMUG with usual care <B>(</B>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>
<B>) </B>and one study was a three-armed trial comparing less intensive SMBG, and more intensive SMBG with a control group <B>(</B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
<B>).</B> Three of these 12 trials had a multi-centred design with centres in two <B>(</B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>)<B>,</B> three (<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>), and seven <B>(</B>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>) countries, respectively. Trial duration ranged from 26 weeks to 12 months. The majority of the trials (seven trials) included over 100 patients in the studies (range 195 to 689).  All trials investigated effects of SMBG in patients with a diabetes duration of at least one year, except for<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
<B> </B>and <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>. These two trials studied SMBG effects in newly diagnosed patients exclusively. Specifications on type, doses or combinations of prescribed oral treatments were provided by <LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
<B>, </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
<B>, </B>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>, <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
<B>, </B>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
<B>, </B>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK> and<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
<B>, </B>however details differed per trial. Furthermore, investigated SMBG interventions differed in accompanying education programmes (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)<B>.</B>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-11-08 22:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were excluded from the review because they had a control group with access to SMBG (i.e. <LINK REF="STD-Polonsky-2011" TYPE="STUDY">Polonsky 2011</LINK>), they had included patients using insulin (i.e. <LINK REF="STD-Lim-2011" TYPE="STUDY">Lim 2011</LINK>), they did not explored one of our primary outcome measures (i.e. <LINK REF="STD-Scherbaum-2008" TYPE="STUDY">Scherbaum 2008</LINK>), were secondary reports of studies all ready included (i.e. <LINK REF="STD-Pignone-2009" TYPE="STUDY">Pignone 2009</LINK>) or because patients were not randomised (i.e. <LINK REF="STD-Bajkowska_x002d_Fiedziukiewicz-2008" TYPE="STUDY">Bajkowska-Fiedziukiewicz 2008</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-29 18:07:58 +0100" MODIFIED_BY="Gudrun Paletta">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a graphical summary of the 'Risk of bias' assessments for included studies, based on the six 'Risk of bias' domains.</P>
<P>
<B>Overall risk of bias</B>
</P>
<P>Initial agreement between both review authors on the 'Risk of bias' domain allocation concealment was 0.56 (kappa). Disagreement was mainly based on reading errors and differences in interpretation of the standard description described in the <I>Cochrane Handbook for Systematic Reviews of Intervention. </I>After the consensus meeting, no disagreement persisted. The third review author was not called to make a final decision<I>.</I>
<BR/>
</P>
<ALLOCATION MODIFIED="2011-11-29 18:02:52 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Five trials had adequate concealment of allocation (<B> </B>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>; <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>) and five trials were unclear about allocation concealment (<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>;<B> </B>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>;<B> </B>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>; <LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>;<B> ; </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>;). In the trial of Guerci et al (<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>) patients were randomised by their general practitioners who were also responsible for intervention and follow-up, and Muchmore et al (<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>) recruited patients were divided over four groups, of which one group was not randomised. Therefore, <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK> and <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> had a high risk of bias for concealment of allocation.</P>
<P>Adequate sequence generation showed a low risk of bias in six trials (<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>;<B> </B>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>;<B> </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>;<B> </B>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>), an unclear risk of bias in five trials (<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>; <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>;<B> </B>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>;<B> </B>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>;<B> </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>)<B> </B>and was not described in one (<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>). The<B> </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> used a computerised partial minimisation procedure for sequence generation; in the <LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK> et al trial<B> </B>sequence was computer generated. <LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK> used a non-defined random sequence, <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK> used randomly generated codes for consecutively numbered sealed envelopes, <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK> had consecutively numbered non-transparent envelopes (range 1 to 60) and <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK> used computer-generated randomisation tables (random permuted blocks).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-11-08 22:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>In none of the studies patients were blinded to the intervention. The care provider was only blinded in the trial of Davidson et al (<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>). In that trial the care provider was a study nurse who was kept blinded for the allocated intervention and followed detailed algorithms to make therapeutic decisions, regardless of randomisation group.</P>
<P>The primary outcome (HbA<SUB>1c</SUB>) was assessed independently of staff responsible for performing analyses in three trials (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>). Additionaly, treatment allocation was concealed for laboratory staff. Blinding of the outcome assessor was not done in <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK> and unclear or not described in the other trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-11-29 18:06:03 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Eight trials described drop-out rates and provided reasons for it (<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>;<B> </B>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>;<B> </B>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>;<B> </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>;<B> </B>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>). Therefore, in these eight trials we assessed risk of bias concerning drop-out rate as low. Drop-out was not clearly described in the <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK> trial.</P>
<P>Intention-to-treat analysis was performed in five trials<B> </B>(<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>;<B> </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>;<B> </B>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>), which we defined as having a low risk of bias. Five trials performed per-protocol analyses only and were considered having a high risk of bias (<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>;<B> </B>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>;<B> </B>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>;<B> </B>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>;<B> </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>)<B> </B>and one trial did not describe performing either intention-to-treat or per-protocol analyses (<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-11-29 18:07:15 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Three trials (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>) had a low risk of selective reporting bias by either publishing their design (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>), by registering their protocol in a trial register (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>) or both. We rated <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK> and <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK> as unclear because they both registered their protocol to a trial register three years after the start of the trial. In addition, <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK> used a hard to interpret primary outcome measure. The rest of the included studies were rated as unclear as no information on pre-designated endpoints or a-priori defined subgroup analysis was identified.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-11-29 18:07:58 +0100" MODIFIED_BY="[Empty name]">
<P>All trials had similar groups at baseline for the most important prognostic indicators, except for <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010.</LINK>
<B> </B>In that study, diabetes duration differed between the intervention and control group. With the exception of<B> </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>, co-interventions were similar or avoided in all studies. We evaluated that the SMBG group in <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK> received a co-intervention by means of a structured counselling program every four weeks during the intervention period while the control group only received non-standardised counselling.</P>
<P>See:<B> </B>
<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for an overview of education programmes for included studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-30 16:04:48 +0100" MODIFIED_BY="Gudrun Paletta">
<P>See <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> for the effects of SMBG on glycosylated haemoglobin A1c (HbA<SUB>1c</SUB>) and fasting plasma glucose (FPG), <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for the effects of SMBG on health-related quality of life, well-being and patient satisfaction and <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for adverse events (e.g. hypoglycaemic episodes).</P>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity</HEADING>
<P>Included studies differed in baseline characteristics and in delivered SMBG education. Due to clinical heterogeneity we decided not to conduct a pooled analysis of all trials. We performed random-effects subgroup meta-analyses on the basis of diabetes duration and follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Glycaemic control measured by HbA<SUB>1c</SUB>
</HEADING>
<P>Glycaemic control as measured by change in HbA<SUB>1c</SUB> between baseline and endpoint improved in the SMBG groups (<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>; <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>), however this was not statistically significantly different from the improvement seen in the control groups. In their study <LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK> compared control with SMBG and SMUG and found no statistically significant differences in HbA<SUB>1c</SUB> between groups at the end of the trial.<B> </B>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
<B> </B>compared SMBG with SMUG and found no statistically significant differences in HbA<SUB>1c</SUB> between groups at the end of the study. Five studies detected a statistically significant difference between the outcomes of the intervention and control groups: The <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK> found an improvement in glycaemic control in the SMBG group compared to the control group, as measured by a statistically significant difference of 0.5% HbA<SUB>1c</SUB> between baseline and endpoint; <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> found a statistically significant difference of 0.4% in HbA<SUB>1c</SUB> between SMBG and control group at the end of the study; <LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK> reported an improvement in glycaemic control as measured with a statistically significant between group difference of 0.2% HbA<SUB>1c</SUB> in favour of the SMBG group; <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
<B> </B>reported a statistically significant difference of 0.5% in HbA<SUB>1c</SUB> between SMBG and control group at the end of the study; <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK> found a statistically significant improvement of 0.5% in HbA<SUB>1c</SUB> in the SMBG group compared to the control group between baseline and endpoint.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>We performed subgroup analyses for diabetes duration and duration of the intervention for the comparison of SMBG versus control and  SMBG versus SMUG. Data available on age groups, gender, presence of complications, different comparison interventions, type of treatment and weight could not be extracted sufficiently or could not be delivered by the original authors to investigate subgroup. In addition, we decided not to investigate baseline glycaemic control because 10 out of 12 studies (<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>; <LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>; <LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>; <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>; <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>; <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>; <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>) were in the a-priori specified medium range (between 7.0% and 11.0% HbA<SUB>1c</SUB>). The remaining two studies (<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>; <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>) had a baseline HbA<SUB>1c</SUB> in the low and the high category, respectively.</P>
<P>For all comparisons, six months follow-up data (published or retrieved by contacting the authors) or 12 months follow-up data were used only:</P>
<SUBSECTION>
<HEADING LEVEL="5">SMBG vs control (diabetes duration greater than one year, six months follow-up)</HEADING>
<P>In the meta-analysis, the overall effect for short-term follow-up (up to six months of follow-up) showed a statistically significant decrease of 0.3% in HbA<SUB>1c</SUB> (95% CI -0.4 to -0.1; 2324 participants, 9 trials, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) in favour of SMBG compared with the control group. For this analysis mild statistical heterogeneity was noticed (I<SUP>2 </SUP>= 29%) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SMBG vs control (diabetes duration greater than one year, 12 months follow-up)</HEADING>
<P>For medium term follow-up (between 6 and 12 months of follow-up) analysis revealed a statistically non-significant decrease in HbA<SUB>1c</SUB> of 0.1% (95% CI -0.3 to 0.04; 493 participants, 2 trials, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and no statistical heterogeneity (I<SUP>2 </SUP>= 0%) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>
<B>SMBG vs control </B>(<B>newly diagnosed diabetes, six months follow-up</B>)</P>
<P>The pooled analysis for short-term follow-up (up to six months of follow-up) in newly diagnosed patients (345 participants, 2 trials) showed notable statistical heterogeneity (I<SUP>2 </SUP>= 68%), indicating a substantial inconsistency in the direction of effect. Therefore, we do not present an effect estimate for HbA<SUB>1c</SUB> for this analysis.</P>
<P>
<B>SMBG vs control </B>(<B>newly diagnosed diabetes, 12 months follow-up</B>)</P>
<P>The meta-analysis for medium-term follow-up (between 6 and 12 months of follow-up) in newly diagnosed patients revealed a statistically significant decrease in HbA<SUB>1c</SUB> of 0.5% (95% CI -0.9 to -0.1; 345 participants, 2 trials, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) accompanied by moderate statistical heterogeneity (I<SUP>2 </SUP>= 44%) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>
<B>SMBG vs SMUG </B>(<B>diabetes duration greater than one year, six months follow-up</B>)</P>
<P>The pooled comparison between SMBG and SMUG for a short-term follow-up (up to six months of follow-up) showed a statistical non-significant decrease in HbA<SUB>1c</SUB> of 0.2% (95% CI -1.0 to 0.6; 194 participants, 2 trials, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>) in HbA<SUB>1c</SUB>. Statistical heterogeneity was not observed (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>Not enough adequate data to perform meaningful sensitivity analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life, well-being and patient satisfaction</HEADING>
<P>A total of five trials reported outcomes on either patient satisfaction (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>;<B> </B>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>;<B> </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>), well-being (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>; <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>) and/or health-related quality of life (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>).</P>
<P>Because of the fragmentation in used (validated) instruments and underlying sub-dimensions for measuring patient satisfaction, well-being and quality of life, risk of bias regarding differences between studies should be taken into account. A detailed specification of used measures can be found in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
<P>None of the trials reporting outcomes on treatment satisfaction (DTSQ) found significant between group changes (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>;<B> </B>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>;<B> </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>;). Well-being was assessed with the Well-being Questionnaire in <LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
<B>, </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK> and<B> </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>, and with the Wellbeing Index in<B> </B>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
<B>. </B>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK> reported a statistically significant decrease of the 22-item Well Being Questionnaire (WBQ-22) sub scale depression in favour of the SMBG group (-0.83 vs -0.26; range 0 to 18). <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK> reported a 6% increase (1.08 points) in the depression sub scale of the WBQ-22 (range 0 to 18) in the SMBG group compared to the control group at 12 months (P = 0.01). Information on baseline differences was not presented. Both studies did not find statistically significant differences on general well-being or the other three well-being sub-scales (anxiety, energy, positive well-being). The <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> found no between group differences in well-being scores (12-item Well Being Questionnaire (WBQ-12)). <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK> found no significant changes between groups in psychological well-being measured with the 5-item Wellbeing Index (WHO-5). Outcomes on health-related quality of life were reported by <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>, <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> and <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>. <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK> found no significant differences between the SMBG group and the control group in the four sub-scales (satisfaction, impact, diabetes related worry, and the social/vocational worry) of the Diabetes Quality-of-Life Inventory. The <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> found that health-related quality of life as measured with the EuroQol 5 dimensions (EQ5D) questionnaire showed a statistically significant difference of &#8211;0.1, (95% CI &#8211;0.127 to &#8211;0.017; range 1 to 3) at the end of the trial when comparing the more intensive monitoring group with the control group. <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
<B> </B>found no significant changes between groups in health related quality of life (36-item Short Form Health Survey (SF-36)). Separate analyses of the SF-36 sub scales identified a statistical significant between groups difference in the sub scale health change at the end of the study in favour of the control group (a 4.2 points decrease in the SMBG group and a 9.7 points increase in the control group; range 0 to 100).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Glycaemic control measured by fasting plasma glucose</HEADING>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
<B>, </B>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> and<B> </B>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK> measured fasting plasma glucose levels. All three studies found that fasting plasma glucose levels decreased as a result of SMBG, however there were no statistically significant differences between SMBG and SMUG and SMBG and no monitoring.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects, hypoglycaemic episodes</HEADING>
<P>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>, <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>, <LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>, <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>, <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK> and <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK> investigated SMBG related hypoglycaemia. Studies reported occurrence of hypoglycaemia by recording asymptomatic or symptomatic hypoglycaemic episodes and/or by using detailed graded definitions. Because of the fragmentation in definitions of hypoglycaemia, risk of bias regarding occurrence and severity of hypoglycaemia between studies should be taken into account. A specification of definitions and cut-off points can be found in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>. In <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> 10.4% SMBG group and 5.2% control group patients reported at least one episode of symptomatic or asymptomatic hypoglycaemia during the study (P = 0.003). This significant difference was caused by a between-group difference in patients reporting asymptomatic hypoglycaemia only (P = 0.001). No patients reported serious episodes of hypoglycaemia. In the <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> episodes of hypoglycaemia with mild symptoms were reported by 9.2%, 22% and 28.5% of the patients in the control group, less intensive group and more intensive group, respectively (P &lt; 0.001). Episodes of severe hypoglycaemia were reported in one patient in the control group (<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>). In the <LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK> study a hypoglycaemic event (symptomatic, asymptomatic or SMBG confirmed) was reported in 8.7% and 7% of the patients in the SMBG group and control group, respectively. All reported events were considered mild (grade 1), moderate (grade 2) or were non-graded. No significant between-group differences were found in reported hypoglycaemia at any time point in the <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK> trial. In<B> </B>the<B> </B>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
<B> </B>trial no severe hypoglycaemic episodes requiring third-party or medical assistance were reported in either group. In the <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK> trial no adverse events including hypoglycaemic events occurred.</P>
<P>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK> and <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> reported adverse effects, but did not specify them. For details on adverse effects see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Costs</HEADING>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK> and the <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> reported outcomes on approximate costs of self-monitoring. <LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK> compared the costs of SMBG with SMUG based on nine measurements per week and with the prices in US dollars for self-monitoring in 1990. They concluded that total costs in the first year of SMBG, with the purchase of a reflectance meter were 12 times more expensive than SMUG (SMBG = $481 or 361 EURO [11/2011 conversion]; SMUG = $40 or 30 EURO [11/2011 conversion]).</P>
<P>As part of the <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> a full economical evaluation of the costs and effects of self-monitoring in the DiGEM trial population was performed and presented in UK Pounds Sterling. At the end of the trial, costs for the intervention were £89 (104 EURO [11/2011 conversion]) for standardized usual care (control group), £181 (212 EURO [11/2011 conversion]) for the less intensive self-monitoring group and £173 (203 EURO [11/2011 conversion]) for the more intensive self-monitoring group.Higher losses to follow-up in the more intensive self-monitoring group were responsible for the difference in costs, compared to the less intensive self-monitoring group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Morbidity, mortality</HEADING>
<P>The <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK> and <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> reported mortality (death of patients during the trial). None of the studies reported data on morbidity. We have summarised the data in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-30 13:34:03 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-11-30 13:34:03 +0100" MODIFIED_BY="[Empty name]">
<P>The aim of this systematic review was to assess the effects of SMBG in patients with type 2 diabetes who are not using insulin. Six randomised controlled trials were added to the six trials included in the original review (<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>). In non-insulin treated type 2 diabetes patients with a diabetes duration of at least one year the overall effect of SMBG compared to control groups and a follow-up of six months showed a statistically significant 0.3% HbA<SUB>1c </SUB>decrease. In contrast, we saw a non-significant decrease of 0.1% in HbA<SUB>1c</SUB> in patients in SMBG groups compared to control groups over a 12 months follow-up period.</P>
<P>Secondly, the overall effect of SMBG compared to SMUG over a follow-up of six months showed a statistically non-significant decrease of 0.2% HbA<SUB>1c</SUB>. Thirdly, it was not possible to estimate an overall effect of SMBG over a follow-up of six months for newly diagnosed non-insulin treated type 2 diabetes patients, due to substantial inconsistency in the direction of the effect. However, the overall effect of SMBG with a follow-up of 12 months demonstrated a statistically significant decrease of 0.5% in HbA<SUB>1c</SUB> compared to control groups (two trials).</P>
<P>Concerning health-related quality of life, well-being and patient satisfaction outcomes, based on a best-evidence synthesis we conclude that there was no significant evidence available that SMBG had an effect on patient satisfaction (4 out of 4 trials), general well-being (4 out of 4 trials) or general health-related quality of life (3 out of 3 trials). Regarding levels of depression (WBQ-22, sub scale), inconsistent findings were observed (2 out of 2 trials).</P>
<P>Lastly, regarding the secondary outcomes we conclude that based on a best-evidence synthesis periods of both asymptomatic and symptomatic hypoglycaemia are more frequent in patients performing SMBG (3 out of 4 trials); and secondly, there is no statistically significant difference in fasting plasma glucose levels between SMBG and control intervention groups (3 out of 3 trials).</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical relevance of findings</HEADING>
<P>The main results suggest that long-term SMBG in new-onset patients is beneficial in lowering HbA<SUB>1c</SUB>. However, when diabetes duration is over one year, the overall glycaemic effect of SMBG is small and more likely to be present at short-term. Because subgroup meta-analyses could not fully take the presence of clinical heterogeneity into account, clinical interpretation and translation into practice of these results is difficult and should be done with caution. Different levels of probability and estimates of outcome variables of included studies might account for differences in presented subgroups. In addition, differences in requested monitoring frequency, HbA<SUB>1c</SUB> level at baseline and SMBG and diabetes education may have contributed to the differences as well. Besides HbA<SUB>1c</SUB> we paid attention to important outcome measures such as health-related quality of life, well-being, patient-satisfaction and hypoglycaemic episodes as well. Because few included trials reported outcomes on health-related quality of life and well-being and used self-report measures varied, presenting a general effect estimate is not possible and interpretation of best-evidence synthesis is difficult. However, similar effects on similar sub-scales or dimensions in similar directions suggested a clinical non-relevant effect of SMBG on general (health-related) quality of life and well-being. In addition, since all trials that measured patient-satisfaction did not report an SMBG related effect, this is considered clinical relevant as well. Experiencing hypoglycaemic events can be confirmed with SMBG. Therefore, it is in the line of expectation that more frequent hypoglycaemic events are reported when using SMBG.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-11-30 12:41:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Risk of bias</HEADING>
<P>Most included trials and specifically earlier trials were exposed to selection and attrition bias . With the advent of new studies (<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>; <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>; <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>) performed after our first review (<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>) the risk of bias was reduced.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<P>SMBG was embedded differently in usual care across included trials and instructions for self-monitoring frequency, 'lifestyle' adjustment and SMBG integration in diabetes management varied between trials. However, we considered clinical heterogeneity induced by trial design not significant and decided to combine the data in subgroup meta-analyses.</P>
<P>We made an a-priori decision to separate pooled estimates of the effect of SMBG on HbA<SUB>1c</SUB> for newly diagnosed patients and patients with a diabetes diagnosis of at least one year. Initiating diabetes management in newly diagnosed and never treated patients results in larger and differential effects in glycaemic control compared to patients with a longer diabetes duration (<LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK>). In addition, being confronted with having a major chronic disease as type 2 diabetes can be accompanied with newly gained worries, which directly reflects in glycaemic control (<LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>In none of the trials, psychological measures were the primary outcome measures. Some trials mentioned contradictory or no psychological effects as secondary outcome measures. Finally, hypoglycaemic episodes were more reported in SMBG groups than in the control groups (<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>;<B> </B>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>;<B> </B>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>). Because patients in the SMBG groups can use their SMBG device to confirm both periods of asymptomatic and symptomatic hypoglycaemic, this is according to expectations.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-11-30 12:44:09 +0100" MODIFIED_BY="[Empty name]">
<P>This update identified six new studies. Inclusion of these new studies made it possible to perform subgroup meta-analyses on duration of diabetes and duration of intervention. Initially, subgroup analyses of studies with a short intervention duration (9 studies, 2324 participants) showed a larger positive effect of self-monitoring compared to studies with a medium duration (2 studies, 493 participants). Effects of short- and medium-term duration in patients with newly diagnosed type 2 diabetes (2 studies, 345 participants) were subject to notable (I<SUP>2 </SUP>= 68%) and moderate (I<SUP>2 </SUP>= 44%) statistical heterogeneity, respectively. Therefore, no summary estimate can be presented for short-term follow-up and long-term follow-up should be interpreted with caution. Concerning the studies evaluating the effect of SMBG compared with SMUG the results of the current review are insufficient to draw final conclusions. Only two studies with 194 participants were identified and included in the analysis. Pooling the data from these two studies showed a non-significant positive effect of SMBG on HbA<SUB>1c</SUB> compared to SMUG. However, one of the trials (<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>) had serious limitations in design and implementation, which may have resulted in selection, attrition and reporting bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-11-30 12:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>With an extensive search without language restriction in four electronic databases, the meta-register of current controlled trials and by scanning references of identified reviews and included studies we attempted to minimise publication bias. Nevertheless, we cannot rule out the possibility that we have missed relevant studies that were not published or are still ongoing. Not all data needed to perform a full effect-modifier investigation could be extracted from the data available or revealed from the original authors. Therefore, differences in baseline glycaemic control, changes in hypoglycaemic medication, age and compliance to the protocol might modify or confound the presented results. In addition, the proposed sensitivity analyses could not be performed.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-11-30 12:47:01 +0100" MODIFIED_BY="[Empty name]">
<P>The efficacy of SMBG in type 2 diabetes patients not using insulin has been subject of a considerable number of systematic reviews and meta-analyses over time. Most included randomised controlled trials only (<LINK REF="REF-Allemann-2009" TYPE="REFERENCE">Allemann 2009</LINK>;<B> </B>
<LINK REF="REF-Clar-2010" TYPE="REFERENCE">Clar 2010</LINK>; <LINK REF="REF-Jansen-2006" TYPE="REFERENCE">Jansen 2006</LINK>;<B> </B>
<LINK REF="REF-Kleefstra-2009" TYPE="REFERENCE">Kleefstra 2009</LINK>; <LINK REF="REF-McIntosh-2010" TYPE="REFERENCE">McIntosh 2010</LINK>; <LINK REF="REF-Poolsup-2008" TYPE="REFERENCE">Poolsup 2008</LINK>;<B> </B>
<LINK REF="REF-Poolsup-2009" TYPE="REFERENCE">Poolsup 2009</LINK>; <LINK REF="REF-Sarol-2005" TYPE="REFERENCE">Sarol 2005</LINK>; <LINK REF="REF-Towfigh-2008" TYPE="REFERENCE">Towfigh 2008</LINK>), but some included other designs as well (<LINK REF="REF-McAndrew-2007" TYPE="REFERENCE">McAndrew 2007</LINK>; <LINK REF="REF-McGeoch-2007" TYPE="REFERENCE">McGeoch 2007</LINK>;<B> </B>
<LINK REF="REF-St-John-2010" TYPE="REFERENCE">St John 2010</LINK>). The aim of our review was to assess the effects of SMBG in type 2 diabetes patients not using insulin. Therefore, studies in which the results of non-insulin users could not be separated from patients using insulin were excluded. Although this stringent exclusion criterion contributes to a decrease in included patients we believe that this has lead to a more clinically homogeneous data set and more valid conclusions about the effect of SMBG in this particular patient group. Furthermore, in contrast to other reviews, clinical and methodological heterogeneity between included studies have been taken into account. We believe that this distinguishes our systematic review and its associated conclusions from previous ones and emphasises the importance of comparability and internal validity of RCTs.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-11-30 12:49:11 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-11-30 12:49:11 +0100" MODIFIED_BY="[Empty name]">
<P>In this update, the addition of six new trials to the original review made it possible to create subgroups to counter the initial lack of clinical and methodological homogeneity between studies. With the present findings it can be concluded that self-monitoring of blood glucose (SMBG) in newly diagnosed type 2 diabetes patients who are not using insulin is beneficial in lowering HbA<SUB>1c</SUB>. However, when diabetes duration is over one year, the overall glycaemic effects of SMBG are small at short-term and subside after one year. Despite possible glycaemic benefits we conclude that SMBG has no relevant effect on general well-being and health-related quality of life. In addition, patients performing SMBG are equally satisfied with their treatment as those not using SMBG. Furthermore, SMBG increases reported hypoglycaemic episodes. However, different definitions of hypoglycaemic episodes make it difficult to distinguish between reported severities.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-11-29 16:39:54 +0100" MODIFIED_BY="[Empty name]">
<P>Qualitative research (<LINK REF="REF-Farmer-2009" TYPE="REFERENCE">Farmer 2009</LINK>; <LINK REF="REF-Peel-2007" TYPE="REFERENCE">Peel 2007</LINK>) suggests that SMBG and its feedback can be important factors for individual patients to improve medication adherence, empower the patient to gain control over their disease or to motivate 'lifestyle' changes. Future studies should investigate whether SMBG attributes to other parts of self-management. In addition, SMBG postulated positive changes in diabetic complications should be investigated as well. Furthermore, more research is needed to explore the psychological impact of SMBG and its accompanying demands on diabetes specific quality of life and well-being.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-11-29 16:20:36 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Alfonso Calle-Pascual (St Carlos Study), Andrew Farmer (DiGEM trial), Nanne Kleefstra (ZODIAC study), Antonio Nicolucci (ROSES study) and Maurice O'Kane (ESMON study) for providing additional and unpublished data of their trials. Raymond Ostelo and Henrica de Vet are thanked for their help with designing the meta-analysis.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-11-08 22:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>URIËLL MALANDA, JACQUELINE DEKKER, GIEL NIJPELS and SANDRA BOT all take part in an ongoing study on the topic of interest of this review. <BR/>
<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-11-29 16:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>URIËLL MALANDA: wrote the draft of this review that was commented on and discussed by LAURA WELSCHEN, INGRID RIPHAGEN, GIEL NIJPELS, JACQUELINE DEKKER and SANDRA BOT.</P>
<P>INGRID RIPHAGEN: performed the searches.</P>
<P>URIËLL MALANDA and LAURA WELSCHEN: independently inspected the titles and abstracts of the references identified to evaluate their potential eligibility.</P>
<P>URIËLL MALANDA and LAURA WELSCHEN: independently assessed the risk of bias of the relevant trials and performed data extraction and data entry.</P>
<P>URIËLL MALANDA, LAURA WELSCHEN, INGRID RIPHAGEN, JACQUELINE DEKKER, GIEL NIJPELS and SANDRA BOT: interpreted the findings and helped writing the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-11-29 16:19:59 +0100" MODIFIED_BY="[Empty name]">
<P>This section relates to the differences between the first <U>review</U> (<LINK REF="REF-Welschen-2005a" TYPE="REFERENCE">Welschen 2005a</LINK>) and the present review-update (Malanda 2011).</P>
<OL>
<LI>Four authors have left the team and three others have joined.</LI>
<LI>Because HbA<SUB>1c</SUB> reflects a more constant view of glycaemic control over time, we believe that  changes in fasting plasma glucose are of less value for assessing the effect of self-monitoring of blood glucose (SMBG). We therefore assessed effects on fasting plasma glucose level as a secondary outcome whereas this was a primary outcome in the first review.</LI>
<LI>We have added PsycInfo to our search strategy because studies investigating the effect of SMBG on quality of life or well-being might not be published in regular medical databases.</LI>
<LI>The mandatory Cochrane 'Risk of Bias' tool has replaced the Amsterdam-Maastricht list.</LI>
<LI>Review has been updated with six new trials (<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>; <LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>; <LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>; <LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>; <LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>; <LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>).</LI>
<LI>Addition of six new studies made it possible to perform pooled random-effects subgroup analyses on the basis of diabetes duration and follow-up.</LI>
<LI>Conclusions could be drawn on the effect of SMBG on glycaemic control for subgroups and for patient satisfaction, general well-being or general health-related quality of life.</LI>
<LI>Conclusions have been changed</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-29 17:44:34 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-11-29 17:44:34 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-11-29 17:44:34 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1990" MODIFIED="2010-08-30 15:12:20 +0200" MODIFIED_BY="[Empty name]" NAME="Allen 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Allen BT, DeLong ER, Feussner JR. Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Randomized controlled trial comparing blood and urine testing. Diabetes Care 1990; 13(10):1044-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen BT, DeLong ER, Feussner JR</AU>
<TI>Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Randomized controlled trial comparing blood and urine testing</TI>
<SO>Diabetes Care</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>10</NO>
<PG>1044-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-08-30 15:12:20 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnett-2008" MODIFIED="2010-10-20 15:24:10 +0200" MODIFIED_BY="[Empty name]" NAME="Barnett 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-20 15:24:10 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2008520851&lt;br&gt;IN - (Barnett) Department of Medicine, University of Birmingham, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, United Kingdom. (Krentz) Department of Diabetes and Endocrinology, University of Southampton, Southampton, United Kingdom. (Strojek) Department of Internal Diseases, Diabetology and Nephrology, Silesian Medical University, Zabrze, Poland. (Sieradzki) Department of Metabolic Diseases, Jagiellonian University, Krakow, Poland. (Azizi) Endocrine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of. (Embong) University of Science, Pulau Pinang, Malaysia. (Imamoglu) Department of Endocrinology, Uludag University, Bursa, Turkey. (Perusicova) Department of Medicine, Charles University, Prague, Czech Republic. (Uliciansky) Department of Diabetology and Internal Medicine, University of Kosice, Kosice, Slovakia. (Winkler) Department of Internal Medicine, St. John's Hospital, Budapest, Hungary&lt;br&gt;CP - United Kingdom&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Article&lt;br&gt;EM - 200850&lt;br&gt;DD - 20081204&lt;/p&gt;" NOTES_MODIFIED="2010-10-20 15:24:10 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnett AH, Krentz AJ, Strojek K, Sieradzki J, Azizi F, Embong M, et al</AU>
<TI>The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)</TI>
<SO>Diabetes, Obesity and Metabolism.10(12)()(pp 1239-1247), 2008.Date of Publication: 2008.</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>12</NO>
<PG>1239-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Davidson-2005" MODIFIED="2010-10-20 15:26:20 +0200" MODIFIED_BY="[Empty name]" NAME="Davidson 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-20 15:26:20 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Davidson MB, Castellanos M, Kain D, Duran P. The effect of self-monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med. In press.&lt;/p&gt;" NOTES_MODIFIED="2010-10-20 15:26:20 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson MB, Castellanos M, Kain D, Duran P</AU>
<TI>The effect of self-monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial.</TI>
<SO>American Journal of Medicine</SO>
<YR>04-2005</YR>
<VL>118</VL>
<NO>4</NO>
<PG>422-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiGEM-trial-2007" MODIFIED="2011-11-29 17:44:34 +0100" MODIFIED_BY="[Empty name]" NAME="DiGEM trial 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-29 17:44:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00590010&lt;br&gt;PUBMED 17591623&lt;br&gt;Journal Article&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/010/CN-00590010/frame.html&lt;br&gt;CC: SR-ENDOC; SR-EPOC&lt;/p&gt;" NOTES_MODIFIED="2011-11-29 17:44:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al</AU>
<TI>Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<NO>7611</NO>
<PG>132</PG>
<IDENTIFIERS MODIFIED="2011-11-29 17:44:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-29 17:42:24 +0100" MODIFIED_BY="Bernd Richter" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-11 17:39:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, et al</AU>
<TI>Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial</TI>
<SO>Health Technology Assessment.</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>15</NO>
<PG>iii-xi, 1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-20 15:23:58 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2008471073&lt;br&gt;IN - (French) Applied Research Centre in Health and Lifestyle Interventions, Coventry University, Coventry, United Kingdom. (Wade) Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States. (Yudkin, Farmer) Department of Primary Health Care, University of Oxford, Oxford, United Kingdom. (Neil) Division of Public Health and Primary Care, University of Oxford, Oxford, United Kingdom. (Kinmonth) General Practice and Primary Care Research Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom. (French) Applied Research Centre in Health and Lifestyle Interventions, Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry CV1 5FB, United Kingdom&lt;br&gt;CP - United Kingdom&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Article&lt;br&gt;EM - 200845&lt;br&gt;DD - 20081104&lt;/p&gt;" NOTES_MODIFIED="2010-10-20 15:23:58 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French DP, Wade AN, Yudkin P, Neil HAW, Kinmonth AL, Farmer AJ</AU>
<TI>Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial</TI>
<SO>Diabetic Medicine.25(10)()(pp 1218-1228), 2008.Date of Publication: October 2008.</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1218-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-18 15:59:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00639012&lt;br&gt;PUBMED 18420663&lt;br&gt;Journal Article&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/012/CN-00639012/frame.html&lt;br&gt;CC: SR-ENDOC&lt;/p&gt;" NOTES_MODIFIED="2009-11-18 15:59:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A, et al</AU>
<TI>Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7654</NO>
<PG>1177-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-25 16:45:49 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dur_x00e1_n-2010" MODIFIED="2010-10-26 13:21:30 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Durán 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-26 13:21:30 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Durán A, Martín P, Runkle I, Pérez N, Abad R, Fernández M, Del Valle L, Sanz MF, Calle-Pascual L.</AU>
<TI>Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: The St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups</TI>
<SO>Journal of Diabetes</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>203-211</PG>
<IDENTIFIERS MODIFIED="2010-10-11 16:19:49 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-10-11 16:15:23 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-11 16:15:23 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontbonne-1989" NAME="Fontbonne 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Fontbonne A, Billault B, Acosta M et al. Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial. Diabete Metab 1989; 15(5):255-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fontbonne A, Billault B, Acosta M, Percheron C, Varenne P, Besse A et al</AU>
<TI>Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial</TI>
<SO>Diabete &amp; Metabolisme</SO>
<YR>1989</YR>
<VL>15</VL>
<NO>5</NO>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franciosi-2011" MODIFIED="2011-07-30 18:21:10 +0200" MODIFIED_BY="[Empty name]" NAME="Franciosi 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-07-30 17:53:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franciosi M, Lucisano G, Pellegrini F, Cantarello A, Consoli A, Cucco L, et al</AU>
<TI>ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomized clinical trial</TI>
<SO>Diabetic medicine : a journal of the British Diabetic Association</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>7</NO>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2011-07-30 17:52:17 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21342243"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerci-2003" NAME="Guerci 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Guerci B, Drouin P, Grange V et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003; 29(6):587-94.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V et al</AU>
<TI>Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study</TI>
<SO>Diabetes Metab</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>6</NO>
<PG>587-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kleefstra-2010" MODIFIED="2010-10-12 10:25:55 +0200" MODIFIED_BY="[Empty name]" NAME="Kleefstra 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-12 10:25:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleefstra N, Hortensius J, Logtenberg SJJ, Slingerland RJ, Groenier KH, Houweling ST, Gans ROB, van Ballegooie E, Bilo HJG</AU>
<TI>Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC)</TI>
<SO>Neth.J.Med.</SO>
<YR>-08-2010</YR>
<VL>68</VL>
<NO>1</NO>
<PG>311-316</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-11-16 14:56:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muchmore-1994" NAME="Muchmore 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994; 31(4):215-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muchmore DB, Springer J, Miller M</AU>
<TI>Self-monitoring of blood glucose in overweight type 2 diabetic patients</TI>
<SO>Acta Diabetol</SO>
<YR>1994</YR>
<VL>31</VL>
<NO>4</NO>
<PG>215-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Kane-2008" MODIFIED="2009-11-16 14:52:53 +0100" MODIFIED_BY="[Empty name]" NAME="O'Kane 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-16 14:52:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00639011&lt;br&gt;PUBMED 18420662&lt;br&gt;Comparative Study&lt;br&gt;Journal Article&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/011/CN-00639011/frame.html&lt;br&gt;CC: SR-ENDOC&lt;/p&gt;" NOTES_MODIFIED="2009-11-16 14:52:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Kane MJ, Bunting B, Copeland M, Coates VE, ESMON study group</AU>
<TI>Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7654</NO>
<PG>1174-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SMBG-study-group-2002" MODIFIED="2010-08-30 15:13:40 +0200" MODIFIED_BY="[Empty name]" NAME="SMBG study group 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-18 15:55:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Schwedes U, Siebolds M, Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002; 25(11):1928-32.&lt;/p&gt;" NOTES_MODIFIED="2009-11-18 15:55:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schwedes U, Siebolds M, Mertes G</AU>
<TI>Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1928-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-18 15:52:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00561123&lt;br&gt;PUBMED 16159705&lt;br&gt;EMBASE 2006266055&lt;br&gt;Comparative Study&lt;br&gt;Journal Article&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/123/CN-00561123/frame.html&lt;br&gt;CC: SR-BEHAVMED; SR-ENDOC&lt;/p&gt;" NOTES_MODIFIED="2009-11-18 15:52:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siebolds M, Gaedeke O, Schwedes U, SMBG Study Group</AU>
<TI>Self-monitoring of blood glucose--psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication</TI>
<SO>Patient education and counseling.</SO>
<YR>2006</YR>
<VL>62</VL>
<NO>1</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-09 22:19:13 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdelgadir-2006" MODIFIED="2010-10-20 15:32:57 +0200" MODIFIED_BY="[Empty name]" NAME="Abdelgadir 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-20 15:32:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdelgadir M, Elbagir M, Eltom M, Berne C</AU>
<TI>The influence of glucose self-monitoring on glycaemic control in patients with diabetes mellitus in Sudan</TI>
<SO>Diabetes Research and Clinical Practice.74(1)()(pp 90-94), 2006.Date of Publication: Oct 2006.</SO>
<YR>2006</YR>
<VL>74</VL>
<NO>1</NO>
<PG>90-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsumi-1997" MODIFIED="2010-10-12 10:16:52 +0200" MODIFIED_BY="[Empty name]" NAME="Atsumi 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-12 10:16:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Atsumi Y, Kadowaki Y, Origasa H</AU>
<TI>Self-monitoring blood glucose improves quality of life in NIDDM patients treated with diet alone or oral hypo-glycaemic agents</TI>
<SO>Diabetes</SO>
<YR>1997</YR>
<VL>46 (Suppl 1)</VL>
<PG>267A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bajkowska_x002d_Fiedziukiewicz-2008" MODIFIED="2010-10-20 15:34:08 +0200" MODIFIED_BY="[Empty name]" NAME="Bajkowska-Fiedziukiewicz 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-20 15:34:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bajkowska-Fiedziukiewicz A, Cypryk K, Kozdraj T, Mikolajczyk-Swatko A, Kosinski M, Jozefowska M</AU>
<TI>Self-monitoring of blood glucose and treatment outcomes in type 2 diabetic patients</TI>
<SO>Polskie Archiwum Medycyny Wewnetrznej.118(5):267-72,</SO>
<YR>2008</YR>
<VL>118</VL>
<NO>5</NO>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chidum-2011" MODIFIED="2011-10-29 16:43:27 +0200" MODIFIED_BY="[Empty name]" NAME="Chidum 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-10-29 16:43:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chidum E, Agbai D, Fidelis O, Teppany S, Martina R, Rian E, et al</AU>
<TI>Self-monitoring of blood glucose improved glycaemic control and 10-year coronary heart disease risk profile of type 2 diabetic patients</TI>
<SO>Chinese medical journal</SO>
<YR>2011</YR>
<VL>124</VL>
<NO>2</NO>
<PG>166-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21362359"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cho-2006" MODIFIED="2011-11-07 21:19:12 +0100" MODIFIED_BY="[Empty name]" NAME="Cho 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-11-07 21:19:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cho JH, Chang SA, Kwon HS, Choi YH, Ko SH, Moon SD, et al</AU>
<TI>Long-term effect of the Internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system</TI>
<SO>Diabetes care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>12</NO>
<PG>2625-31</PG>
<IDENTIFIERS MODIFIED="2011-11-07 21:19:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17130195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2004" MODIFIED="2011-11-09 21:05:05 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-11-09 21:05:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Davidson Mayer B, Castellanos Maria, Kain Don</AU>
<TI>Self-monitoring of blood glucose (SMBG) linked to nutritional counseling in minority type 2 diabetic patients on diet and oral antidiabetes medication does not improve glycemic outcomes</TI>
<SO>Diabetes</SO>
<YR>2004</YR>
<VL>53 (Suppl)</VL>
<PG>A73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drouin-2002" MODIFIED="2010-10-12 10:16:52 +0200" MODIFIED_BY="[Empty name]" NAME="Drouin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-12 10:16:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, Passa P, et al</AU>
<TI>An impact of self-monitoring blood glucose (SMBG) on metabolic control in type 2 diabetic patients</TI>
<SO>Diabetologia</SO>
<YR>2002</YR>
<VL>45 (Suppl 20)</VL>
<PG>A310</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franciosi-2005" MODIFIED="2010-10-20 15:33:36 +0200" MODIFIED_BY="[Empty name]" NAME="Franciosi 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-20 15:33:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Di Nardo B, Greenfield S, et al</AU>
<TI>Self-monitoring of blood glucose in non-insulin-treated diabetic patients: A longitudinal evaluation of its impact on metabolic control</TI>
<SO>Diabetic Medicine.22(7)()(pp 900-906), 2005.Date of Publication: Jul 2005.</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>7</NO>
<PG>900-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallego-2007" MODIFIED="2010-10-20 15:35:34 +0200" MODIFIED_BY="[Empty name]" NAME="Gallego 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-20 15:35:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallego MS, Ramirez LC, Lopez FME, Lopez YJ</AU>
<TI>Self-Monitoring of Glucaemia (SMG): A non-randomised study with control. [Spanish]</TI>
<SO>Atencion Primaria.39(6)()(pp 326-327), 2007.Date of Publication: 01 Jun 2007.</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>6</NO>
<PG>326-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffmann-2011" MODIFIED="2011-11-07 21:40:01 +0100" MODIFIED_BY="[Empty name]" NAME="Hoffmann 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-07 21:40:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann F, Andersohn F</AU>
<TI>Immortal time bias and survival in patients who self-monitor blood glucose in the Retrolective Study: self-monitoring of Blood Glucose and Outcome in Patients with Type 2 Diabetes (ROSSO)</TI>
<SO>Diabetologia</SO>
<YR>2011</YR>
<VL>54</VL>
<NO>2</NO>
<PG>308-11</PG>
<IDENTIFIERS MODIFIED="2011-11-07 21:39:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20853097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2006" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson JA, Majumdar SR, Bowker SL, Toth EL, Edwards A</AU>
<TI>Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy</TI>
<SO>Diabetic medicine : a journal of the British Diabetic Association.</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2007" MODIFIED="2011-11-07 21:40:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-07 21:40:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kelly KL, Ellison JM, Goldstein E, Nomura DM, Price DA</AU>
<TI>Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy</TI>
<SO>Diabetic medicine : a journal of the British Diabetic Association</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>7</NO>
<PG>802</PG>
<IDENTIFIERS MODIFIED="2011-11-07 21:39:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17596241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwon-2004" NAME="Kwon 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Kwon HS, Cho JH, Kim HS et al. Establishment of blood glucose monitoring system using the internet. Diabetes Care 2004; 27(2):478-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwon HS, Cho JH, Kim HS, Song BR, Ko SH, Lee JM et al</AU>
<TI>Establishment of blood glucose monitoring system using the internet</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>2</NO>
<PG>478-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laffel-2007" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Laffel 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laffel LM Hsu WC McGill JB Meneghini</AU>
<TI>Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial</TI>
<SO>Diabetes technology &amp; therapeutics</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>3</NO>
<PG>254-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecomte-2008" MODIFIED="2010-10-20 15:35:51 +0200" MODIFIED_BY="[Empty name]" NAME="Lecomte 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-20 15:35:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lecomte P, Romon I, Fosse S, Simon D, Fagot-Campagna A</AU>
<TI>Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: The Entred study 2001</TI>
<SO>Diabetes and Metabolism.34(3)()(pp 219-226), 2008.Date of Publication: June 2008.</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>3</NO>
<PG>219-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2011" MODIFIED="2011-07-30 17:53:38 +0200" MODIFIED_BY="[Empty name]" NAME="Lim 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-07-30 17:53:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim S, Kang SM, Shin H, Lee HJ, Won Yoon J, Yu SH, et al</AU>
<TI>Improved glycemic control without hypoglycemia in elderly diabetic patients using the ubiquitous healthcare service, a new medical information system</TI>
<SO>Diabetes care</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>2</NO>
<PG>308-13</PG>
<IDENTIFIERS MODIFIED="2011-07-30 17:52:17 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21270188"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohan-2010" MODIFIED="2011-11-07 21:19:12 +0100" MODIFIED_BY="[Empty name]" NAME="Mohan 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-07 21:19:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohan V, Ravikumar R, Poongothai S, Amutha A, Sowmya S, Karkhuzali K, et al</AU>
<TI>A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in type 2 diabetic subjects</TI>
<SO>Journal of diabetes science and technology</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>4</NO>
<PG>942-8</PG>
<IDENTIFIERS MODIFIED="2011-11-07 21:19:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20663460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreland-2006" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Moreland 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreland EC, Volkening LK, Lawlor MT, Chalmers KA, Anderson BJ, Laffel LM</AU>
<TI>Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>6</NO>
<PG>689-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Kane-2006" MODIFIED="2010-10-12 10:16:52 +0200" MODIFIED_BY="[Empty name]" NAME="O'Kane 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-12 10:16:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>O'Kane MJ, Coates VE, Bunting B</AU>
<TI>The efficacy of self blood glucose monitoring in type 2 diabetes: the ESMON study</TI>
<SO>Diabetologia</SO>
<YR>2006</YR>
<VL>49 (Suppl 1)</VL>
<PG>550</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pignone-2009" MODIFIED="2010-10-20 15:35:02 +0200" MODIFIED_BY="[Empty name]" NAME="Pignone 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-20 15:35:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pignone M</AU>
<TI>Value of self-monitoring of blood glucose in non-insulin-using patients with type 2 diabetes</TI>
<SO>Clinical Diabetes.27(1)()(pp 17-18), 2009.Date of Publication: January 2009.</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>1</NO>
<PG>17-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polonsky-2011" MODIFIED="2011-11-07 16:34:43 +0100" MODIFIED_BY="[Empty name]" NAME="Polonsky 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-07 16:34:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al</AU>
<TI>Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study</TI>
<SO>Diabetes care</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>2</NO>
<PG>262-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21270183"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scherbaum-2008" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Scherbaum 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scherbaum WA Ohmann C</AU>
<TI>Effect of the frequency of self-monitoring blood glucose in patients with type 2 diabetes treated with oral antidiabetic drugs-a multi-centre, randomized controlled trial</TI>
<SO>PLoS.ONE.</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>8</NO>
<PG>e3087</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiraiwa-2010" MODIFIED="2011-07-30 17:53:38 +0200" MODIFIED_BY="[Empty name]" NAME="Shiraiwa 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-07-30 17:53:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Shiraiwa T, Takahara M, Kaneto H, Miyatsuka T, Yamamoto K, Yoshiuchi K, et al</AU>
<TI>Efficacy of occasional self-monitoring of postprandial blood glucose levels in type 2 diabetic patients without insulin therapy</TI>
<SO>Diabetes research and clinical practice</SO>
<YR>2010</YR>
<VL>90</VL>
<NO>3</NO>
<PG>e91-2</PG>
<IDENTIFIERS MODIFIED="2011-07-30 17:52:17 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21030103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tengblad-2007" MODIFIED="2010-10-20 15:36:28 +0200" MODIFIED_BY="[Empty name]" NAME="Tengblad 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-20 15:36:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tengblad A, Grodzinsky E, Lindstrom K, Molstad S, Borgquist L, Ostgren CJ</AU>
<TI>Self-monitoring of blood glucose and glycaemic control in type 2 diabetes</TI>
<SO>Scandinavian Journal of Primary Health Care.25(3):140-6,</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>3</NO>
<PG>140-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2004" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Wen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen L, Parchman ML, Linn WD, Lee S</AU>
<TI>Association between self-monitoring of blood glucose and glycemic control in patients with type 2 diabetes mellitus</TI>
<SO>American journal of health system pharmacy : AJHP : official journal of the American Society of Health System Pharmacists.</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>22</NO>
<PG>2401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wysocki-1989" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Wysocki 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wysocki Tim</AU>
<TI>Impact of blood glucose monitoring on diabetic control: Obstacles and interventions</TI>
<SO>Journal of Behavioral Medicine</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>2</NO>
<PG>183-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-07-30 18:22:43 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-10-20 11:09:58 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Bergenstal-2005" MODIFIED="2010-10-20 10:26:47 +0200" MODIFIED_BY="[Empty name]" NAME="Bergenstal 2005" YEAR="2005">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malanda-2009" MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" NAME="Malanda 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-20 09:47:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malanda UL, Bot SD, Kostense PJ, Snoek FJ, Dekker JM, Nijpels G</AU>
<TI>Effects of self-monitoring of glucose in non-insulin treated patients with type 2 diabetes: design of the IN CONTROL-trial</TI>
<SO>BMC.family.practice.</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-09 21:55:25 +0100" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-09 21:55:25 +0100" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-ADA-1999" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of the expert committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2008" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="ADA 2008" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Standards of medical care in diabetes - 2008</TI>
<SO>Diabetes Care</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>S12-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18165335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ADA-2010" MODIFIED="2010-10-21 12:49:53 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ADA 2010" TYPE="JOURNAL_ARTICLE">
<AU>ADA</AU>
<TI>Standards of medical care in diabetes--2010</TI>
<SO>Diabetes Care</SO>
<YR>2010</YR>
<VL>33 Suppl 1</VL>
<NO>1935-5548 (Electronic), 0149-5992 (Linking)</NO>
<PG>S11-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allemann-2009" MODIFIED="2011-02-07 13:15:31 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Allemann 2009" TYPE="JOURNAL_ARTICLE">
<AU>Allemann S, Houriet C, Diem P, Stettler C</AU>
<TI>Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>1473-4877 (Electronic), 0300-7995 (Linking), 12</NO>
<PG>2903-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bode-1999" MODIFIED="2010-10-26 13:15:11 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Bode 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bode BW, Gross TM, Thornton KR, Mastrototaro JJ</AU>
<TI>Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>3</NO>
<PG>183-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradley-1994a" MODIFIED="2010-10-12 10:06:16 +0200" MODIFIED_BY="[Empty name]" NAME="Bradley 1994a" TYPE="BOOK_SECTION">
<AU>Bradley C</AU>
<TI>The Well-Being Questionnaire</TI>
<SO>Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice</SO>
<YR>1994</YR>
<PG>89-109</PG>
<ED>Bradley C</ED>
<PB>Harwood Academic</PB>
<CY>Chur, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradley-1994b" MODIFIED="2010-10-12 10:13:55 +0200" MODIFIED_BY="[Empty name]" NAME="Bradley 1994b" TYPE="BOOK_SECTION">
<AU>Bradley C</AU>
<TI>Diabetes Treatment Satisfaction Questionnaire</TI>
<SO>Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice</SO>
<YR>1994</YR>
<PG>111-32</PG>
<ED>Bradley C</ED>
<PB>Harwood Academic</PB>
<CY>Chur</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clar-2010" MODIFIED="2011-02-07 13:15:31 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Clar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Clar C, Barnard K, Cummins E, Royle P, Waugh N</AU>
<TI>Self-monitoring of blood glucose in type 2 diabetes: systematic review</TI>
<SO>Health Technology Assessment Reports</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>1366-5278 (Print), 1366-5278 (Linking), 12</NO>
<PG>1-140</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2005a" MODIFIED="2011-11-07 22:34:54 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Davidson 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Davidson MB</AU>
<TI>Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: response to Welschen et al. and Kleefstra et al</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>0149-5992 (Print), 0149-5992 (Linking), 10</NO>
<PG>2597-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2010" MODIFIED="2011-02-07 13:32:14 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Davidson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Davidson MB</AU>
<TI>Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck</TI>
<SO>Rev Recent Clin Trials</SO>
<YR>2010</YR>
<VL>-</VL>
<NO>1876-1038 (Electronic)</NO>
<PG>-</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DCCT-1993" MODIFIED="2010-10-22 12:34:52 +0200" MODIFIED_BY="[Empty name]" NAME="DCCT 1993" TYPE="JOURNAL_ARTICLE">
<AU>DCCT group</AU>
<TI>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>14</NO>
<PG>977-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farmer-2005" MODIFIED="2011-02-07 13:29:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Farmer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Farmer A, Wade A, French DP, Goyder E, Kinmonth AL, Neil A</AU>
<TI>The DiGEM trial protocol--a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes [ISRCTN47464659]</TI>
<SO>BMC Family Practice</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>1471-2296 (Electronic)</NO>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farmer-2007" MODIFIED="2010-10-20 11:05:17 +0200" MODIFIED_BY="[Empty name]" NAME="Farmer 2007" TYPE="JOURNAL_ARTICLE">
<AU>Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al</AU>
<TI>Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2007</YR>
<VL>335</VL>
<NO>7611</NO>
<PG>132</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farmer-2009" MODIFIED="2011-02-07 13:27:08 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Farmer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, et al</AU>
<TI>Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial</TI>
<SO>Health Technology Assessment</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>15</NO>
<PG>iii-xi, 1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2008" MODIFIED="2011-02-07 13:27:01 +0100" MODIFIED_BY="Gudrun Paletta" NAME="French 2008" TYPE="JOURNAL_ARTICLE">
<AU>French DP, Wade AN, Yudkin P, Neil HAW, Kinmonth AL, Farmer AJ</AU>
<TI>Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial</TI>
<SO>Diabetic Medicine</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1218-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-10-12 10:06:16 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</SO>
<YR>2009</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jansen-2006" MODIFIED="2010-10-26 13:10:17 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Jansen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jansen JP</AU>
<TI>Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>0300-7995 (Print), 4</NO>
<PG>671-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karter-2001" MODIFIED="2010-10-26 13:08:24 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Karter 2001" TYPE="JOURNAL_ARTICLE">
<AU>Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB Jr, Ferrara A, Liu J, et al</AU>
<TI>Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry</TI>
<SO>The American Journal of Medicine</SO>
<YR>2001</YR>
<VL>111</VL>
<NO>0002-9343 (Print), 1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kempf-2008" MODIFIED="2010-10-21 12:48:56 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kempf 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kempf K, Neukirchen W, Martin S, Kolb H</AU>
<TI>Self-monitoring of blood glucose in type 2 diabetes: a new look at published trials</TI>
<SO>Diabetologia</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>0012-186X (Print), 4</NO>
<PG>686-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleefstra-2005" MODIFIED="2010-10-21 12:48:51 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kleefstra 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kleefstra N, Houweling ST, van Ballegooie E, Bilo HJ</AU>
<TI>Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: response to Welschen et al</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>0149-5992 (Print), 0149-5992 (Linking), 10</NO>
<PG>2596-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleefstra-2009" MODIFIED="2010-10-26 13:10:26 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kleefstra 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kleefstra N, Hortensius J, Van Hateren KJJ, Logtenberg SJJ, Houweling ST, Gans ROB, et al</AU>
<TI>Self-monitoring of blood glucose in non insulin-treated type 2 diabetes: An overview</TI>
<SO>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</SO>
<YR>2009</YR>
<VL>2</VL>
<PG>155-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klonoff-2008" MODIFIED="2010-10-26 13:12:08 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Klonoff 2008" TYPE="JOURNAL_ARTICLE">
<AU>Klonoff DC, Bergenstal R, Blonde L, Boren SA, Church TS, Gaffaney J, et al</AU>
<TI>Consensus report of the coalition for clinical research-self-monitoring of blood glucose</TI>
<SO>Journal of Diabetes Science and Technology</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>1932-2968 (Electronic), 1932-2968 (Linking), 6</NO>
<PG>1030-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolb-2010" MODIFIED="2010-10-26 13:13:38 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kolb 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kolb H, Kempf K, Martin S, Stumvoll M, Landgraf R</AU>
<TI>On what evidence-base do we recommend self-monitoring of blood glucose?</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2010</YR>
<VL>87</VL>
<NO>1872-8227 (Electronic), 0168-8227 (Linking), 2</NO>
<PG>150-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-2006" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lau 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I</AU>
<TI>The case of the misleading funnel plot</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leventhal-1980" MODIFIED="2011-02-07 13:26:02 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Leventhal 1980" TYPE="BOOK_SECTION">
<AU>Leventhal H, Meyer D, Nerenz D</AU>
<TI>The common sense representation of illness danger</TI>
<SO>Contributions to medical psychology</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>17-30</PG>
<ED>Rachman S</ED>
<PB>Pergamon Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leventhal-1997" MODIFIED="2010-10-20 15:46:37 +0200" MODIFIED_BY="[Empty name]" NAME="Leventhal 1997" TYPE="BOOK_SECTION">
<AU>Leventhal L, Benyamini Y, Brownlee S, Diefenbach M, Leventhal EL, Patrick-Miller L, et al</AU>
<TI>Illness representations: theoretical foundations</TI>
<SO>Perceptions of health and illness</SO>
<YR>1997</YR>
<PG>19</PG>
<ED>Petrie,K.J.; Weinman,J.</ED>
<PB>Harwood Academic Publisher</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2010-10-21 12:48:40 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al</AU>
<TI>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<NO>1468-5833 (Electronic), 0959-535X (Linking)</NO>
<PG>b2700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAndrew-2007" MODIFIED="2011-02-07 13:25:49 +0100" MODIFIED_BY="Gudrun Paletta" NAME="McAndrew 2007" TYPE="JOURNAL_ARTICLE">
<AU>McAndrew L, Schneider SH, Burns E, Leventhal H</AU>
<TI>Does patient blood glucose monitoring improve diabetes control? A systematic review of the literature</TI>
<SO>Diabetes Educator</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>0145-7217 (Print), 0145-7217 (Linking), 6</NO>
<PG>991-1011</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGeoch-2007" MODIFIED="2010-10-26 13:19:38 +0200" MODIFIED_BY="Gudrun Paletta" NAME="McGeoch 2007" TYPE="JOURNAL_ARTICLE">
<AU>McGeoch G, Derry S, Moore RA</AU>
<TI>Self-monitoring of blood glucose in type-2 diabetes: what is the evidence?</TI>
<SO>Diabetes/metabolism Research and Reviews</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>1520-7552 (Print), 6</NO>
<PG>423-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntosh-2010" MODIFIED="2010-10-21 12:46:45 +0200" MODIFIED_BY="Gudrun Paletta" NAME="McIntosh 2010" TYPE="JOURNAL_ARTICLE">
<AU>McIntosh B, Yu Changhua, Lal A, Chelak K, Cameron C, Singh SR, et al</AU>
<TI>Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis</TI>
<SO>Open Medicine</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>2</NO>
<PG>online</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nathan-1996" MODIFIED="2010-10-26 13:17:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Nathan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nathan DM, Mckitrick C, Larkin M, Schaffran R, Singer DE</AU>
<TI>Glycemic control in diabetes mellitus: have changes in therapy made a difference?</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>2</NO>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Kane-2009" MODIFIED="2011-02-07 13:15:31 +0100" MODIFIED_BY="Gudrun Paletta" NAME="O'Kane 2009" TYPE="JOURNAL_ARTICLE">
<AU>O'Kane MJ, Pickup J</AU>
<TI>Self-monitoring of blood glucose in diabetes: is it worth it?</TI>
<SO>AACN Clinical Issues</SO>
<YR>2009</YR>
<VL>46</VL>
<NO>1758-1001 (Electronic), 0004-5632 (Linking), Pt 4</NO>
<PG>273-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivarius-2001" MODIFIED="2010-10-21 12:48:11 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Olivarius 2001" TYPE="JOURNAL_ARTICLE">
<AU>Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA</AU>
<TI>Randomised controlled trial of structured personal care of type 2 diabetes mellitus</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>0959-8138 (Print), 7319</NO>
<PG>970-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peel-2007" MODIFIED="2010-10-21 12:48:07 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Peel 2007" TYPE="JOURNAL_ARTICLE">
<AU>Peel E, Douglas M, Lawton J</AU>
<TI>Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients' perspectives</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<NO>1468-5833 (Electronic), 7618</NO>
<PG>493</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piatt-2006" MODIFIED="2010-10-21 12:48:04 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Piatt 2006" TYPE="JOURNAL_ARTICLE">
<AU>Piatt GA, Orchard TJ, Emerson S, Simmons D, Songer TJ, Brooks MM, et al</AU>
<TI>Translating the chronic care model into the community: results from a randomized controlled trial of a multifaceted diabetes care intervention</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>0149-5992 (Print), 4</NO>
<PG>811-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poolsup-2008" MODIFIED="2011-02-07 13:24:08 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Poolsup 2008" TYPE="JOURNAL_ARTICLE">
<AU>Poolsup N, Suksomboon N, Jiamsathit W</AU>
<TI>Systematic review of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients</TI>
<SO>Diabetes Technology and Therapeutics</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>SUPPL. 1</NO>
<PG>S51-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poolsup-2009" MODIFIED="2011-02-07 13:24:36 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Poolsup 2009" TYPE="JOURNAL_ARTICLE">
<AU>Poolsup N, Suksomboon N, Rattanasookchit S</AU>
<TI>Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update</TI>
<SO>Diabetes Technology and Therapeutics</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>1557-8593 (Electronic), 1520-9156 (Linking), 12</NO>
<PG>775-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothman-2005" MODIFIED="2011-02-07 13:15:31 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Rothman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, DeWalt DA, et al</AU>
<TI>A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes</TI>
<SO>American Journal of Medicine</SO>
<YR>2005</YR>
<VL>118</VL>
<NO>0002-9343 (Print), 3</NO>
<PG>276-84</PG>
<PB>Am.J.Med.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarol-2005" MODIFIED="2011-02-07 12:55:16 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Sarol 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB</AU>
<TI>Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004)</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>0300-7995 (Print), 2</NO>
<PG>173-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwedes-2002" MODIFIED="2010-10-20 11:05:27 +0200" MODIFIED_BY="[Empty name]" NAME="Schwedes 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schwedes Ulrich, Siebolds Markus, Mertes Gabriele</AU>
<TI>Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1928-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siebolds-2006" MODIFIED="2010-10-26 13:20:56 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Siebolds 2006" TYPE="JOURNAL_ARTICLE">
<AU>Siebolds M, Gaedeke O, Schwedes U, SMBG Study Group</AU>
<TI>Self-monitoring of blood glucose--psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication</TI>
<SO>Patient education and Counseling</SO>
<YR>2006</YR>
<VL>62</VL>
<NO>1</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simon-2008" MODIFIED="2010-10-20 11:05:33 +0200" MODIFIED_BY="[Empty name]" NAME="Simon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Simon Judit, Gray Alastair, Clarke Philip, Wade Alisha, Neil Andrew, Farmer Andrew</AU>
<TI>Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7654</NO>
<PG>1177-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-St-John-2010" MODIFIED="2011-02-07 13:22:27 +0100" MODIFIED_BY="Gudrun Paletta" NAME="St John 2010" TYPE="JOURNAL_ARTICLE">
<AU>St John A, Davis WA, Price CP, Davis TM</AU>
<TI>The value of self-monitoring of blood glucose: a review of recent evidence</TI>
<SO>Journal of Diabetic Complications</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>1873-460X (Electronic), 1056-8727 (Linking), 2</NO>
<PG>129-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Davey Smith G</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care; Meta-analysis in Context</SO>
<YR>2001</YR>
<PG>189-208</PG>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towfigh-2008" MODIFIED="2011-02-07 13:22:05 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Towfigh 2008" TYPE="JOURNAL_ARTICLE">
<AU>Towfigh A, Romanova M, Weinreb JE, Munjas B, Suttorp MJ, Zhou A, et al</AU>
<TI>Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis</TI>
<SO>American Journal of Managed Care</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>1936-2692 (Electronic), 7</NO>
<PG>468-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-2001" MODIFIED="2010-10-21 12:47:18 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wagner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K, et al</AU>
<TI>Chronic care clinics for diabetes in primary care: a system-wide randomized trial</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>0149-5992 (Print), 4</NO>
<PG>695-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1992" MODIFIED="2010-10-21 12:47:14 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Ware 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE Jr, Sherbourne CD</AU>
<TI>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</TI>
<SO>Med.Care</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>0025-7079 (Print), 0025-7079 (Linking), 6</NO>
<PG>473-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2011-02-02 15:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alberti KM, Zimmet PZ</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>539-53</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-10-21 12:47:10 +0200" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-Welschen-2005a" MODIFIED="2010-10-21 12:47:10 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Welschen 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al</AU>
<TI>Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin</TI>
<SO>Cochrane Database.Syst.Rev.</SO>
<YR>2005</YR>
<VL>issue 2</VL>
<NO>1469-493X, 2</NO>
<PG>CD005060</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Welschen-2005b" MODIFIED="2010-10-21 12:47:07 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Welschen 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al</AU>
<TI>Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>0149-5992, 6</NO>
<PG>1510-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-10-20 11:05:33 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-30 15:47:39 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-30 15:47:39 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim of study">
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1990">
<CHAR_METHODS MODIFIED="2009-11-26 16:46:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. Randomised in groups of 10 with the use of a computer-generated table of random numbers.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Number of participants: 54</P>
<P>Inclusion criteria:</P>
<UL>
<LI>type 2 diabetes, not treated with insulin;</LI>
<LI>fasting plasma glucose level &gt; 8.8 and &lt;22 mM;</LI>
<LI>no history of ketoacidosis;</LI>
<LI>current treatment with diet alone or diet and an oral hypoglycaemic agent;</LI>
<LI>no active infection or serious illness;</LI>
<LI>no physical or mental handicap precluding participation in the treatment program (determined by the Cognitive-capacity screening examination and a physical-abilities questionnaire).</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>SMBG devices used previously;</LI>
<LI>serum creatinine level &gt; 177 mM.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 58.2 ± 9.7</LI>
<LI>SMUG: 57.9 ± 10.7</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 6.8 ± 6.5</LI>
<LI>SMUG: 9.0 ± 10.3</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:19 +0100" MODIFIED_BY="Gudrun Paletta">
<OL>
<LI>SMBG group (n = 27) and standardized treatment program including diet and exercise counselling. At least 36 blood glucose determinations/month, before each meal every other day.</LI>
<LI>SMUG group (n = 27) and standardized treatment program including diet and exercise counselling. At least 36 urine glucose determinations/month, before each meal every other day.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 21:46:23 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Fasting plasma glucose, obtained monthly by glucose oxidase method.</LI>
<LI>Glycosylated haemoglobin, obtained initially and at 3 and 6 months by affinity chromatography.</LI>
<LI>Total cholesterol and high-density lipoprotein cholesterol, measured by spectrophotometer with Beckman Dri-STAT reagents.</LI>
<LI>Weight, obtained monthly, patients fully clothed.</LI>
<LI>Respective costs of the two monitoring techniques.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-26 16:46:17 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-11-02 21:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: the Veterans Administration Health Services Research and Development Service and additional funds from the A.W. Mellon Foundation<BR/>
</P>
<P>Publication status: Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 21:27:27 +0100" MODIFIED_BY="[Empty name]">
<P>"To compare the relative efficacy and cost of self-monitoring of blood glucose with routine urine testing as part of a standardized treatment programme in the management of patients with type 2 non insulin dependent diabetes, not treated with insulin".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barnett-2008">
<CHAR_METHODS MODIFIED="2009-11-17 14:20:34 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised parallel-group trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:36 +0100" MODIFIED_BY="[Empty name]">
<P>Countries: Czech Republic, Hungary, Iran, Malaysia, Poland, Slovakia, Turkey</P>
<P>Number of participants: 610</P>
<P>Inclusion criteria:</P>
<UL>
<LI>patients with type 2 diabetes;</LI>
<LI>40 to 80 years of age;</LI>
<LI>treatment with diet alone &#8805; 3 months, diet and biguanides or alpha-glucosidase inhibitor or diet plus any inulin secretagogue for &lt; 12 months;</LI>
<LI>HbA<SUB>1c</SUB> between 7 and 10%.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>current management with SMBG;</LI>
<LI>lifestyle or concurrent condition (medical or psychiatric) that could interfere with end-point evaluation (serious anaemia, haemoglobinopathy and haemolysis) or ability to comply with study procedures including SMBG and diary keeping;</LI>
<LI>abnormalities on laboratory screening including creatinine clearance &lt; 20 ml/min and/or serum creatinine &gt; 140 mM and alanine aminotransferase or aspirate aminotransferase more than 3 times the upper limit of normal range;</LI>
<LI>therapy with systemic glucocorticoids;</LI>
<LI>known contraindication to gliclazide;</LI>
<LI>know drug or alcohol dependence;</LI>
<LI>pregnancy, lactation or planned pregnancy.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 56.1 ± 9.1</LI>
<LI>Control: 55.9 ± 9.3</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 2.8 ± 3.7</LI>
<LI>Control: 2.8 ± 4.5</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:21 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>SMBG (n = 311): measurement of glucose levels 2 days a week (one working and one non-working day) at 5 times (before each meal (breakfast, lunch, dinner), 2 h after main meal and before bedtime). Once per month postprandial measurements after each of the three meals. Instructions in SMBG included information on how to use the glucose metre, how to check it was working, when to take measurements, how to record them in a patient diary and what to do in the event of asymptomatic hypoglycaemia (measured glucose &lt; 3 mmol/L without symptoms suggestive of hypoglycaemia) or SMBG-confirmed glycaemia.</LI>
<LI>Control (n = 299): all randomised patients received diet and lifestyle advice, reinforced at each clinic visit. Oral antidiabetic agent therapy (gliclazide MR) was standard for all patients. Those on insulin secretagogue were transformed to gliclazide MR. A diary was used to record symptoms of hypoglycaemia, actions taken.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 21:47:32 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<OL>
<LI>&#916; HbA<SUB>1c</SUB> between groups at week 27.</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Mean changes from baseline HbA<SUB>1c</SUB> and FPG at week 27.</LI>
<LI>Gliclazide MR dose.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-17 12:54:41 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of intervention: 27 weeks.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-17 13:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Unristricted grant from Servier<BR/>
</P>
<P>Publication status:Peer reviewed journal<BR/>
</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 21:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>"First, to evaluate the contribution of SMBG in the management of patients with type 2 diabetes, with an emphasis on glycaemic control. Second, to compare the efficacy, tolerability and acceptability of an identical once daily gliclazide modified release (MR) based regimen in patients with type 2 diabetes with and without SMBG".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-11-17 13:41:56 +0100" MODIFIED_BY="[Empty name]">
<P>DYNAMIC-1 study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2005">
<CHAR_METHODS MODIFIED="2009-11-18 16:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 22:05:18 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Number of participants: 89</P>
<P>Inclusion criteria:</P>
<UL>
<LI>patients not taking insulin.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 49.8 ± 11.2</LI>
<LI>Control: 50.9 ± 11.0</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 5.5 ± 4.7</LI>
<LI>Control: 5.8 ± 5.8</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:23 +0100" MODIFIED_BY="Gudrun Paletta">
<OL>
<LI>SMBG (n = 43): measurement of glucose levels before and between one and two hours after eating meals six days a week.</LI>
<LI>Control (n = 45): patients in both groups were scheduled to meet with dietician five times; at randomisation and 2, 4, 8 and 12 weeks later. Dietician used glucose levels and meal descriptions in nutritional counselling. A nurse followed detailed algorithms to make therapeutic decisions.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 19:42:43 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>HbA<SUB>1c</SUB>, measured at entry to the study and every two months</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-18 16:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-11-02 21:40:29 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding:<BR/>
</P>
<P>Publication status: Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-08 19:42:43 +0100" MODIFIED_BY="[Empty name]">
<P>"To answer the important question of whether self monitoring of blood glucose concentrations improves HbA<SUB>1c</SUB> responses" through a blinded and randomised study.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DiGEM-trial-2007">
<CHAR_METHODS MODIFIED="2009-11-18 16:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>Three arm, open, parallel group randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 21:49:10 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom</P>
<P>Number of participants: 453</P>
<P>Inclusion criteria:</P>
<UL>
<LI>patients with type 2 diabetes;</LI>
<LI>25 years of age or more at diagnosis;</LI>
<LI>managed with diet or oral hypoglycaemic agents alone;</LI>
<LI>HbA<SUB>1c</SUB> level &#8805;6.2% at the assessment visit;</LI>
<LI>independent in activities of daily living.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>use of blood glucose monitor twice a week or more often over the previous three months;</LI>
<LI>current use of insulin;</LI>
<LI>co-morbidity or limited life expectancy that would make intensive glycaemic control inappropriate;</LI>
<LI>inability to follow trial procedures.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>Less intensive SMBG: 65.2 ± 10.6</LI>
<LI>More intensive SMBG: 65.6 ± 9.9</LI>
<LI>Control: 66.3 ± 10.2</LI>
</UL>
<P>Diabetes duration (median years (q1-q3)):</P>
<UL>
<LI>Less intensive SMBG: 3 (2-7)</LI>
<LI>More intensive SMBG: 3 (2-6)</LI>
<LI>Control: 3 (2-6)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:25 +0100" MODIFIED_BY="Gudrun Paletta">
<OL>
<LI>Less intensive SMBG (n = 150): Self testing group performing blood glucose self testing 2 days a week, 3 tests daily (1 after fasting, 2 before meal or 2 hours after meal) with instruction to aim for 4-6mmol/Lfasting and 6-8 mmol/L after meals. Results were interpreted by the study nurse.</LI>
<LI>More intensive SMBG (n = 151): Self monitoring group who, in addition to self testing group, are provided with training and support in interpreting and applying the results of blood glucose readings to enhance motivation and maintain adherence to diet physical activity and medication regimens.</LI>
<LI>Control (n = 152): Standardised usual care and three monthly HbA<SUB>1c</SUB> measurements.</LI>
</OL>
<P>All patients received the use of goal setting and review techniques. A diary was used to record self care goals and strategies for achieving them.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 21:49:48 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<OL>
<LI>HbA<SUB>1c</SUB> level at 12 months</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Blood pressure.</LI>
<LI>Weight.</LI>
<LI>Total cholesterol level.</LI>
<LI>Ratio of total cholesterol to high density lipoprotein cholesterol.</LI>
<LI>Body mass index.</LI>
<LI>Well-being (WBQ-12).</LI>
<LI>Self-reported smoking status, dietary intake and physical activity (DSCAQ).</LI>
<LI>Medication adherence (MARS).</LI>
<LI>Patient treatment satisfaction (DTSQ).</LI>
<LI>Beliefs about diabetes and its management (IPQ).</LI>
<LI>Beliefs about medicine (BMQ).</LI>
<LI>Beliefs about physical activity, eating and (using) blood glucose monitoring.</LI>
<LI>Quality adjusted life years (EQ5D).</LI>
<LI>Healthcare costs.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-18 16:01:23 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of intervention: 12 months.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-18 16:01:23 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: National Health Service and the National Institute for Health Research health technology assessment programme.<BR/>
</P>
<P>Publication status:Peer reviewed journal<BR/>
</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 21:41:57 +0100" MODIFIED_BY="[Empty name]">
<P>"To test whether elf monitoring of blood glucose with or without instruction in incorporating findings into self care, compared with standardised usual care can improve glycaemic control in patients with non-insulin treated diabetes".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-11-09 21:05:51 +0100" MODIFIED_BY="[Empty name]">
<P>Diabetes Glycaemic Education Monitoring (DiGEM) trial</P>
<P>Data was extracted from four manuscripts: <LINK REF="REF-Farmer-2007" TYPE="REFERENCE">Farmer 2007</LINK>, <I>BMJ</I>; <LINK REF="REF-French-2008" TYPE="REFERENCE">French 2008</LINK>, <I>Diabetic Medicine</I>; <LINK REF="REF-Simon-2008" TYPE="REFERENCE">Simon 2008</LINK>, <I>BMJ</I>; <LINK REF="REF-Farmer-2009" TYPE="REFERENCE">Farmer 2009</LINK>, <I>Health Technology Assessment</I>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dur_x00e1_n-2010">
<CHAR_METHODS MODIFIED="2011-02-03 16:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>a prospective randomised clinic-based interventional study with parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Number of participants: 195</P>
<P>Inclusion criteria:</P>
<UL>
<LI>newly diagnosed type 2 diabetes after two fasting glucose plasma values &gt; 125 mg dL;</LI>
<LI>age 18 to 80 years;</LI>
<LI>&lt; 6 months from the first fasting plasma glucose value &gt; 126 mg dL;</LI>
<LI>absence of ketones in two first morning urine samples.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>any fasting glucose levels &gt; 125 mg dL in previous 12 months;</LI>
<LI>HbA<SUB>1c</SUB> levels &gt; 8% at diagnosis;</LI>
<LI>unable to perform SMBG;</LI>
<LI>life threatening disease.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 62.5 ± 10.4</LI>
<LI>Control: 64.7 ± 9.6</LI>
</UL>
<P>Diabetes duration (years):</P>
<UL>
<LI>SMBG: 0</LI>
<LI>Control: 0</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:27 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>SMBG based step-by-step treatment (n = 99): lifestyle intervention that used SMBG as an educational tool to adhere to lifestyle changes, as well as a therapeutic tool to apply step-by-step pharmacological treatment.</LI>
<LI>HbA<SUB>1c</SUB> based step-by-step treatment (n = 62): standard treatment based on HbA<SUB>1c</SUB> values without SMBG.</LI>
</OL>
<P>All patients were treated with 850 mg metformin (half a tablet at breakfast, nothing at lunch and another half tablet at dinner; ½&#8211;0&#8211;½). Lifestyle interventions were similar for all patients and were developed after a 2h session for each patient individually and were reinforced at each follow-up visit.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 22:09:10 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Primary outcome:</P>
<OL>
<LI>Remission and regression rate of type 2 diabetes.</LI>
</OL>
<P>Secondary outcomes:</P>
<P>changes in</P>
<OL>
<LI>HbA<SUB>1c;</SUB>
</LI>
<LI>fasting insulin;</LI>
<LI>homeostasis model assessment of insulin resistance (HOMA-IR);</LI>
<LI>total cholesterol (high-density lipoprotein (HDL) and low density lipoprotein (LDL));</LI>
<LI>triglycerides;</LI>
<LI>apolipoprotein B;</LI>
<LI>body weight;</LI>
<LI>waist circumference;</LI>
<LI>blood pressure;</LI>
<LI>adherence to the suggested lifestyle changes.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-10-11 17:14:50 +0200" MODIFIED_BY="[Empty name]">
<P>Duration: 12 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-10-11 17:16:14 +0200" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Ministerio de Sanidad from Spain (Fondos de Cohesion 2008)<BR/>
</P>
<P>Publication status:Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 21:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>To investigate the hypothesis that " in combination with simple algorithms that modify the doses of glucose-lowering medication, SMBG can prevent acute complications, such as hypoglycaemia as well as alerting the patient when specialist help and support are needed".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-11-02 21:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>St. Carlos study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:30 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Fontbonne-1989">
<CHAR_METHODS MODIFIED="2009-11-18 16:33:23 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.<BR/>Randomisation procedure stratified by clinic.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:40 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Country: France<BR/>Number of participants: 208</P>
<P>Inclusion criteria:</P>
<UL>
<LI>non-insulin dependent diabetes patients;</LI>
<LI>treated with diet and/or oral hypoglycaemic agents;</LI>
<LI>poorly controlled at entry to trial, FPG &gt; 8.8 mmol/L, or postprandial blood glucose level &gt; 11.1 mmol/L, 3 times within the preceding year;</LI>
<LI>presence of at least occasional glucosuria (renal glucose threshold &lt; 11 mmol/L) was to be ascertained;</LI>
<LI>no rapidly progressing diabetic complications, no severe illness;</LI>
<LI>at least 3 years duration of diabetes;</LI>
<LI>first contact to the diabetes clinic at least 6 months before entry to trail;</LI>
<LI>having attended to at least 2 outpatient visits since their first contact;</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 54.5 ± 10.7</LI>
<LI>Urine glucose: 54.9 ± 10.2</LI>
<LI>Control: 56.3 ± 9.</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 12.2 ± 6.6</LI>
<LI>Urine glucose: 13.3 ± 6.8</LI>
<LI>Control: 12.7 ± 0.8</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>SMUG: self-urine glucose monitoring, twice every other day (n = 54).</LI>
<LI>SMBG: self blood glucose monitoring, twice every other day (n = 56).</LI>
<LI>Control: regular HbA<SUB>1c</SUB> determinations every two months, no self-monitoring (n = 54).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 19:42:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Weight, measured every two months.</LI>
<LI>HbA<SUB>1c</SUB> assayed by low-pressure liquid chromatography, measured every 2 months.</LI>
<LI>Number of reactive strips reported in a diary, recorded every two months.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-18 16:33:28 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-26 16:55:49 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Ames Division, Miles Laboratories.<BR/>
</P>
<P>Publication status:Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:01:50 +0100" MODIFIED_BY="[Empty name]">
<P>"To  determine if the use of self glucose monitoring could help this rather common type of non insulin-treated diabetic patients (poorly controlled)  in achieving improved metabolic control, by increasing their disease awareness and hence their compliance with treatment, as well as by giving the physician new evidence on which to adjust diet and oral treatment".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:46:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franciosi-2011">
<CHAR_METHODS MODIFIED="2011-11-08 22:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled pilot study </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 22:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Number of participants: 62</P>
<P>Inclusion criteria:</P>
<UL>
<LI>patients with type 2 diabetes;</LI>
<LI>age 45 to 75 years;</LI>
<LI>HbA<SUB>1c</SUB> between 7% and 9% ;</LI>
<LI>treated with oral hypoglycaemic agent monotherapy;</LI>
<LI>no experience in SMBG in previous 12 months;</LI>
<LI>first time in diabetes clinic.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>incapable of performing SMBG;</LI>
<LI>requiring insulin or multiple oral hypoglycaemic agent therapy;</LI>
<LI>requirement of regular use of SMBG;</LI>
<LI>diabetes care not exclusive managed by diabetes clinic.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 48.9 ± 0.5</LI>
<LI>Control: 48.7 ± 0.6</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 3.4 ±3.5</LI>
<LI>Control: 3.2 ± 4.4</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 22:42:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Standardized Specific education addressing how to perform SMBG, how to modify diet and level of physical activity according to blood glucose levels and the actions to undertake in case of abnormal values.</LI>
<LI>Control group receiving standard counselling with focus on diet and lifestyle.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-30 15:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<OL>
<LI>Change in HbA<SUB>1c</SUB>, between groups after 6 months.</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Percentage of patients reaching HbA<SUB>1c</SUB> target (&lt; 7.0%) .</LI>
<LI>Percentage of patients requiring therapy modifications.</LI>
<LI>Changes in body weight.</LI>
<LI>Changes in lipid profile.</LI>
<LI>Changes in blood pressure values.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 22:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-11-08 22:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Unconditionally support by LifeScan Inc. Clinical Research Management and Monitoring<BR/>
</P>
<P>Publication status:Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>"To evaluate the feasibility and efficacy of a self-monitoring disease management strategy in patients with Type 2 diabetes on oral hypoglycaemic agent therapy".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-11-08 17:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>ROSES-study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guerci-2003">
<CHAR_METHODS MODIFIED="2009-11-18 16:33:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:42 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number of participants: 689</P>
<P>Inclusion criteria:</P>
<UL>
<LI>type 2 diabetes with a known duration over 1 year;</LI>
<LI>insufficiently controlled with oral antidiabetic treatment (HbA<SUB>1c</SUB> &gt; 7.5 and &lt; 11.0%);</LI>
<LI>age between 40 and 75 years;</LI>
<LI>not previously treated with insulin;</LI>
<LI>not requiring insulin at inclusion;</LI>
<LI>not previously received SMBG;</LI>
<LI>able to carry out SMBG.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>type 1 diabetes, MODY and secondary diabetes;</LI>
<LI>recent weight loss of more than 3 kg during the last 3 months;</LI>
<LI>impending complications of diabetes;</LI>
<LI>pregnant women;</LI>
<LI>unable to read or write;</LI>
<LI>uncooperative.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 60.9 ± 9.4</LI>
<LI>Control: 62.2 ± 9.1</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 7.7 ± 6.3</LI>
<LI>Control: 8.4 ± 6.6</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:32 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>SMBG (n = 345) in addition to the conventional laboratory work-up. Education on weight loss and physical activity; treatment alterations by physician. Measurements at least 6 times per week, on 3 different days, including weekends.</LI>
<LI>Control (n = 344): conventional laboratory work-up based solely on laboratory measurement of HbA<SUB>1c</SUB> every 12 weeks. Education on weight loss and physical activity; treatment alterations by physician.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 21:54:11 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Weight, systolic and diastolic blood pressure at baseline, 3 and 6 months.</LI>
<LI>HbA<SUB>1c</SUB>, determined using the DCA analyser and blood glucose. Measured at baseline, 3 and 6 months.</LI>
<LI>Number of hypoglycaemic episodes.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-18 16:33:44 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-26 17:17:30 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding:<BR/>
</P>
<P>Publication status:Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:10:57 +0100" MODIFIED_BY="[Empty name]">
<P>"To compare, over a 6-month period, metabolic control in patients with poorly controlled type 2 diabetes, managed wither with usual recommendations alone (conventional assessment group) or combined with self-monitoring of blood glucose (SMBG group)".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-11-08 17:37:01 +0100" MODIFIED_BY="[Empty name]">
<P>ASIA-study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kleefstra-2010">
<CHAR_METHODS MODIFIED="2009-11-17 16:07:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 22:10:11 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands</P>
<P>Number of participants: 41</P>
<P>Inclusion criteria:</P>
<UL>
<LI>type 2 diabetes patients from the ZODIAC shared care project;</LI>
<LI>18 to 70 years of age;</LI>
<LI>HbA<SUB>1c</SUB> between 7 and 8.5% at current annual check-up and inclusion;</LI>
<LI>use of 1 or 2 different oral blood glucose lowering agents;</LI>
<LI>oral blood glucose lowering agents were not changed during the past 3 months;</LI>
<LI>no use of insulin;</LI>
<LI>no use of devices for SMBG at the start of the study or in the previous 6 months;</LI>
<LI>sufficient knowledge of the Dutch language to understand the requirements of the study;</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 59.5 ± 8.0</LI>
<LI>Control: 58.7 ± 7.8</LI>
</UL>
<P>Diabetes duration (median years (q1-q3)):</P>
<UL>
<LI>SMBG: 5.0 (4.0 - 7.0)</LI>
<LI>Control: 8.0 (3.8 - 11.3)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:35 +0100" MODIFIED_BY="Gudrun Paletta">
<OL>
<LI>SMBG (n = 22): SMBG with no further education except for handling the device and knowing which glucose values were considered normal or acceptable (fasting 4-8 mmol/L and post-prandial 4-10 mmol/L) and which abnormal.</LI>
<LI>Control (n = 18): Usual care provided by their own health care giver. No other instructions were given, except for the explicit request not to use any form of SMBG during the study.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 22:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<OL>
<LI>&#916; HbA<SUB>1c</SUB> between groups.</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Differences between groups in Health Related Quality of Life measures (SF-36; WHO-5).</LI>
<LI>Diabetes related complaints (DSC-r).</LI>
<LI>Treatment satisfaction (DTSQ).</LI>
<LI>Cumulative incidence of (necessity to start) insulin therapy.</LI>
<LI>Bodyweight.</LI>
<LI>Body mass index.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-17 16:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of intervention: 12 months.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-18 12:23:37 +0200" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Roche Diagnostics<BR/>
</P>
<P>Publication status: Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:13:55 +0100" MODIFIED_BY="[Empty name]">
<P>"To investigate the effects of SMBG on glycaemic control, quality of life and treatment satisfaction in patients with T2DM not using insulin, who are in persistent moderate glycaemic control".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-11-02 22:13:08 +0100" MODIFIED_BY="[Empty name]">
<P>ZODIAC study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muchmore-1994">
<CHAR_METHODS MODIFIED="2009-11-18 16:34:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 22:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Number of participants: 23</P>
<P>Inclusion criteria:</P>
<UL>
<LI>obese participants (BMI 27.5-44 kg/m2);</LI>
<LI>aged 40 to 75 years;</LI>
<LI>history of at least 1 year of non-insulin requiring diabetes;</LI>
<LI>treated either with diet alone or diet plus oral sulphonylurea hypoglycaemic agents;</LI>
<LI>HbA<SUB>1c</SUB> within the range of 9.5%-13.5%;</LI>
<LI>ability to comply with the protocol;</LI>
<LI>absence of serious underlying medical or psychiatric illness, drug abuse or alcohol.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>participants who had performed SMBG within the previous 3 months;</LI>
<LI>participants who have previously been instructed in dietary carbohydrate counting.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 57.3 ± 8.0</LI>
<LI>Control: 60.1 ± 7.3</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 5.7 ± 4.8</LI>
<LI>Control: 5.2 ± 4.6</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>Four groups were formed over a period of 6 months, blocking for variables of weight, HbA<SUB>1c</SUB>, diet vs. oral agent use, and sex.</P>
<P>Weeks -8 to 0: identical run-in for all 4 groups: weekly behavioural weight control program + counselling by diabetes nurse educator + session with dietician. Follow-up session educator at weeks 1, 3 and 24 and dietician at weeks 1 and 3.</P>
<P>Week 0: randomly assignment to control or SMBG interventions.</P>
<OL>
<LI>Intervention (n = 12): individual and group teaching on CarboHydrate counting and SMBG, measured 6 times daily for 4 weeks. Reduced to pre- and postprandial testing of a single meal per day for weeks 4-20. Beyond week 20, individual's election and expense.</LI>
<LI>Control (n = 11): identical amount of attention, focus on general principles of diabetes nutrition.Groups continued to meet weekly for weeks 0-4 and then every 4 weeks for weeks 4-20.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 19:43:02 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>HbA<SUB>1c</SUB>, measured at weeks -8, 0, 16, 28 and 44.</LI>
<LI>Body weight measured at every patient encounter.</LI>
<LI>Diabetes Quality of Life Inventory at weeks 0, 24 and 44.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-18 16:34:23 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 28 weeks (-8, 0-20 intervention) and follow-up till 44 weeks</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-11-02 22:17:23 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Department of Academic Affairs, Scripps Clinic and Research Foundation<BR/>
</P>
<P>Publication status: Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:17:15 +0100" MODIFIED_BY="[Empty name]">
<P>"To test the hypothesis that measuring and linking carbohydrate intake to incremental postprandial SMBG results would allow to modify specific, proximate behaviours in the management of type 2 diabetic patients".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Kane-2008">
<CHAR_METHODS MODIFIED="2009-11-17 17:20:46 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Norhtern Ireland</P>
<P>Number of participants: 195</P>
<P>Inclusion criteria:</P>
<UL>
<LI>Patients with newly diagnosed type 2 diabetes;</LI>
<LI>&lt; 70 years of age.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>secondary diabetes;</LI>
<LI>use of insulin;</LI>
<LI>previous use of SMBG;</LI>
<LI>major illness within the previous six months;</LI>
<LI>chronic kidney disease;</LI>
<LI>chronic liver disease;</LI>
<LI>alcohol misuse.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 57.7 ± 11.04</LI>
<LI>Control: 60.9 ± 11.5</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 0</LI>
<LI>Control: 0</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>SMBG (n = 96): SMBG and ongoing advice and support in interpretation of and response to high or low readings.</LI>
<LI>Control (n = 88): no SMBG.</LI>
</OL>
<P>All patients received a structured education programme with nurse practitioners, dieticians, podiatrist and medical staff at 3-monthly intervals and a treatment algorithm for dietary and pharmacological management of glycaemia based on HbA<SUB>1c</SUB> targets. At each visit aspects of diabetes care including glycaemic control (HbA<SUB>1c</SUB>) were reviewed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 22:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<OL>
<LI>&#916; HbA<SUB>1c</SUB> between groups.</LI>
<LI>Psychological indices (DTSQ, modified diabetes attitude scale, WBQ).</LI>
<LI>incidence of hypoglycaemia.</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>&#916; body mass index between groups.</LI>
<LI>Use of oral hypoglycaemic drugs.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-17 17:51:10 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of intervention: 12 months.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-11-02 22:18:50 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Northern Ireland research and development office<BR/>
</P>
<P>Publication status: Peer reviewed journal<BR/>
</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:19:48 +0100" MODIFIED_BY="[Empty name]">
<P>"To investigate the effect of self monitoring on glycaemic control and attitudes and satisfaction with treatment in patients with newly diagnosed type 2 diabetes".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-11-17 17:52:02 +0100" MODIFIED_BY="[Empty name]">
<P>ESMON study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-30 15:47:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SMBG-study-group-2002">
<CHAR_METHODS MODIFIED="2009-11-18 16:07:13 +0100" MODIFIED_BY="[Empty name]">
<P>Multicenter, randomised controlled design<BR/>Randomised in blocks of eight.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany and Austria<BR/>Number of participants: 250 patients.</P>
<P>Inclusion criteria:</P>
<UL>
<LI>type 2 diabetes patients;</LI>
<LI>body mass index &gt; 25 kg/m2;</LI>
<LI>HbA<SUB>1c</SUB> values between 7.5 and 10%;</LI>
<LI>treated either with diet alone or diet in combination with sulphonylureas or metformin;</LI>
<LI>age between 45 and 70 years;</LI>
<LI>diabetes known for at least 3 months;</LI>
<LI>participation in a diabetes educational program within the previous 2 years.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>incapable of maintaining an eating diary and of documenting their state of well-being;</LI>
<LI>sensomotor disturbances;</LI>
<LI>used regular SMBG during the 6 months before the start of the study;</LI>
<LI>participated in another clinical trial within 30 days before the start of the study-pregnant or lactating females or without a safe contraception method;</LI>
<LI>treatment with other antidiabetic agents such as insulin or with nonselective ß-blockers, glucocorticoids, amphetamines, or anabolic agents;</LI>
<LI>diet reduction during course of the study (&lt; 1,000 kcal/day);</LI>
<LI>serum creatinine &gt; 3 mg/dl-serum transaminases &gt; 50 units/L;</LI>
<LI>serious underlying medical or psychiatric disorders or drug or alcohol abuse;</LI>
<LI>use of acarbose.</LI>
</UL>
<P>Mean age (years ± SD):</P>
<UL>
<LI>SMBG: 58.7 ± 7.6</LI>
<LI>Control: 60.5 ± 6.6</LI>
</UL>
<P>Diabetes duration (years ± SD):</P>
<UL>
<LI>SMBG: 5.5 ± 4.8</LI>
<LI>Control: 5.2 ± 3.9</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-30 15:47:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>SMBG (n = 113): Measurements of blood glucose 6 times on 2 days per week and recordings of values obtained in a diary for blood glucose data and documentation of eating habits and state of well-being. Continuing of using the glucometer during the follow-up period.</LI>
<LI>Control (n = 110): non standardized counselling with a focus on their diet and lifestyle.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 22:03:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>HbA<SUB>1c</SUB>, determined using the DCA 2000 analyser.</LI>
<LI>Body weight.</LI>
<LI>Lipids and micro albumin.</LI>
<LI>Well-being and treatment satisfaction, measured by the Patient Well-being Questionnaire and the Diabetes Treatment Satisfaction Questionnaire.</LI>
</OL>
<P>Laboratory parameters and body weight were assessed at randomisation and at 8, 16 and 24 weeks. Questionnaires were completed at randomisation, 24 weeks and follow-up. HbA<SUB>1c</SUB>, body weight, SMBG acceptance, treatment satisfaction, and well-being were also assessed during two visits in the 6-month follow-up period.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-18 16:07:07 +0100" MODIFIED_BY="[Empty name]">
<P>Duration: 6 months and 6 months follow-up</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-18 16:09:37 +0100" MODIFIED_BY="[Empty name]">
<P>Language of publication: English</P>
<P>Funding: Unrestricted grant from Bayer AG &amp; Bayer Vital GmbH<BR/>
</P>
<P>Publication status:Peer reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-11-02 22:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>"To investigate the effect of meal-related SMBG on diabetes control in non-insulin-treated type 2 diabetic patients on a biometrical basis".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-11-08 22:12:44 +0100" MODIFIED_BY="[Empty name]">
<P>SMBG study group</P>
<P>Data was extracted from 2 manuscripts: <LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK>, <I>Diabetes Care</I>; <LINK REF="REF-Siebolds-2006" TYPE="REFERENCE">Siebolds 2006</LINK>, <I>Patient Education and Counseling</I>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<I>SMBG = Self-Monitoring of Blood Glucose; SMUG = Self-Monitoring of Urine Glucose </I>
</P>
<P>
<I>DCCT= Diabetes Control and Complications Trial</I>
</P>
<P>
<I>BMQ: Beliefs about Medicine Questionnaire; DSC-r: Diabetes Symptom Checklist; DSCAQ: Diabetes Self-care Activities Questionnaire; DTSQ: Diabetes Treatment Satisfaction Questionnaire; DQOL: Diabetes Quality Of Life Inventory; EQ5D: EuroQol-5D; MARS: Medication Adherence Reporting Scale; SF-36: Short-Form 36; WBQ-12/22: Well Being Questionnaire-12/22; WHO-5: World Health Organization-5.</I>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-11-30 12:59:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:38:48 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Abdelgadir-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:38:48 +0200" MODIFIED_BY="Bernd Richter">
<P>not randomised, also included patients with type 1 diabetes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:38:51 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Atsumi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:38:51 +0200" MODIFIED_BY="Bernd Richter">
<P>abstract, no detailed information could be retrieved</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 09:50:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bajkowska_x002d_Fiedziukiewicz-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 09:50:49 +0200" MODIFIED_BY="[Empty name]">
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-29 16:44:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chidum-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-29 16:44:23 +0200" MODIFIED_BY="[Empty name]">
<P>after 3 months follow-up, no data on control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 12:59:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cho-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 12:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>intervention group received an Internet based SMBG system. SMBG not the main intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-29 16:15:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-29 16:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>abstract that has been identified as an already included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:38:59 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Drouin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:38:59 +0200" MODIFIED_BY="Bernd Richter">
<P>abstract that has been identified as an already included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 09:53:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franciosi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 09:53:06 +0200" MODIFIED_BY="[Empty name]">
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 09:53:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallego-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 09:53:15 +0200" MODIFIED_BY="[Empty name]">
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 12:59:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffmann-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 12:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-21 12:38:44 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Johnson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-21 12:38:44 +0200" MODIFIED_BY="Gudrun Paletta">
<P>control group is using SMBG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 21:46:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 21:46:22 +0100" MODIFIED_BY="[Empty name]">
<P>non-relevant study design (letter to the editor)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:39:39 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kwon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:39:39 +0200" MODIFIED_BY="Bernd Richter">
<P>both groups received SMBG; the intervention group received an Internet-based SMBG system and the control group just the SMBG. SMBG was not the main intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:39:42 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Laffel-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:39:42 +0200" MODIFIED_BY="Bernd Richter">
<P>insulin treated patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 09:56:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lecomte-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 09:56:32 +0200" MODIFIED_BY="[Empty name]">
<P>not randomised, also included patients with type 1 diabetes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 21:52:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lim-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 21:52:34 +0100" MODIFIED_BY="[Empty name]">
<P>included insulin treated patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-29 16:16:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-29 16:16:44 +0100" MODIFIED_BY="[Empty name]">
<P>both intervention and control used SMBG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 09:55:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moreland-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 09:55:54 +0200" MODIFIED_BY="[Empty name]">
<P>also included patients with type 1 diabetes and insulin users</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:39:53 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-O_x0027_Kane-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:39:53 +0200" MODIFIED_BY="Bernd Richter">
<P>abstract that has been identified as an already included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:40:02 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Pignone-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:40:02 +0200" MODIFIED_BY="Bernd Richter">
<P>reprint of already included trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 21:48:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polonsky-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 21:48:17 +0100" MODIFIED_BY="[Empty name]">
<P>control group uses SMBG also</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-06 12:40:18 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Scherbaum-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-06 12:40:18 +0200" MODIFIED_BY="Bernd Richter">
<P>control group uses SMBG also</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-29 16:17:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiraiwa-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-29 16:17:01 +0100" MODIFIED_BY="[Empty name]">
<P>detailed information on trial could not be retrieved (letter to the editor)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 09:57:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tengblad-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 09:57:59 +0200" MODIFIED_BY="[Empty name]">
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-21 12:38:58 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Wen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-21 12:38:58 +0200" MODIFIED_BY="Gudrun Paletta">
<P>not randomised, no control group, SMBG not the prime intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 10:02:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wysocki-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 10:02:20 +0200" MODIFIED_BY="[Empty name]">
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-07-30 18:22:43 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-11-30 15:46:17 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-11-30 15:46:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergenstal-2005">
<CHAR_STUDY_NAME MODIFIED="2010-10-20 10:27:15 +0200" MODIFIED_BY="[Empty name]">
<P>Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-11-08 09:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: Randomised, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-30 15:46:17 +0100" MODIFIED_BY="[Empty name]">
<P>Type 2 diabetes patients with the following criteria:</P>
<UL>
<LI>Treatment with diet and exercise alone or with the addition of 1 or 2 oral agent</LI>
<LI>Enrolled in Type 2 BASICS program</LI>
<LI>A1c between 7.0 and 11%, inclusive</LI>
<LI>Able to understand spoken English</LI>
</UL>
<P>Exclusion Criteria:</P>
<UL>
<LI>Insulin therapy</LI>
<LI>Unable/unwilling to perform SMBG</LI>
<LI>Participating in another research study</LI>
<LI>Currently performing SMBG &gt; 3 times/week</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-20 10:31:09 +0200" MODIFIED_BY="[Empty name]">
<P>Behavioral: frequency of self monitoring blood glucose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 19:43:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: HbA<SUB>1c</SUB> 2 years</P>
<P>Secondary: blood glucose testing frequency 2 years</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-10-20 10:28:28 +0200" MODIFIED_BY="[Empty name]">
<P>September 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-10-20 10:29:09 +0200" MODIFIED_BY="[Empty name]">
<P>Richard M Bergenstal, MD, Principal Investigator, Park Nicollet Institute/International Diabetes Center</P>
<P>International Diabetes Center<BR/>Minneapolis<BR/>Minnesota<BR/>55416</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-11-08 21:08:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malanda-2009">
<CHAR_STUDY_NAME MODIFIED="2010-10-20 10:34:49 +0200" MODIFIED_BY="[Empty name]">
<P>Effect of self-monitoring of glucose in non-insulin treated patients with type two diabetes: The In Control Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-02-03 16:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>Three-armed randomised controlled active parallel group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 19:43:36 +0100" MODIFIED_BY="[Empty name]">
<P>Type 2 diabetes patients with the following criteria:</P>
<UL>
<LI>known disease duration of over 1 year</LI>
<LI>recent HbA<SUB>1c</SUB> 7.0% or higher</LI>
<LI>treated with diet and/or oral hypoglycaemic agents</LI>
<LI>do not require insulin at inclusion</LI>
<LI>aged between 45 and 75 years</LI>
<LI>used SMBG or SMUG less than 3 times in the previous year</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-20 10:18:00 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>intervention group A, performing SMBG with specific SMBG education, in addition to usual diabetes care provided by the regional diabetes care system.</LI>
<LI>intervention group B, performing SMUG with specific SMUG education, in addition to usual diabetes care provided by the regional diabetes care system.</LI>
<LI>control group receiving usual diabetes care provided by the regional diabetes care system</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-20 10:37:21 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures:</P>
<UL>
<LI>changes in diabetes specific emotional distress</LI>
<LI>changes in self-efficacy.</LI>
</UL>
<P>Secondary outcomes</P>
<UL>
<LI>changes in glycaemic control,</LI>
<LI>changes in patient treatment satisfaction,</LI>
<LI>changes in physical activity,</LI>
<LI>changes in health status,</LI>
<LI>status of depression,</LI>
<LI>occurrence of hypoglycaemia,</LI>
<LI>cost-effectiveness and cost-utility.</LI>
<LI>process evaluation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-10-20 10:35:59 +0200" MODIFIED_BY="[Empty name]">
<P>01-07-2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 21:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>VU Medical Centre Amsterdam<BR/>EMGO-Instituut<BR/>Afdeling Huisartsgeneeskunde</P>
<P>g.nijpels@vumc.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-08 19:43:54 +0100" MODIFIED_BY="[Empty name]">
<P>IN CONTROL study</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-11-30 15:46:00 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-08 22:48:12 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 13:50:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: "Patients were randomised in groups of 10...... with the use of a computer-generated table of random numbers".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomised in a sequential manner using a centrally generated random allocation sequence...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:17:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Comment: No randomisation method described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:28:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote: " we used computerised randomisation incorporating a partial minimisation procedure to adjust the randomisation probabilities between groups..." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:42:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Quote: "Newly diagnosed T2DM patients who were eligible for inclusion in the study were randomly (2:1) assigned to one of two groups".</P>
<P>Comment: No further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 15:53:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Quote: "They then were randomly assigned to one of three monitoring groups. The randomisation procedure was stratified by clinic." </P>
<P>Comment: No information on the sequence generation available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 22:48:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: "Eligible patients were centrally randomised by telephone to intervention group vs. control group on the basis of random permuted block computer-generated randomisation tables, stratified by centre and produced by the coordinating centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:12:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Quote: "the patients were randomised to two groups...". </P>
<P>Comment: No information on randomisation sequence is available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:30:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Quote: "After inclusion.... a telephone call to a third party was made, who had numbers ranging from 1 to 60 in non-transparent envelopes, and was asked to draw an envelope".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:46:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Quote: "At week 0, groups I-III were randomly assigned to control or SMBG interventions, group IV being assigned to control status in order to equalize the number of groups in each intervention".</P>
<P>Comment: No information presented on randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: ".. with a randomly generated allocation code in consecutively numbered sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 17:10:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Quote: " a total of 250 patients were enrolled and randomised within blocks of eight to receive one of the two treatments". </P>
<P>Comment: Information on randomisation method is not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 13:50:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Comment: No information is available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:08:26 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Quote: "....a centrally generated random allocation sequence" was used for randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:18:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Comment: No treatment allocation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:30:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote: "the minimisation procedure to assign patients to their allocated intervention was conducted independently of the research nurses who managed recruitment and carried out assessment visits. The allocation was also concealed from laboratory staff".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:42:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 15:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: No information on allocation concealment available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: "...patients were centrally randomised by telephone...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:13:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: Patients were randomised by their GPs who also carried out the usual care, dietary advice and the follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:30:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Quote: "Randomisation was done using an independent third party".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Quote: "At week 0, groups I-III were randomly assigned to control or SMBG interventions, group IV being assigned to control status in order to equalize the number of groups in each intervention".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:55:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: &#8220;The study diabetes nurse at each hospital site performed the treatment allocation&#8221;. </P>
<P>Comment: Information is not presented if these diabetes nurses are involved in the  three monthly patient reviews</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 17:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Comment: Method of allocation concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Was the outcome assessor blinded to the intervention?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Was the care provider blinded to the intervention?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01">
<NAME>Was the patient blinded to the intervention?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 13:52:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: " Blinding of the patients or study physician to the interventions, either urine or blood testing, was not possible"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 13:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: " Blinding of the patients or study physician to the interventions, either urine or blood testing, was not possible"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 13:51:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Comment: No information is available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 14:08:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Comment: patient cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 14:09:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Comment: care provider cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 19:42:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Comment: Primary outcome was difference between groups in HbA<SUB>1c</SUB>. Though HbA<SUB>1c</SUB> values were measured in a central national laboratory according to DCCT standards, un sufficient information on the HbA<SUB>1c</SUB> outcome assessor is given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 14:18:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Comment: The patient cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 14:19:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Quote: "the nurse ,who acted as care provider, was unaware of whether the patient was randomised to the monitoring group or not...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 14:19:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Comment: No detailed information described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 14:30:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 14:30:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 14:31:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote: "Treatment allocation was concealed for study nurses and laboratory staff".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 14:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Comment: The patient cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 15:37:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Comment: The care provider cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 15:38:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Comment: No information stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 15:53:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 21:56:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 15:53:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: No information presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: &#8220;participants, providers and assessors were not blinded on group/treatment allocation.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: &#8220;participants, providers and assessors were not blinded on group/treatment allocation.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: &#8220;participants, providers and assessors were not blinded on group/treatment allocation.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 16:13:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 16:14:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 16:14:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: No information about the outcome assessor available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 16:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 16:30:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 16:31:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Quote: " All laboratory tests were performed in local hospital laboratories,, where staff was unaware of treatment allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 16:47:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 16:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 19:43:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Comment: It is not clear who assessed the primary outcome, HbA<SUB>1c</SUB>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 16:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 16:57:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 19:43:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: &#8220;Measurement of HbA<SUB>1c</SUB> was performed in the local hospital laboratory with a DCCT aligned HbA<SUB>1c</SUB> assay".  "All laboratory tests were also performed in the local hospital laboratory, where staff were blinded to treatment allocation&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 17:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Comment: Patient cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-08 17:11:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Comment: Care provider cannot be blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 17:11:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Quote: &#8220;Assistants and nursing staff received structured instructions on the correct use of the monitoring device, DCA 2000, and HemoCue and learned how to supervise and document the correct use and documentation by the patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-08 22:48:29 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Was an intention to treat analysis performed?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Was the drop-out rate described and acceptable?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 13:55:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: "Five patients were inappropriately randomised and participated for less than one week". Quote: After 2 months of participation, 2 patients dropped out for unknown reasons".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 13:56:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: "Of the 61 patients randomised to the competing interventions, 54 completed the study". Comment: Only 54 out of 61 patients were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 14:13:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>610 randomised. SMBG: 37 withdrawals; Control: 47 withdrawals.</P>
<P>Quote: "...271 subjects (87%) in the SMBG group and 248 (83%) in the non-SMBG group completed the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 21:36:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Quote: "the primary analysis population was the full analysis set, defined a priori in the protocol as all randomised patients who took at least one dose of gliclazide MR during the study, who performed SMBG at least once (SMBG group) and with a baseline HbA<SUB>1c</SUB> and at least one post baseline HbA<SUB>1c</SUB> value".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 14:20:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Quote: "one patient did not return after being randomised to see the nurse or dietician and was not included in the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 14:20:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Quote: "an intention to treat analysis was used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 14:34:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote; " only 57 patients where lost to follow up (12,6%) which did not differ between groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 19:42:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote: "we carried out a single intention to treat analysis of the main trial end points at the end of the study using ANCOVA to compare mean levels of HbA<SUB>1c</SUB> at follow up between the three allocated groups, with the baseline level of HbA<SUB>1c</SUB> as covariate. If no follow-up data were available we imputed values by carrying forward the last available measurement".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 15:42:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Quote: " 29 patients from the supervised exercise program subgroup of the SMBG arm were excluded and 5 patients (SMBG 2, control 3) were lost to follow-up".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 15:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Comment: Ninety-nine out of 130 randomised patients in the SMBG group were analysed and 62 in the control group were analysed.</P>
<P>Quote: &#8220;a supervised exercise program was offered to half the patients in the SMBG group (we expected a 1:1 allocation in these subgroups) but, surprisingly, only 29 patients agreed to participate. Given the small number of SMBG patients in the exercise program and the possible influence of physical activity on the three endpoints evaluated, the patients in this subgroup were excluded from subsequent analysis&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 15:56:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Quote: "Two-hundred and eight patients entered the trial..." "Forty-four patients were lost to follow-up, i.e. did not attend the last visit....".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 15:58:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: Differences for outcome criteria between last and first visits are analysed per protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: "Sixty-two patients were recruited , of whom five did not complete the follow-up".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 22:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: &#8220;all the efficacy analyses were performed on the intention-to-treat population" </P>
<P>Quote: "all randomised patients were included in the analyses".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 19:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: Nine hundred and eighty-eight patients were randomised. Of those 689 patients had at least two evaluations for the primary criterion HbA<SUB>1c</SUB>.</P>
<P>Quote: "Three hundred and three patients discontinued the study early</P>
<P>(164 SMBG; 139 control)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 16:21:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: The primary criterion was not estimable for 299 patients in the initial intention to treat analysis. A modified intention to treat analysis is performed with 689 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 16:32:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Quote: "..one patient in the control group refused to continue the study and withdrew".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 16:35:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Comment: Data from all patients initially randomised were retrieved and analysed. (40 patients)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 16:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Quote: "Of the 29 individuals recruited to the study, 6 dropped out prior to or at the time of randomisation...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 16:50:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Comment: Even though endpoint data was available for 23 patients, no information is available on the number of patients included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 17:00:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Comment: No patients were lost to follow up. </P>
<P>Quote: "4 patients failed to complete the study (2 in each group)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 17:01:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: &#8220;The analysis was performed on an intention to treat basis, with missing data imputed through the use of full information likelihood&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 17:11:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Comment: Twenty-seven patients were not included in the analysis, but reasons for exclusion are not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-08 17:23:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Quote: "Of the 250 randomised patients, 223 per-protocol analysis". </P>
<P>Quote: "Per-protocol analysis was performed as the main efficacy analysis'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-11-30 12:58:47 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 13:57:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Comment: No trial registration or protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:15:44 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Comment: Insufficient information about the study protocol is available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:22:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Comment: No trial record or protocol publication with pre-designated endpoints is available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:36:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Comment: All outcomes are pre-specified available in the published study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-30 12:58:47 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Comment: Outcomes in the report are identical to those stated in the recorded trial register. &#8220;Clinical trial number ISRCTN81672669 available at http://www.controlled-trials.com/ISRCTN81672669&#8221;. However, the trial started in January 2006 but was registered in 2009. All outcomes are expressed as median (q1-q3) which indicates skewness.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 15:58:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: No trial register or published design available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Comment: The trial is registered in the Clinical Trials register but was registered 3 years after study start date.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:21:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Comment: No trial registration or protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Comment: Primary outcomes are pre-specified in trial register.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 16:51:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Comment: No trial registration or protocol publication available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 17:02:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Comment: All described pre-designated primary endpoints were reported in trial register</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 17:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Comment: Although planned no information on the follow-up data is reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-11-16 15:55:00 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-11-30 15:46:00 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.03" NO="3">
<NAME>Was the compliance acceptable in all groups?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Where co-interventions avoided or similar?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Where groups similar at baseline?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 13:57:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: "The two groups were similar in all baseline measurements".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 14:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Comment: All patients received the same diet instructions and were individually instructed in testing techniques. </P>
<P>Quote: "Physician-initiated treatment alterations were guided by an explicit algorithm with the patients's urine or blood test results and the monthly fasting glucose values".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 14:05:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1990">
<DESCRIPTION>
<P>Quote: "Compliane levels were similar for both groups of patients".</P>
<P>Comment: 87% SMUG and 90% SMBG of patient records were complete and attendance exceeded 98% in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 14:16:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Quote: "patient characteristics at study entry were similar between the randomisation groups with the exception of a higher proportion of menopausal women in the SMBG group".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 14:16:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Comment: Care for both groups is equal. However, no information is given on a joint multicenter training on giving diet and lifestyle advice</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 14:17:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2008">
<DESCRIPTION>
<P>Comment: insufficient information on compliance is provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 14:23:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Quote: "There were no differences in the baseline characteristics of the patients randomised to the monitoring group and those who were randomised to the control group".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 14:23:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Comment: All patients received the same care with the same detailed algorithm and dietician care</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 14:26:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-2005">
<DESCRIPTION>
<P>Quote: "patients in the monitoring group averaged 4.0 vs 3.2 visits in the control group. </P>
<P>Comment: The monitoring group performed an average number of 129 tests per person instead of the maximum of 6x6x26=936.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 14:37:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote: "Baseline, personal and clinical characteristics were well balanced between the groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 14:37:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Comment: All groups received the same goal setting and review techniques.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 14:39:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DiGEM-trial-2007">
<DESCRIPTION>
<P>Quote: Ninety nine (67%) in the less intensive group and 52% in the more intensive group continued to use the meter at least twice a week for the 12 months of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 19:42:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Quote: &#8220;Patient characteristics at the time of study entry were similar between the two groups, with the exception of higher LDL cholesterol levels in the SMBG compared with the HbA<SUB>1c</SUB> group&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 15:46:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Quote: &#8220;a supervised exercise program was offered to half the patients in the SMBG group (we expected a 1:1 allocation in these subgroups) but, surprisingly, only 29 patients agreed to participate. Given the small number of SMBG patients in the exercise program and the possible influence of physical activity on the three endpoints evaluated, the patients in this subgroup were excluded from subsequent analysis&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 15:46:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dur_x00e1_n-2010">
<DESCRIPTION>
<P>Quote: &#8220;In the SMBG group, 96 of 99 patients (97%) performed a median of 251 capillary measurements (range 148-300) during follow-up&#8221;. Comment: This is approximally 1 six point profile per week, which was recommended.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 15:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: No differences between groups were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 15:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Comment: No specific information is mentioned. However, none of the groups received any extra or different advice or treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 16:02:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fontbonne-1989">
<DESCRIPTION>
<P>Quote: "The number of urine strips used in the SMUG group was significantly lower than expected indicating low compliance..." The number of blood strips used was as expected".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 22:48:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: "clinical and socio-demographic characteristics compared well between the two groups. Some variables varied slightly but not significantly".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: "The control group received standard counselling with focus on diet and lifestyle". No information is provided whether the intervention group received this also.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franciosi-2011">
<DESCRIPTION>
<P>Quote: "..mean number of SMBG measurements during the trial was 71 ±11 as compared with the 76 required by protocol. Only 7.1% of the patients performed less than 80% of the required number of measurements".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 16:22:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Quote: "No statistically significant difference was observed between the two groups..".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 19:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Quote: "At visit 3 each GP could modify treatment of their patients according to HbA<SUB>1c</SUB>, keeping with ANAES recommendations. At each consultation both groups were equally informed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 22:48:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guerci-2003">
<DESCRIPTION>
<P>Quote: No statistically significant difference between the two groups was found during the study in terms of diet prescribed". "Compliance to physical activity was similar in both groups".</P>
<P>Comment: No information is available on performance of SMBG</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 16:36:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Quote: "BMI and diabetes duration where different between groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 16:40:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Comment: No education was given to ensure there are no education differences between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 16:42:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleefstra-2010">
<DESCRIPTION>
<P>Quote: "Of the 22 patients in the SMBG group 17 performed at least 80% of the requested glucose registrations".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 16:51:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Quote: "...treatment groups were well matched for all pre randomisation variables except initial treatment modality....".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 16:52:38 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Quote: " Throughout the study, individuals remained under medical care of their primary GP and decisions on medical adjustments were coordinated through these providers".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 16:52:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muchmore-1994">
<DESCRIPTION>
<P>Quote: "Subject compliance with protocol requirements was good".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 19:43:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: &#8220;There was no significant difference in baseline HbA<SUB>1c</SUB>, age, or sex between groups, although participants in the self monitoring group had a higher baseline body mass index&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 17:05:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: "Patients in both groups underwent an identical structured education programme...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-30 15:46:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Kane-2008">
<DESCRIPTION>
<P>Quote: &#8220;...63 patients in the intervention group carried out at least 80% of the requested blood glucose monitoring&#8221;.</P>
<P>Comment: Compliance was defined as a monitoring frequency of &gt; 80% of that requested.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-08 17:15:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Quote: "The baseline demographic characteristics compared well for both groups". "There were no statistically significant differences regarding baseline efficacy parameters".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2011-11-08 17:17:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Quote: "SMBG patients received a defined counselling algorithm...". </P>
<P>"The control group received non standardized counselling with a focus on their diet an lifestyle...".</P>
<P>Comment: The intervention group received counselling focused on psychological aspects and the control group counselling was non standardized. Both interventions could therefore cause bias. Furthermore, no details are given whether both groups had different nurses delivering the counselling.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2011-11-08 17:34:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SMBG-study-group-2002">
<DESCRIPTION>
<P>Quote: "Patients were included in the analysis if they met protocol criteria, completed the entire study, showed valid efficacy parameter measurements and were over 70% compliant". </P>
<P>Comment: Twenty-seven out of 250 were excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-12-01 16:47:51 +0100" MODIFIED_BY="Bernd Richter">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-12-01 16:47:51 +0100" MODIFIED_BY="Bernd Richter" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-11-30 13:04:31 +0100" MODIFIED_BY="Bernd Richter">Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Self-monitoring of blood glucose compared to control or self-monitoring of urine glucose for type 2 diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Patients with type 2 diabetes mellitus<BR/>
<B>Intervention:</B> Self-monitoring of blood glucose (SMBG)<BR/>
<B>Comparison: </B>Control, self-monitoring of urine glucose (SMUG)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Control / SMUG</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SMBG</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Morbidity</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>523<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Probably no clinically relevant differences</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Well-being</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>928<BR/>(4 studies)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Probably no clinically relevant differences</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Patient satisfaction</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>928<BR/>(4 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Probably no clinically relevant differences</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Hypoglycaemic episodes</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>2492<BR/>(6 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Probably no clinically relevant differences</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Costs</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>514<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>HbA1c [%]</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>-0.3 (-0.4 to -0.1) at 6 months<BR/>-0.1 (-0.3 to 0.04) at 12 months<BR/>-0.5 (-0.9 to -0.1) at 12 months*<BR/>-0.2 (-1 to 0.6) at 6 months**<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2324 (9 studies)<BR/>493 (2 studies)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Results refer to subgroup-analyses<BR/>* newly diagnosed diabetes<BR/>** SMBG vs SMUG</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Because few included trials reported outcomes on health-related quality of life, well-being and patient satisfaction and self-reported measures varied substantially, presenting a general effect estimate was not possible and interpretation of best-evidence synthesis is difficult. Similar effects on similar sub-scales or dimensions in similar directions suggested a clinical non-relevant effect of SMBG on general (health-related) quality of life and well-being. Since all trials that measured patient-satisfaction did not report an SMBG related effect, this is considered clinical relevant as well.</P>
<P>
<SUP>2 </SUP>Data for adverse events could not be extracted separately for intervention and control groups. Studies reported occurrence of hypoglycaemia by recording asymptomatic or symptomatic hypoglycaemic episodes and/or by using detailed graded definitions. Due to substantial variation in definitions of hypoglycaemia, high risk of bias regarding occurrence and severity of hypoglycaemia between studies exists. Experiencing hypoglycaemic events can be confirmed with SMBG. Therefore, it is in the line of expectation that more frequent hypoglycaemic events seem to have been reported when using SMBG.</P>
<P>
<SUP>3</SUP> Only two trial, Allen 1990 and the DiGEM trial 2007 reported outcomes on approximate costs of self-monitoring. Allen 1990 compared the costs of SMBG with SMUG based on nine measurements per week and with the prices in US dollars for self-monitoring in 1990. They concluded that total costs in the first year of SMBG, with the purchase of a reflectance meter were 12 times more expensive than SMUG (SMBG = $481 or 361 EURO [11/2011 conversion]; SMUG = $40 or 30 EURO [11/2011 conversion]). In the DiGEM trial 2007 a full economical analysis was performed. At the end of the trial, costs for the intervention were £89 (104 EURO [11/2011 conversion]) for standardized usual care (control group), £181 (212 EURO [11/2011 conversion]) for the less intensive self-monitoring group and £173 (203 EURO [11/2011 conversion]) for the more intensive self-monitoring group. Higher losses to follow-up in the more intensive self-monitoring group were responsible for the difference in costs, compared to the less intensive self-monitoring group.</P>
<P>
<SUP>4</SUP> Different levels of probability and estimates of outcome variables of included studies might account for differences in presented subgroups. In addition, differences in requested monitoring frequency, glycosylated haemoglobin A1c (HbA<SUB>1c</SUB>) level at baseline and SMBG and diabetes education may have contributed to the differences as well.</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-11-30 13:24:49 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-11-30 13:24:49 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2010-10-20 12:04:59 +0200" MODIFIED_BY="[Empty name]">Overview of study populations</TITLE>
<TABLE COLS="8" ROWS="41">
<TR>
<TH>
<P>Characteristic &#9658;</P>
<P>Study ID &#9660;</P>
</TH>
<TH>
<P>Intervention(s) &amp; control(s)</P>
</TH>
<TH>
<P>Screened (n)</P>
</TH>
<TH>
<P>Randomised (n)</P>
</TH>
<TH>
<P>ITT (n)</P>
</TH>
<TH>
<P>Randomised<BR/>patients finishing study (%)</P>
</TH>
<TH>
<P>Finishing study (n)</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>89</P>
</TD>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="LEFT">
<P>Seven patients dropped out (5 were inappropriately randomised, 2 gave no reasons for drop-out).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>311</P>
</TD>
<TD ALIGN="CENTER">
<P>311</P>
</TD>
<TD ALIGN="CENTER">
<P>87</P>
</TD>
<TD ALIGN="CENTER">
<P>271</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>299</P>
</TD>
<TD ALIGN="CENTER">
<P>299</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
<TD ALIGN="CENTER">
<P>248</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
<TD ALIGN="CENTER">
<P>610</P>
</TD>
<TD ALIGN="CENTER">
<P>610</P>
</TD>
<TD ALIGN="CENTER">
<P>85</P>
</TD>
<TD ALIGN="CENTER">
<P>519</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>89</P>
</TD>
<TD ALIGN="CENTER">
<P>89</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="LEFT">
<P>Initially 89 patients were randomised. One patient did not return after randomisation. It is not stated in which group this patient was randomised.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>SMBG more intensive</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>151</P>
</TD>
<TD ALIGN="CENTER">
<P>151</P>
</TD>
<TD ALIGN="CENTER">
<P>89</P>
</TD>
<TD ALIGN="CENTER">
<P>134</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>SMBG less intensive</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>150</P>
</TD>
<TD ALIGN="CENTER">
<P>150</P>
</TD>
<TD ALIGN="CENTER">
<P>91</P>
</TD>
<TD ALIGN="CENTER">
<P>136</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>152</P>
</TD>
<TD ALIGN="CENTER">
<P>152</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
<TD ALIGN="CENTER">
<P>126</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>364,527</P>
</TD>
<TD ALIGN="CENTER">
<P>453</P>
</TD>
<TD ALIGN="CENTER">
<P>453</P>
</TD>
<TD ALIGN="CENTER">
<P>87</P>
</TD>
<TD ALIGN="CENTER">
<P>396</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>130</P>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
</TD>
<TD ALIGN="CENTER">
<P>76</P>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
</TD>
<TD ALIGN="LEFT">
<P>Twenty-nine patients participated in an exercise supervised program and were excluded. Two were lost to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>65</P>
</TD>
<TD ALIGN="CENTER">
<P>62</P>
</TD>
<TD ALIGN="CENTER">
<P>95</P>
</TD>
<TD ALIGN="CENTER">
<P>62</P>
</TD>
<TD ALIGN="LEFT">
<P>Three patients were lost to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>250</P>
</TD>
<TD ALIGN="CENTER">
<P>195</P>
</TD>
<TD ALIGN="CENTER">
<P>161</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
<TD ALIGN="CENTER">
<P>161</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>82</P>
</TD>
<TD ALIGN="CENTER">
<P>56</P>
</TD>
<TD ALIGN="LEFT">
<P>Twelve patients were lost to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>72</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="LEFT">
<P>Eighteen patients were lost to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="LEFT">
<P>Fourteen patients were lost to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
<TD ALIGN="CENTER">
<P>208</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER">
<P>164</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
</TD>
<TD ALIGN="CENTER">
<P>91</P>
</TD>
<TD ALIGN="CENTER">
<P>42</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>94</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>62</P>
</TD>
<TD ALIGN="CENTER">
<P> 62</P>
</TD>
<TD ALIGN="CENTER">
<P>92</P>
</TD>
<TD ALIGN="CENTER">
<P>57</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>510</P>
</TD>
<TD ALIGN="CENTER">
<P>345</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>346</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>478</P>
</TD>
<TD ALIGN="CENTER">
<P>344</P>
</TD>
<TD ALIGN="CENTER">
<P>71</P>
</TD>
<TD ALIGN="CENTER">
<P>339</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
<TD ALIGN="CENTER">
<P>988</P>
</TD>
<TD ALIGN="CENTER">
<P>689</P>
</TD>
<TD ALIGN="CENTER">
<P>69</P>
</TD>
<TD ALIGN="CENTER">
<P>685</P>
</TD>
<TD ALIGN="LEFT">
<P>Two-hundred and forty patients had a reason for discontinuation</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>95</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD ALIGN="LEFT">
<P>One patient withdrew consent</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>41</P>
</TD>
<TD ALIGN="CENTER">
<P>41</P>
</TD>
<TD ALIGN="CENTER">
<P>98</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>80</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="LEFT">
<P>Three patients dropped out</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="LEFT">
<P>Three patients dropped out</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="CENTER">
<P>29</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER">
<P>23</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>96</P>
</TD>
<TD ALIGN="CENTER">
<P>96</P>
</TD>
<TD ALIGN="CENTER">
<P>98</P>
</TD>
<TD ALIGN="CENTER">
<P>94</P>
</TD>
<TD ALIGN="LEFT">
<P>Two patients withdrew from intervention</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>98</P>
</TD>
<TD ALIGN="CENTER">
<P>86</P>
</TD>
<TD ALIGN="LEFT">
<P>Two patients withdrew from intervention</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>212</P>
</TD>
<TD ALIGN="CENTER">
<P>184</P>
</TD>
<TD ALIGN="CENTER">
<P>184</P>
</TD>
<TD ALIGN="CENTER">
<P>98</P>
</TD>
<TD ALIGN="CENTER">
<P>180</P>
</TD>
<TD ALIGN="LEFT">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>113</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>110</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>(total)</P>
</TD>
<TD ALIGN="CENTER">
<P>250</P>
</TD>
<TD ALIGN="CENTER">
<P>250</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>89</P>
</TD>
<TD ALIGN="CENTER">
<P>223</P>
</TD>
<TD ALIGN="LEFT">
<P>Per protocol analysis performed</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<I>total</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>3259</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>80</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>2590</I>
</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>"-" denotes not reported</P>
<P>ITT = intention-to-treat analysis; SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-30 11:42:41 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-30 11:42:00 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>SMBG vs control (6 months follow-up)</NAME>
<CONT_OUTCOME CHI2="11.294717689066765" CI_END="-0.13333658305212376" CI_START="-0.39142890239321476" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.26238274272266926" ESTIMABLE="YES" I2="29.170429751033414" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2011-10-29 16:31:55 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18555283800678413" P_Q="1.0" P_Z="6.745418984388422E-5" Q="0.0" RANDOM="YES" SCALE="2.57" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.009947916395642582" TOTALS="YES" TOTAL_1="1261" TOTAL_2="1063" UNITS="%" WEIGHT="100.0" Z="3.98509128217513">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>SMBG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SMBG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.04652534447027015" CI_START="-0.43347465552972964" EFFECT_SIZE="-0.23999999999999988" ESTIMABLE="YES" MEAN_1="-1.15" MEAN_2="-0.91" MODIFIED="2011-07-30 20:05:32 +0200" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="1.14" SD_2="1.29" SE="0.09871337282513001" STUDY_ID="STD-Barnett-2008" TOTAL_1="311" TOTAL_2="299" WEIGHT="22.01398807391734"/>
<CONT_DATA CI_END="0.5779227266488561" CI_START="-0.9779227266488563" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.6" MODIFIED="2011-07-30 20:05:04 +0200" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="1.6" SD_2="2.1" SE="0.3969066435837655" STUDY_ID="STD-Davidson-2005" TOTAL_1="43" TOTAL_2="45" WEIGHT="2.5883546038131544"/>
<CONT_DATA CI_END="0.07778772139683639" CI_START="-0.2177877213968364" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" MEAN_1="-0.15" MEAN_2="-0.08" MODIFIED="2011-07-30 20:05:05 +0200" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="0.81" SD_2="0.73" SE="0.07540328422489753" STUDY_ID="STD-DiGEM-trial-2007" TOTAL_1="301" TOTAL_2="152" WEIGHT="27.72910029518371">
<FOOTNOTE>Both intervention groups are combined</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.9712433204302526" CI_START="-0.6912433204302526" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.5" MODIFIED="2011-07-30 20:05:06 +0200" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="3.14" SD_2="1.54" SE="0.424111528062247" STUDY_ID="STD-Fontbonne-1989" TOTAL_1="68" TOTAL_2="68" WEIGHT="2.283786175558127"/>
<CONT_DATA CI_END="-0.08474637802510782" CI_START="-0.9152536219748921" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.7" MODIFIED="2011-08-01 21:45:05 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="0.81" SD_2="0.7" SE="0.21186798596829318" STUDY_ID="STD-Franciosi-2011" TOTAL_1="46" TOTAL_2="16" WEIGHT="7.905485337324339"/>
<CONT_DATA CI_END="-0.17002022010672926" CI_START="-0.6299797798932708" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" MODIFIED="2011-07-30 20:05:37 +0200" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="1.54" SD_2="1.54" SE="0.11733877852211669" STUDY_ID="STD-Guerci-2003" TOTAL_1="345" TOTAL_2="344" WEIGHT="18.278769416803442"/>
<CONT_DATA CI_END="0.19545348720748534" CI_START="-0.6954534872074853" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="0.07" MODIFIED="2011-07-30 20:05:09 +0200" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="0.67" SD_2="0.75" SE="0.22727636360727319" STUDY_ID="STD-Kleefstra-2010" TOTAL_1="22" TOTAL_2="18" WEIGHT="7.037135590384304"/>
<CONT_DATA CI_END="0.6896995666743163" CI_START="-2.0696995666743163" EFFECT_SIZE="-0.6900000000000001" ESTIMABLE="YES" MEAN_1="-1.54" MEAN_2="-0.85" MODIFIED="2011-07-30 20:05:10 +0200" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="1.46" SD_2="1.87" SE="0.70394128543035" STUDY_ID="STD-Muchmore-1994" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.8576082237940219"/>
<CONT_DATA CI_END="-0.12972565387050566" CI_START="-0.7902743461294943" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.54" MODIFIED="2011-07-30 20:05:38 +0200" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="1.08" SD_2="1.41" SE="0.16851041587225898" STUDY_ID="STD-SMBG-study-group-2002" TOTAL_1="113" TOTAL_2="110" WEIGHT="11.30577228322156"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-11-30 11:42:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>SMBG vs control (12 months follow-up)</NAME>
<CONT_OUTCOME CHI2="0.27695806167123915" CI_END="0.040558046981714946" CI_START="-0.30781791390082996" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1336299334595575" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-06-22 14:21:12 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5987020363639077" P_Q="1.0" P_Z="0.13268319391392938" Q="0.0" RANDOM="YES" SCALE="2.25" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="323" TOTAL_2="170" UNITS="%" WEIGHT="100.0" Z="1.5036046469665552">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>SMBG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SMBG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.03454910245641826" CI_START="-0.3345491024564182" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="-0.15" MEAN_2="0.0" MODIFIED="2011-06-22 14:21:12 +0200" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="0.78" SD_2="1.02" SE="0.0941594355366313" STUDY_ID="STD-DiGEM-trial-2007" TOTAL_1="301" TOTAL_2="152" WEIGHT="89.08662230637167">
<FOOTNOTE>Both intervention groups are combined</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.5272767127618511" CI_START="-0.5272767127618511" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.1" MODIFIED="2010-08-30 09:58:21 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="0.9" SD_2="0.8" SE="0.2690236743740918" STUDY_ID="STD-Kleefstra-2010" TOTAL_1="22" TOTAL_2="18" WEIGHT="10.913377693628332"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-11-30 11:42:30 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>SMBG vs control (newly diagnosed patients, 6 month follow-up)</NAME>
<CONT_OUTCOME CHI2="3.1563694590640843" CI_END="-0.005856291889590248" CI_START="-1.0563715961497904" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5311139440196903" ESTIMABLE="YES" I2="68.31803079552935" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-10-20 17:13:30 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07563153489970376" P_Q="1.0" P_Z="0.04749979907184289" Q="0.0" RANDOM="YES" SCALE="2.25" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.10712267228738988" TOTALS="YES" TOTAL_1="195" TOTAL_2="150" UNITS="%" WEIGHT="100.0" Z="1.9818163481182016">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>SMBG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SMBG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6021730923548926" CI_START="-0.8578269076451076" EFFECT_SIZE="-0.7300000000000001" ESTIMABLE="YES" MEAN_1="-0.68" MEAN_2="0.05" MODIFIED="2010-10-11 16:31:40 +0200" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="0.45" SD_2="0.37" SE="0.06521900843759876" STUDY_ID="STD-Dur_x00e1_n-2010" TOTAL_1="99" TOTAL_2="62" WEIGHT="64.48463286065895"/>
<CONT_DATA CI_END="0.4344229472332479" CI_START="-0.7744229472332482" EFFECT_SIZE="-0.17000000000000015" ESTIMABLE="YES" MEAN_1="-1.81" MEAN_2="-1.64" MODIFIED="2010-10-11 16:31:33 +0200" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="2.1" SD_2="2.08" SE="0.3083847213524632" STUDY_ID="STD-O_x0027_Kane-2008" TOTAL_1="96" TOTAL_2="88" WEIGHT="35.51536713934106"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-11-30 11:42:41 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>SMBG vs control (newly diagnosed patients, 12 months follow-up)</NAME>
<CONT_OUTCOME CHI2="1.7893436951603523" CI_END="-0.14257325845907043" CI_START="-0.8880277819525475" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.515300520205809" ESTIMABLE="YES" I2="44.1135874172913" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-10-20 17:13:38 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18100628444430644" P_Q="1.0" P_Z="0.006734877451676071" Q="0.0" RANDOM="YES" SCALE="2.25" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.04078301156728589" TOTALS="YES" TOTAL_1="195" TOTAL_2="150" UNITS="%" WEIGHT="100.0" Z="2.7096769259244495">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>SMBG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SMBG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4488992775119845" CI_START="-0.8111007224880158" EFFECT_SIZE="-0.6300000000000001" ESTIMABLE="YES" MEAN_1="-0.56" MEAN_2="0.07" MODIFIED="2010-10-11 16:37:59 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="0.52" SD_2="0.6" SE="0.09240002567216286" STUDY_ID="STD-Dur_x00e1_n-2010" TOTAL_1="99" TOTAL_2="62" WEIGHT="73.32570237344393"/>
<CONT_DATA CI_END="0.4034531839516814" CI_START="-0.8034531839516813" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.88" MEAN_2="-1.68" MODIFIED="2010-10-11 16:38:08 +0200" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="2.06" SD_2="2.11" SE="0.3078899350761764" STUDY_ID="STD-O_x0027_Kane-2008" TOTAL_1="96" TOTAL_2="88" WEIGHT="26.674297626556076"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-10-29 16:28:46 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>SMBG vs SMUG (6 months follow-up)</NAME>
<CONT_OUTCOME CHI2="0.061965719809732" CI_END="0.6098423311982248" CI_START="-0.9554933028905142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17282548584614463" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2010-12-22 17:24:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8034155924303603" P_Q="1.0" P_Z="0.6651664829477197" Q="0.0" RANDOM="YES" SCALE="2.25" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="99" UNITS="%" WEIGHT="100.0" Z="0.4327911797220067">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>SMBG</GROUP_LABEL_1>
<GROUP_LABEL_2>SMUG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SMBG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SMUG</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5697849200922311" CI_START="-1.5697849200922311" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-2.0" MODIFIED="2010-08-30 10:56:20 +0200" MODIFIED_BY="[Empty name]" ORDER="37" SD_1="3.4" SD_2="2.4" SE="0.8009253907084488" STUDY_ID="STD-Allen-1990" TOTAL_1="27" TOTAL_2="27" WEIGHT="24.85848441471972"/>
<CONT_DATA CI_END="0.6728955258978041" CI_START="-1.132895525897804" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.13" MODIFIED="2010-08-30 10:54:48 +0200" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="3.14" SD_2="2.2" SE="0.460669447510122" STUDY_ID="STD-Fontbonne-1989" TOTAL_1="68" TOTAL_2="72" WEIGHT="75.14151558528029"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-11-30 15:46:01 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-11-08 23:01:39 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-11-30 15:46:01 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-11-30 15:46:01 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-11-29 15:14:20 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 SMBG (self-monitoring of blood glucose) vs control (6 months follow-up), outcome: 1.1 HbA1c [%].</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-11-29 15:14:55 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 SMBG (self-monitoring of blood glucose) vs control (12 months follow-up), outcome: 2.1 HbA1c [%].</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2011-11-30 11:45:15 +0100" MODIFIED_BY="Bernd Richter" NO="6" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 SMBG (self-monitoring of blood glucose) vs control (newly diagnosed patients, 12 months follow-up), outcome: 4.1 HbA1c [%].</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzYAAACQCAMAAADtPA4dAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAAgNElEQVR42u1de3Abx3n/+Lg7HAAB3CNZU4mdSCJtt0lGiSWZEl9JC8pxFCX1jGunHXvkUfJHPG08dmeiSfMcx8lM02QmnWmbl/2Po7ppk0ni2q6fsYmxDIKWEIVyM45bu6RI27GpmOQdSREEgSOJ7u29X8CBBEFI3J8E3t7d3u5vv91v99vFfrgGBBQUFJWhkYqAgoKqDQUFVRsKCqo2VUGmOMhyERkSiYQMKfxXCbEsnwFIHWEHI5na0lHyjDrzbAvbzzHJrQQRVVuiBAt8jwsJhKgQYnnls9WMM2UZs6EHCWPEcWHlQ9WmBP5s8N8Kcwc/pwSvgD9XryUL8z0fhqnDL1w4d/AjNWUzdTh14Vz3nzqu7j1Ub1I7BSulIySnmj6UgmQSFnsvvLXYm31rqxnfCD8tw/hC80NthHHf1O+VD1WbEpDhfcAnH8AhrgAFTrvKwxp09IUFMZmrKZuOPh7nuQQQ49i40vcJYe5BFgdwMIp77BMcF6sDoY3cDCsj+CieYLmiCDLP4SEFU0QRTpeX8DR8DF9h++GWjn64URCLHBsT8ZVwGIwwiS/GOAYP91pam8VYhEHCOMZyOOtMmGXCOU2+OuMQLCmMB+CWK/BHwLzYEwrLCA9GmMRX+Efa9bS2pdo0wXV8SrWPVmE1pV3NQQj/e7XmbPQ84weeiOxvwYHV8b6/LuCuEAen34L4aPiJA/GtF1rzHXBbMz7uHo2GB3dBTMxne7Cuwxrfd48e5/1kQFK4E/67BsPzB3bjK7PzZpjE33XgiZaDcSWtZ3Fam4TcnRBSNHr3gUjkwC74yGxh6RDS5KvHeQ1WNcYyYXzgieiowvLp3+PHnlXDJD7mnz24qKe1LdXm1Aj03EtmMEyP3Mtohu7RF5+DIigdaG2nEX04TwV5iI2DUs0TO/G4p9W8gC+Px/CfLQfzStuYIqplGBvH7Sx3VWwHoTkxAyf1OAIWoAXXw3iOUM8xZpjEL8C+aTzA4rQ+oLTZzYEw1t6HCOPxMSzl3NkTMaIkFvk6GRcgNobj4w6gFZMNqWESH/NnsBmipbUt1ab77d+MAJnBvAIt+EPM3ORLeG5zHETSy9cSw6AO+qvQLWhVCf1GrSqa3E1qe4vxDG4y74DC55ZbMJ+Wvas7CE0BzGYkQoNtrUOJuqbGsYb7oFftKrS0Ngnv4H/TJIRzGYLn7v1hFAbs8nUyXoUv3qILnoSLevyihfHQ9lQbEObfHiV1uDMtp3caElyD++GampNh4VpyPAyioxJ1YiK+t/V9zUghrYw2DfCLJLZoluBNtz17DTTbGweOWnCH8bRD7Sq0tDZrfEyzI6opQbI+6s24yW6+46h5S9iTcWF7qk0okRP+S61hpp8x+8YmuJBeEltqzIZnvyoKiTCkYbQTT3QcYxC+0jkKI3UgtW/3f0fjM4XZHodrO136vQy8vUPYIyfC7rByNtqOz7S0Nm06NtBkMFaI5d2Mp/EoamOMeUXcYeWsU8aJcHpa21BtXsh8gjmcmSOS1fvHBDv44inY+VxDx9LpYzVlM/2fT3dkM8/D5Nmj2d/M6VfvH75SDUyczR49O18HUrsXvq7x2XXmeehJ73UuKCV2rrw0Y70weXZ/JDPvDuOzoaPzZ+bVtDavbP8IpE+c2Jd97+lTEOna5bQHEx38sQEbY4XXnDus8M9GMgswqaa1UTTQrZwUFNtjbkNBQdWGgoKqDQUFVRsKCgqqNhQUVG0oKLZQbcQoR3xV2uzfBpXY4aX7vZSPWRaB/EGghW0BiArg2Hdm8b9hjyAjdpzDsYs5Z+wEgX5m8YtxxtJ8eUoTuh/gn1LOLOQiy7F3txs+LFpsROiXIZTyIySDyCZYEeTEEdd9LZQK2wnyiTaliPr3ezgXhuPbPcviW0w5qu4/VkkSmZ7Qtky38Sx7QtYeLlE/wRoAn1Ba0rCFLMeG2yojK0Y4NiZjESVs8lZlw3DRjJUsg+sukloPWavaPNS9o/D4wQ/D3p6gD1v8XqqA8v4gsPz6MsgrIjj2nZk8khdeuC6nx87HcGyed8ZOJtWPihJ+MYYvjz+hT2XvhqkvDjizQIPxfOzlRdB9WLTYS9lPgbxahtC9h3zl87t+6P8dPqYsD9rgfJYDpSXKwBlZyc/1LFZWLa3dQ+EDCD4GNyWTmky/r7bs9oWmC/OjLeXrJxhYUHTk4/iop5ePHcpWlsZ7Ds5FD7TihpRRyBryVlT8cMMf5ro/Yq27JVx3awPrImtRmy/g3PjkMqN6ihClliMh3HnziXasv2TbiOo7ovqRmH4vWmyA+BFehkw41EIcLsNh0weFfBKJB7mw3xamAP4gsLpzDZrdWyNM/xsQwmD0pmvTq9Aa8i06KQvxi9HyckD35dH8NtojLBtqU8rAh4zviE8yRfhjzpV0Hgowo7r9EB8WDUXmJLRyvoSIrAghklfKcftm+ASk8edmYDQZkRriEBF9G39EIM9aMU12AC9rGyIJBmDNIdsMH2qx1q3AczGkD5KKP8bAOG7Mq+oeAyJTrQi5/pDAJ60N26d+guFZssG6gI8GZnC2drnLYQ4ZslJKEGZbWjguZbQEfgwncYW6vcAq7+W+OUzW6onlU3eVqk0j7FO8WGSL+jUfDItKNyDDQ6THMnxHponnn+n3oreL0z0/gOsPPa4OG7Nvmj4oGu6JHGr2YRLEH6RRbpT5cdejVh6vwm1G7KlGsXDer+RqWYhfiZGXDakV1ZdH89tY5Aqv917E538b7TWlLx8X8+4sGNh/l25evN8cRI9jO+uv/AkRWRFCizM4L+f2zztwe2DwpwCvmH4urQe1fuhr0fxSwdlzMqf7cpDqO82Yl3K4nk3ZhrFsEz2Pr1nrdnWh78DqYu+S0SxwExiCb8CtHG4MVpnK8JqzNXnXTzB0n+lNQVvv6W5LFUCzQ+7Nh8KrYPFtWhvv37c22XeD3gAVskXcMyx9NjJrk/dtcNHV23rWXaVqs2B4sVgG+bFfA1zANXUXGTuXdd+RHOmLTjmfmByHxyAEMUmtoVbTB0WPMAZ++h3EH4SPhNq5Pcp8wm6+WHgI8GP9cmgXv4f9OeuztdPiB4Pzust04TAI9aq+PJrfRq4x9hmyD31i2ozLR/bv4XZzzizmOXhl792yRsjwCNkf4Xf/bI8/IUNWmNBn7I4kAOlX5LXhN4bX5N7hnaafC66RN8jtY9PuEigV+DXot4g8kTh6ZsEsLy7KSTgI+yat8pjAhZ5kjNQY6HoUH76S/n740FWqTDvVIuiORiZ86icgGEx12bTRMNl7z0QccudgfBLsvk0wa/rfsPCo4uRbTMd6Dt5nk/eYB1nPuqtUbZi3RzUvFgP9iq8I8OmVqZWRabD4jqgUTL8XDYKAO4g16Ga0BmP6oJgRGnyYBPEHmSucX55Q5hOOfsrCw7I/cS5/Pjd5N7ZvPWHxg2nZ+82HTRcOHbovj+a3gfau/Von1G8SunV5RrH3HQ3gJ+fS8HJcI2SU+M7C+cKMYv97wiIrIy8LlqG5jxHYvlbcNqx+LoLLyceCd9L/InJps/9P3jdsLS+RbVFNwla3ltTeOJP9XBpgMc+M43GTyHRJlWkanJtBfeonIM4P86I8bPb/ySeGV191yL1fJWv1bVIMMp2slLmzfbgRsvnpm+BHNnl7kfWsu4oXoIW5t89plZEmxpqy+13JjOm/up90AscdviOa38uw3lqJw0kTiLJpPpFLKT1Cxt+NO4g/CEAnK4wxRedVw/8G4FpLdwWjnNDHnPRddtHLsgTHPPLSfXk0v40svPGaRyJdzUzvtMtTS5CmRjXjzObD0rXE9O5c86Zj8ddZ9MgL4Z6WwWnl8cf0c2kAsdTv9DBM33v6my0910D44Jcc5R1RK9nPL0jI5pfWWL2rAdhjyJTxcG7yrp9gENjeXbhnsIwHfO8uh9zTKtkmH98mZrGw2KB54DTY5M3AjoB1V6HahBKC8Biuky7SQU61kbGwS7Ggn4Ru1V/+Z3bfEd3v5Ti0EUMbdndiejkYbTZXR4gPShO0qxEOd/kaaQH8QRRGr0JaPu64aPG/Eb8KT5k3PslBl98ShOYHo/jFHIdrvPLSfHk0v41G2DHqESknwciU89svPpESmtVpqd2HJbcC6Xaf78o0fx2lW2yCa0e9TJhp/K8Ph0w/Fw46r7c1KsdT07jqZqxrtnMv/rNsLy+ur93g5RekPhRm5RcGWOC5Np6UJG/IVEotiznTo8W/foJbaQfIkohBdn5kecoud1zeXWa7cpHluSmhbxZ4tv1l0tBMef9fukV8weEblOM96q5Stbl4Jst+PfM8/GL4KpDSn1EqfeX04j8pEh2GEeJD6fAd0f1eetKLanfUtDSSBOnF7yJlACJzmbNHs2fnQBq5+KSa3eKZWT8qZf1BlPUi2Al8eL/jqul/k7ji6XOmA0Zb47Ri33pnp5VF8YvpSX/QaxRsUjVR89sIpyNPu+OkmhjgdjmzWMgMcgtDhJDNhyXVyAA/79NxaP46keF347zmXXlNDwPHAMPB8KsWP5fZMzmk2AYqlGcdWp2G4RyZXBsNr7/FXt6VF7/VCJ5+QSTdZ5rC3zonwqmmhfi+CZtMmfhqR/zsXPn6CYrxYRge1/NV+7b+q+1yn+WWmsx2ZQVpcZGGXUvneIgy8zecnbTJe+dza1fcN/R7e91NK3O19TAN4m8jwrt6fzsTfP09fH7si2e8FtwTG/Hztz9cLqnKYl+6hLjQRP7200vlok3tWcePYLVfXN40cVQvX11hs7kakg2iNlyxMVzBT0ulProKTHja8wutDXhxM43FgoVSmaTwtFm2nDRswk/H2DjY8vMkVGw0ObANxSr93ouQW2lsmmfKRYs+NVB52hF+ZtPqp3r56g/N8Ouvu4rJUu9OCgoKim2Jv6htds10tKG4HFDbdtxMBU5R97At8NXBDwNTfxsKCqo2FBT1oTYSlRIFhe/cRvKcWknIpUXIPGi3pU2dk5mpSyrDktlVFttVoIoJIT/JlXloXYT0nFyJSeQq2oBgbXlKxtFJ2qc9mG2FSF0CtF3URhUcKr1EIam1ox20oUhaR5VVULmW1FHZ7CqL7SpQZYS0EAowKLseWhchLSdXYuR/xVrjkYqeJ/IhLZUQt2RyRJe3jeIy0pTySlrdkD+SeiZJXlok1bZPsWSHAsdGtaYWBKjsbVQqp4rkEJwSqkIxq98kHK7+W/wWVPdo4yEBo5NBnvKo9UhsWAqBcpZqR7CyxlKGfsnbEtqUBhvQqippXKpDTNWlnix5Wn9qY+l/0NYNMQ5GJZTYJ3ZZxlKN1z7K0Ddul4xkVAkJKZMJCdY/o9Dz9E0BBdYGtKUtpA7UpqZtKch4gSoa5ALGktQmIdXOHkdV4I0sEzjdbAvYm3gNCciVrOTuKx2JS5696bbYdtJcvhdyak4tu5LqZFWaMapCVpsiE89ES9loUjUFW3kMaRsMM35LAhJyDjJbqDUbG/qkQIxrbaFVRRWlzbEGNpQYQgjQNvmar9kpNQQ2g8Vlu0jq2Gw3ddGmTr611CUj15LZuWJLpSepQdIsl0VVHwpC2yMxNYyqK1g/0qZKmzFq0hbqBNTfhmIdVmeN16HLb+VM1HZ9je6AptiMZl9dUy1eb9KhakOxjgUBtMHnL7slAQoKCqo2FBRUbSgoqNpQUFyCsC8J6F4XqOyeKLt/xjpcViqChDyzLUktMK31kF8nIePL5HJfwPqn6XaMAe1rnnXuBVuHz439KxwPfxsEtfC30Zal41utNo59R4F9QtbhslJpzXplW5IaBPWkWQ/5dRIKtiOhZJqum6YDTuX+NuXEhQII1OVvo164zP1tmp1dKLIJRPde1L5/NnqWmq4vVrTZyptaNfd+OgmhwKnqO+s30KaQR7BKXVXdrhlLpScY5PYva1ueZl8BSsjSl+j+g1uyJQ1tXO6oarGchCqxRlAV61NyGn5bv49S2qQhBpU20sjtetklYJoAPsw9HHY3fTdSwP1jkssFNcBuzgp23bvSrpDQxgopefkIbNTfJhDPbbHdbENqY6wKBBouPadGVRqf0QbnIeVqWt+sitZDyGX+V2n9o2whvX9koDLNL68E5X1u1ts3XKZqg9RJjsPdBtVaSGi97W6z8qgFocoSs9ho0gaFW+7nV8qrYU1VZwt3qjU6xmDHDnD3CCPVfdciVVzZ9UWoholVNWnN32b7jTYO2xWRdURLH4YsS/pWr5t1uKysr1aDZKRRCxh7I+QrJlSFuY1d8BJysqlY/mZKnp5U4O+Vo81+qb8NBUXw0afMMkttG1aNV9Lo5hqKzbBfL3PXaOpvQ7HO5Q+0gWcvddDRhoKCqg0FBVUbCgqqNhQUVG0oKKjaUFBQULWhoKBqQ0FB1YaCgqoNBQVVGwoKCqo2FBRUbSgoqNpQUFC1oaCgakNBUQcQ4xzbItcBEeoUTXGpQG7NzuDDnyzy06571CmagsID7eHQ64rWwP+8+VoIiXVjpCUI9LO2sOUGOQghkKMsVxQho8aMcy0AxZwWn2fZE7ISN3TJDGBRXLBMlPCWbYXfKkQwA41JJjqo8PLgS67LJ1g2miF9cJHloiIgFldGNFdB360+B0aObWGOvVvWWgKJYnKQIxwbkfX6t1hNUY4t6izD5CmZS5gpVA3C4GtvzRhnU+fbT2yprdbEG8GJid2QnNDPDl1pBHeDEhTf/t88uv7BX/Te2fDLjpt+ODEBDbGlFTnSoPYFC8xbX9sxK+O44fw7374UlGbqRwdxwf6jW2RgLl+4ZmhyYmKLjZAdhzChwjWZVzGTBwa+/Ajm5eKrXUcN4iPnv6TIHvXPMgdOFIrZT/9GZivITXsOh7Syr63FxJhYIBWumjw4r0eLhEP00IOP7J+Rtfo3E/mHgRmuV2UpR3tIOxEUlhNqm6nWlOb+/WdeUQKtWrfQmltK7uAuMmaU3bWtOw8j7QTHxQBXQAJknmN5Qbu8Z6wJlmFgHD4Oq/B15cra9Cq0htS7uf6QwCezSvCJ3s5LYqy5fU35WwBxHP/pqIMfjbiR/L0CSGvgYZ/Cy8VXu16AsX3AqwUYH4cBKDInoZWrIDftOQyt7Mv56Yv2HHFeY0B0Yg0GZmBFr38TH4fzY9ozN6raJOerLZZMtH3iRUVXAGZbzeNsYZmJZbbeSNMQHw0/cSCORZGEmJjP9izpfSGMQQPgEXoIvgG3cmERGqcaxcJ5/e5regLvg/wloTY3vaX8Pa4UqYibRI6NzG4tocybyt9VWPostofuAEHAvFx8tetF5XCHcoGEhuC4DGL+fAW5ac9hkLITm6cTBq1RSF4EDORSuFq1+jcxZLLMqC8A+EG4ukLJha9+cwaUmnF/3nn9UGSqTtQmD+MxreHnrordBWuG2ghYel2P4uBX0t8PH7oKQrv4PezPFZsaoA8EY3EO1/ylgHsI4xDwXUrFNyxGD753awkttpJDerHn4OdxH0Watouvdr1POZxUJU+wP8LvDu1RKyMQ+sygUvbPK/PTLJy2RjE5vDFy9N70il7/JvpNlotkkGx7usqT9Z8WS91tKD5dJ2qDe6FureG37P3mw6pkiDZg6d2U/VwaSyjPjOM+ai5/Pjd5d/ZTpK7BEJejk6xzfDcTy6cbIDvEjNktlK1CNs/cBD+EYV3mDmjX00Z7TavX7yycL8wsv74cOJ+0maNS9h/hJn+x/8uSR14YV/Xe99s+pNe/VwwNy1+usjg+nVu+qlWzzZyf9l3LS5+uE7XBMzARDpPAEhx71aJOIgj35JeKjH4OMMoJfcxJdRS/xnjcq7brFsyinC02mj1DfaARmpRq8FrDUa83gphRK69BuaDYVo8uMb071wIlryx0Gc/pZc9chJcO26KQvBpUOw7PbQq2+icxBo0YGrrvVdbRqiqLnYsz0Q9q8xmwHG/rXJln6mZuE4LOURjB/YiI7f5rzNm9skoTZuUX+jnguTaezEc/yUGXuhDIdy2LuURECe64pH7qk+fahX4ewp9t6wKuLgixZzoxEwY6u8Bj7NCu48ON8G1lvR9XwSg8ie/8zQqk24N9D5dMJvXncApa2Q83TIr2KCQvVonSqMxtGL3+1dVlJUYaRjvVGJbHoNpfPQoLL3X+HegzT3Js/9foU+JWdmtOTJzNHj07D/cPXwk96Q+Klvrqgmeawt86J8KppoX4vgk8qjdOKza1cnf64dWO+Nk5tWf63iWkNpHG+ewxESI/WbhuaLIeCEWZgaWzk/BcJru4b8V9W7s+uy+bzfQoF2aGFo9msG2VamSAnw8Fzkd/DneGatnzvbc7vm4heZFWeupMy+CZOb3+VdtMwWTmaHaoBispgvjA1e82zlo7Ot+5h9nKSgq+uUbcGZoPFDFWeFsAiksYiTLjRVs2t9Ek1gPxPcvKrppP/Hdoxp1fsk7VBlIfDfYddDgk0pZ3SYOFhpLfIURm+DIpcMVNWV8R9ywB/2y3l5rWrdpQUNTvAEm3clJQ1Dmo2lBQULWhoKBqQ0FB1YZim0PapLi/rC0HqjYUFBXDug9GfSe2+Wbsit+RrbzcHrlVFbn0F7lUGjlC1nS0i5J+xyMFI76kZSg5okjkGvJ+SE/U7XNjSUaTjnLBQs6bjckVtGwlutB/uarNhoHc5+7mglwjn4SsKqs1Na/b2vPuFMxz7WHJI2sXFcl2C4H3I7oGWC4gazwPNvoFyehLqNZsB7VR+1RS41rjN4JK5ykZ3bnS2SKwnklGfFenrTVCKagjpWX0Q7Z+22PYkEqoh/ac84btofJcJJ/xLXh56IRmEyc3tYiLSquN2adKltZuHCRLP6xdQWbzltwDj63v18cCz/HJ1/RBFhvQnQKCklqjqrxlGHM85NJxNzP7qZJWifJoQjBVbZsPNqhU7ZTrNusybnMwLUT2RuNvl6maU6rNISilMEGkHywFyZMyKhkflUsXSX4KhUo8og/CFJelkaZPeq1Wf7CBTqreqFiVzlltqxuamIH/OByMvoTcAyXF5Ty3QeUbE6qgzUm+k3jkq2auiYiPLvosqaGSCozK63jFq4hWI80osj49k2hL2wZqAyXXob0tduPMc9lIcg47qHTHb6aB/Hp4VMF4JVUwpqxvVEAu+nTZeYPCreO4zaUseGVZwDTe1aBm/tiNfMuZ5P7exfKMZ7eLjIU2e6r6wCEFLalV1yzNtqzF5rs+bEvGcSG4SqgFoxqkd2DBJRFYxpuTqn+66/K3kVC1aG1yOhLanJwkOpJsoEYqUAa0lamWSLfizTUSRm20ppamg1RjfaZG2paJuZJUUcVzm/WXG22FiDeYAqo8Wao69aRiNU6VbuWk2AI77VJn20yrkaL+FgOkOh/NqdpQ1NbmCjTY1I3O+LClRhoFNdEqZttsGxg9FN3YN1/hGohze6Tzmwvr1k7w98Ax3GAq8Y0x9mobu/rpzv26sdQ2w/5Cm2TU+bJttg2Mvo1rg62u1Jas0n4u+q7lSnxj7Fu2Lc4OFPViqVU7NtocDr4xvYw0SZKMg6Q1Wkm/LOkOW+pdcNzRnrWnhe9Yb+rpSr5K6e92sA0MA4r6R7N3IzM6a2R4iUnI0w8TwMMpx5EWsnnlkP9Wj5VS1prux+OjAoG2XVoc3SgoNkltygxS9s1myOauHHT889zdXHbLs11b6HeOFFsGfyMNOe2tEq3YjOlppPndXLcJhTBo3VFsEsr/9H+z/1gQfEphN6Ek33GlzF42axwJBVKqIEYatc7qDOpLpQJHl+OrxdAsAzw3B9BSWFKeH27cMQ2QGuwfjs1sIGloy65xs6435dxup5sMNtpo8/xACmP7oSVHyOuC5Lpk+ukgcxAJ2tStz1BcKkiSd64FxQ5u6oLyps6evAji8iHy/AX+IkBucCg5f7F9A0nLF381NRl3tZ/ybzpv9FIFssdZOxhNHNm2PlvPLGHk2B5te8hMWE1XXVYje6qdPwFlLtS52flqsKT/oo69AHTMqU+08ywnQGgKZB4yYZbPqIOF8u7P+BHIMRzfRuIVxwVhQWnJTTz8TrOOBGkNID40APyc13t0UmE21AIhGTI8yFHy9ng96RYOBJY5kiLxWiIDgvA8vqvnj0KsgKMlSDw5wqjvnS+nNkjvws0DMqbe2rnZzxtPWO4gpK0MIGs0ZE0B9HSROV4gj0FEe8ZrJcJv5AFHPnTZoI7xl5FCJAu598EfMXB9qBC63rzV9BO4J5r/1c3k5Du7X5DJAMBeAUd1g0rgAfoHcID3esXfR58p8DlgT8GNLDQzhUctU5HHpiD7pPzw35OTFeUV8t2LYOS/+nZ0ERt5SRKv9VGZbQ2+JFDfWJ9fPh1s6mlyQ14R+r0ZEPvgxzIUOAiNwbjltaNjAvy7nHr/A+Tk2OqRyBFl4Gnqg5Um7fkPfcealDPp3ABIffCHx0B+HELjELMk/QEBmgdzuafUgUx/W6ae/6Qg9hvxlvfBuM8L6+nb1ChqrjXq7ENul9d6kuK7lvHAoFxiZHLAH+Ugo3zjDn26L+4uKHG4qY6Cdrsdm21qOrYZu3aSuWF1FSe9M8+psdiCNWnxyhWITxNtuaiMXqLgzl8LAZevZEmAgmKzES/ORLG11YTwCJLGs321KeqLv8ziH8KLJMSJIMyvkmsPsfrD00WAYeVdsqmUR9IfbmAXcNJMnMOxRD1NPWlh6UJ0QTUGr1DU913W/C1Ii75L0VRtKLYIKzM5MmO5Dnf8DA+dy4oiiLr1E8oJj62qarNHFuNkTvPIF5oMUx2Hhu7JQeqhBY+ki8yYMp15ZD/+m+dhFOfTlRN3aXd5QXhLDYWzKZB38Eb++oqCqi3LL0MnR9WGoq4wv+NWpfW9owwayVYuj+es8/GOH2t3dyBWs44mpWjHyhxRpb7HtQkMu3wKYOBYPDF4zOul1ZEDHcq8KDaMp/wrbcxNK3iGFL9Vb+u/OsjGI+qY9dwNXDQkGflr4DpUvT7CFmbp3IaCokqgow0FBVUbCgqqNhQUVG0oKKjaUFBQtaGgoKBqQ0FB1YaCgqoNBQVVGwqK7YL/B7CW5wJmiCIOAAAAAElFTkSuQmCC</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-04-05 17:02:05 +0200" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-11-07 16:14:15 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Comment to the review by Welschen</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-02-03 16:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>Welschen reports some conclusions and implications for the practice that do not seem to be closely and accurately based in the results of the review.</P>
<P>The conclusions of Welschen are: &#8230;self-monitoring of blood glucose (SMBG) might be effective in improving glycaemic control in patients with type 2 diabetes who are not using insulin..&#8230;.by using SMBG, patients can achieve a more individual management of their disease and thereby a better quality of life and this might result in a decrease in consultations with the general practitioner.</P>
<P>In my opinion, it is unclear on what results is Welschen based to write these conclusions. In fact, after reading the results I believe the conclusions should have been neutral or even the opposite ones. In Results Welschen wrote:</P>
<P>- The studies of <LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK> and <LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK> [no efficacy of SMBG] were considered of high quality&#8230; The studies of <LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>, <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK> &#8230;&#8230;and <LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK> and <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> [the only two trials reporting efficacy of the SMBG] &#8230;were considered to be of low quality.</P>
<P>- Heterogeneity... Because of differences in baseline data of the patients and type of interventions between the studies, it was not possible to perform either a meta-analysis and/or subgroup or sensitivity analyses.</P>
<P>- Glycaemic control measured by HbA1c&#8230; <LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>, <LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK> and <LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK> [the only one blinded and with a high quality score] found no statistically significant differences in the decrease of HbA1c between the SMBG and the control groups&#8230; <LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK> [low quality] found a statistically significant difference of 0.5% in HbA1c in favour of SMBG&#8230;<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> [low quality] also found a statistically significant difference of 0.4% in HbA1c at the end of the study between the SMBG and control group.</P>
<P>- We considered that the SMBG group in <LINK REF="REF-Schwedes-2002" TYPE="REFERENCE">Schwedes 2002</LINK> did receive a co-intervention by means of a structured counseling program every four weeks during the intervention period. The control group only received a non-standardised counseling [see results]&#8230;&#8230;. However, because this was considered as a co-intervention, the effect of SMBG only is not clear [see Discussion].</P>
<P>- <LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK> reported a dropout rate of more than 40% [48% in the intervention group], which was considered non-acceptable.</P>
<P>- In addition, there is no evidence that SMBG has a beneficial effect on fasting plasma glucose, quality of life, well-being, patient satisfaction and number of hypoglycaemic episodes.</P>
<P>In medical statistics the presumption of efficacy does not exist, but it is the opposite. It starts with the null hypothesis (there are not significant differences between an intervention [SMBG] versus other [blood glycated haemoglobin every 2-4 months]) and clinical trials are performed to try to pull the null hypothesis down.</P>
<P>Welschen has failed to achieve it in her review. Her conclusions on the efficiency of the self-monitoring are based on two studies that herself has almost rejected before for deficient quality: one because a co-intervention in favour of the group of self-monitoring (risk of attrition bias), and the second because a clinical trial where the drop-outs and withdrawals rise up to 48 % of the participants loses the benefit of the randomisation, of the sample size, set doubts about the internal validity and more obvious doubts about the external validity (the applicability to the general population) of the results.</P>
<P>None of these inconveniences have been reported in the conclusions.</P>
<P>1. Coster S. Monitoring blood glucose control in diabetes mellitus: a systematic review. NHS R&amp;D HTA Programme. Health Technology Assessment. 2000;4(12).</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-11-07 16:14:15 +0100" MODIFIED_BY="[Empty name]">
<P>In our review, we tried to assess the effects of self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes who are not using insulin in order to eliminate the debate on the effectiveness of SMBG as a tool in the self-management of these patients.<BR/>Sáenz comment was that our conclusions were not based on accurate results. We respectfully disagree with Sáenz and we will argue below that we still stick to the conclusion from our review that SMBG might improve glycaemic control.</P>
<P>The review of Coster 2000 (1) cannot be used as an adequate summary of the evidence for the effect of SMBG by health care professionals, as was suggested by Sáenz, because it is out-dated and because of the inclusion of a trial with patients using insulin (Wing 1986).<BR/>Our review included all randomised controlled trials until September 2004 (2).</P>
<P>The direction of the effect of the combined studies is clearly in favour of SMBG and definitely not the opposite as Sáenz stated. The absence of a statistical significant effect should not be interpret as evidence of no effect (3). Moreover, since the largest studies included in our review found statistically significant differences suggests that the other smaller studies possibly did not include enough patients.</P>
<P>In our review we reported clearly that the evidence for an effect of SMBG on HbA1c was moderate, based on the overall methodological quality of the trials. In addition, in our methods section it was described that we did not intend to exclude trials on the basis of methodological quality criteria as suggested by Sáenz. In our discussion section, we explicitly described all methodological issues that should be taken into account before reading definitive conclusions.</P>
<P>We concluded that SMBG might be effective which in our opinion implies that the conclusions should be interpreted with caution. Because of the remaining uncertainty we also recommend a high quality randomised controlled trial to provide more solid evidence of the effect of SMBG on a large range of outcomes. We believe that, apart from glycaemic control, quality of life, well-being and patient satisfaction are all very important outcome measures. Unfortunately, these outcome measures where not measured in most of the studies and therefore we could not draw conclusions on these important outcomes.</P>
<P>With respect to our review, we conclude that we paid sufficient attention to all the limitations in the available evidence in our review. In our view it is too early to reject a potentially helpful tool for patients with diabetes who need to incorporate their chronic disease into their daily lives.</P>
<P>Laura MC Welschen, MSc<BR/>Evelien Bloemendal, MSc<BR/>Giel Nijpels, MD, PhD<BR/>Jacqueline M. Dekker, PhD<BR/>Robert J. Heine, MD, PhD<BR/>Wim A.B. Stalman, MD, PhD<BR/>Lex M. Bouter, PhD</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Antonio Sáenz, Instituto Madrileno de la Salud, Spain</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2012-04-05 17:02:05 +0200" MODIFIED_BY="Bernd Richter" NO="2">
<TITLE MODIFIED="2012-04-05 16:30:27 +0200" MODIFIED_BY="Bernd Richter">Comments to the review by Malanda et al</TITLE>
<DATE_SUBMITTED>
<DATE DAY="6" MONTH="3" YEAR="2012"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-04-05 17:01:53 +0200" MODIFIED_BY="Bernd Richter">
<P>In the review, the authors conclude that &#8220;the overall effect of self-monitoring of blood glucose on glycaemic control in patients with type 2 diabetes who are not using insulin is small up to six months after initiation and subsides after 12 months&#8221; [1]. For the meta-analysis on the effects of SMBG vs. control in patients with a diabetes duration greater than one year, nine studies with a six months follow-up (2324 patients) were included. For the corresponding 12 months follow-up, two of the 9 studies (493 patients) were included. The HbA1c reduction of -0.3% (-0.4 to -0.1) at six months [1] was statistically significant and in view of UKPDS, in which a 1% reduction in HbA1c was associated with a 37% decrease in risk for microvascular complications and a 21% decrease in the risk of any end point or death related to diabetes [2], a statistically significant reduction of HbA1c 0.3% at six months should be recognized and valued for the treatment of type 2 diabetes. We feel it is a limitation of the analysis that only two studies, DiGEM trial and ZODIAC-17 [3,4], were included in the 12 month follow-up meta-analysis. In the analysis a non-significant decrease in HbA1c (-0.13% (-0.13 to -0.04)) was reported. Both studies, furthermore, are characterized by several limitations, which need to be considered: In the DiGEM trial, HbA1c values of the patients in the three different groups ranged from 7.41% to 7.53%. Inclusion of patients with a stable and relatively good metabolic control at entry into the study may have attenuated the need for a modification or intensification of treatment within any of the three groups. In the study, therefore, the usage of oral antidiabetic agents (OADs) was increased only in less than one-third of the patients. In both the less intensive and the more intensive intervention groups, OADs were not increased more frequently as compared with the control group (29% and 32% vs 30%). No specific algorithm for modification of treatment plans was mentioned. It is also noteworthy, that the enrolled patients were a highly selected population (453 patients out of 2986 total eligible ones) [5]. ZODIAC-17 is a small Dutch study, in which only 22 patients were included in the SMBG group, of whom 17 performed at least 80% of the requested glucose measurements. The authors of the study mention in the discussion the sample size as an important limitation of the study. In the study, structured testing of blood glucose was not applied and any information on modification of treatment is missing [3]. We, therefore, would like to point out that due to the limitations of the two studies the conclusions given in the Cochrane analysis for the 12 months follow-up are not warranted. The fact that recent prospective and randomized studies which demonstrated benefits of structured self-monitoring of blood glucose approaches in non-insulin treated type 2 diabetes mellitus, e.g. STeP-study, St. Carlos study and ROSES [6-8], report significant outcome results opposite to your meta-analysis, further limits your conclusions.</P>
<P/>
<P>References </P>
<P>1. Malanda UL, Welschen LM, Riphagen, II, et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012;1:CD005060.<BR/>2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.<BR/>3. Kleefstra N, Hortensius J, Logtenberg SJ, et al. Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). Neth J Med 2010;68:311-316. <BR/>4. Farmer A, Wade A, French DP, et al. The DiGEM trial protocol--a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes [ISRCTN47464659]. BMC Fam Pract 2005;6:25.<BR/>5. Schnell O, Heinemann L. Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: a never ending story? J Diabetes Sci Technol 2007;1:614-616 6. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011;34:262-267. <BR/>7. Duran A, Martin P, Runkle I, et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. J Diabetes 2010;2:203-211.<BR/>8. Franciosi M, Lucisano G, Pellegrini F, et al. ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomized clinical trial. Diabet Med 2011;28:789-796.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-04-05 17:02:05 +0200" MODIFIED_BY="Bernd Richter">
<P>In our review<SUP>1</SUP>, we explored whether newer trials with possible good or improved methodological quality and design, published after Welschen et al.<SUP>2</SUP> would provide new evidence of the effects of self-monitoring of blood glucose on glycaemic control in patients with type 2 diabetes mellitus who are not using insulin.<BR/>We thank Schnell et al. for their comments regarding the clinical relevance of a 0.3% reduction in HbA1c after six months of self blood glucose monitoring and the limited amount of available evidence for longer-term effects in patients with longer duration of diabetes.</P>
<P>In our discussion we have acknowledged that the reduction in HbA1c of 0.3% observed in the subgroup of patients with diabetes duration of at least one-year and a six month follow-up is statistically significant. Indeed, in the UKPDS the observed difference of 7.9% and 7.0 % between the control and the intervention groups was associated with considerably reduced morbidity and mortality. Since then, a reduction of 0.5% had generally been accepted to be of clinical relevance<SUP>3</SUP> and most included and more recent trials have based their power on this<SUP>4-7</SUP>. These expected effects were not achieved, and compared to the expectations, a reduction of 0.3% is relatively small.</P>
<P>We agree that from a public health perspective, small reductions might have an important role - however, under the condition that these are achieved at a large scale and at low cost. For SMBG so far, this is not the case<SUP>3;8</SUP>.</P>
<P>With respect to the limited number of longer-term studies, we like to stress that our review was performed under the stringent conditions of the Cochrane Collaboration. Therefore, an extensive assessment of risk of bias was performed following previously determined guidelines. Both the DiGEM trial and ZODIAC-17<SUP>4;9</SUP> were assessed with low risk of bias on most domains, indicating proper internal validity.</P>
<P>Both trials assessed and compared SMBG effects with patients not using SMBG in an existing usual diabetes care structure and with oral glycaemic titration schedules in line with the national diabetes guidelines at the time the study was performed<SUP>9;10</SUP>.</P>
<P>The subgroup under critique was a-priori defined, was designed to limit clinical heterogeneity and met the widely acknowledged GRADE working group criteria<SUP>11</SUP>. The results from the 12-months analysis show an estimate of the effect comparable to the estimate found in the 12 months analysis ([-0.4 to -0.1] vs. [-0.3 to 0.04]) indicating a similar precision in effect. Further, a best-evidence synthesis would have shown a similar non-significant direction in effect.</P>
<P>Summarized, we stress that the 12-months analysis is correctly performed, that included studies met the highest criteria for inclusion and thus results are valid.</P>
<P>We agree that patients in the specific subgroup were moderately controlled (range 7.4% to 7.7%) and therefore potentially less susceptive to benefit from SMBG. However, this was according to the predefined cut points. Furthermore, in a recent published individual patient data meta-analysis<SUP>12</SUP> the effects of SMBG did not differ between groups with different levels of baseline entry HbA1c.</P>
<P>All studies that were mentioned to demonstrate benefits of structured SMBG were indeed included in our review and taken up in the appropriate subgroup analyses, except for the STeP study<SUP>5</SUP>. This study did not comply with our inclusion criteria having a control-group with access to self-monitoring. The ROSES-study<SUP>7</SUP> is included in the subgroup of patients with a diabetes duration of one year and a follow-up of six months; the St. Carlos study<SUP>13</SUP> is taken up in the subgroup of newly diagnosed patients with a follow-up of six and 12 months. Conclusions resulting from these subgroup analyses are not comparable with the conclusion of the subgroup under critique and therefore do not limit our analysis.</P>
<P>Thus, though we acknowledge the amount of available evidence for longer-term effect in patients with diabetes duration of over one year is limited, predefined protocols were followed leading to the inclusion of good quality studies.</P>
<P>At the present state of evidence, we feel our conclusions are justified. Of course, in future studies, with more innovative interventions, extended behavioural strategies or in additional subgroups, SMBG may be proven beneficial on the long-term. Still, these future studies have to prove cost-effectiveness. As we stated in our discussion: translation into practice of the presented results is difficult, and should be done with caution.</P>
<P/>
<P>Reference List: </P>
<P>     (1)   Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012; 1:CD005060.<BR/>     (2)   Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2005;(2):CD005060.<BR/>     (3)   Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14(12):1-140.<BR/>     (4)   Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ (Clinical research ed ) 2007; 335(7611):132.<BR/>     (5)   Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011; 34(2):262-267.<BR/>     (6)   O'Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008.<BR/>     (7)   Franciosi M, Lucisano G, Pellegrini F, Cantarello A, Consoli A, Cucco L et al. ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type-2 diabetes not receiving insulin. A pilot randomized clinical trial. Diabetic Medicine 2011.<BR/>     (8)   Davidson MB. Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck. Rev Recent Clin Trials 2010.<BR/>     (9)   Kleefstra N, Hortensius J, Logtenberg SJ, Slingerland RJ, Groenier KH, Houweling ST et al. Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). Neth J Med 2010; 68(1):311-316.<BR/>   (10)   Farmer A, Wade A, French DP, Goyder E, Kinmonth AL, Neil A. The DiGEM trial protocol-a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes [ISRCTN47464659]. BMC Fam Pract 2005; 6:25.<BR/>   (11)   Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004; 4(1):38.<BR/>   (12)   Farmer AJ, Perera R, Ward A, Heneghan C, Oke J, Barnett AH et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ 2012; 344:e486.<BR/>   (13)   Duran A, Martin P, Runkle I, Perez N, Abad R, Fernandez M et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: The St Carlos study, a prospective randomized clinic-based interventional study with parallel groups. Journal of Diabetes 2 (3) ()(pp 203-211), 2010 Date of Publication: September 2010 2010;(3):203-211.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-04-05 16:56:19 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>Oliver Schnell</B>
<BR/>Email Address: <A HREF="mailto:oliver.schnell@lrz.uni-muenchen.de">oliver.schnell@lrz.uni-muenchen.de</A>
<BR/>Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.<BR/>
</P>
<P>Oliver Schnell(1), Hasan Alawi(2), Tadej Battelino(3), Antonio Ceriello(4), Peter Diem(5), Anne-Marie Felton(6), Wladyslaw Grzeszczak(7), Kari Harno(8), Peter Kempler(9), Ilhan Satman(10), Bruno Vergès(11) </P>
<P>Author Affiliations: <BR/>(1) Diabetes Research Group, Helmholtz Center, Munich, Germany <BR/>(2) Diabetes Centrum Saar, Saarlouis, Germany <BR/>(3) University Children´s Hospital, Ljubljana, Slovenia <BR/>(4) Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain <BR/>(5) Bern University Hospital, Bern, Switzerland <BR/>(6) Foundation of European Nurses in Diabetes, London, UK <BR/>(7) Department of Internal Medicine and Diabetology, Zabrze, Poland <BR/>(8) University of Eastern Finland, Finland <BR/>(9) Semmelweis University, Budapest, Hungary <BR/>(10) Istanbul university, Istanbul Faculty of Medicine, Istanbul, Turkey <BR/>(11) Hôpital du Bocage, Dijon, France</P>
<P/>
<P>
<B>Uriëll Malanda</B> on behalf of the authors.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2011-11-30 13:01:46 +0100" MODIFIED_BY="Gudrun Paletta">
<APPENDIX ID="APP-01" MODIFIED="2011-11-29 14:54:51 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2009-04-20 13:20:20 +0200" MODIFIED_BY="Gudrun Paletta">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-29 14:54:51 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P/>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) substitutes one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.<BR/>
</P>
<P/>
<P>
<B>MEDLINE</B>
<BR/>
</P>
<P>1. exp Blood glucose self-monitoring/<BR/>2. self monitor$.ti,ab.<BR/>3. exp Blood Glucose/ or (blood adj glucos$).ti,ab. or (blood adj sugar$).ti,ab.<BR/>4. 1 or (2 and 3)<BR/>5. exp Diabetes mellitus, non insulin dependent/ or exp Insulin resistance/<BR/>6. (impaired glucose toleran$ or glucose intoleran$ or insulin resistan$).ti,ab.<BR/>7. (obes$ adj2 diabet$).ti,ab.<BR/>8. (mody or niddm).ti,ab.<BR/>9. (diabet$ and (non insulin$ depend$ or noninsulin$ depend$ or noninsulindepend$ or non insulindepend$ or noninsulinsdepend$ or non insulinsdepend$)).ti,ab.<BR/>10. ((typ$ 2 or typ$ II) adj diabet$).ti,ab.<BR/>11. ((ketoresist$ or keto$ resist$ or nonketo$ or non keto$) adj diabet$).ti,ab.<BR/>12. ((adult$ or matur$ or late or slow or stabl$) adj diabet$).ti,ab.<BR/>13. ((plurimetabolic$ or metabolic) adj syndrom$).ti,ab.<BR/>14. (insulin$ defic$ adj relativ$).ti,ab.<BR/>15. 6 or 11 or 7 or 9 or 12 or 14 or 8 or 10 or 13 or 5<BR/>16. exp Diabetes insipidus/<BR/>17. (exp Child/ or exp Infant/) not (exp adult/ or exp adolescent/)<BR/>18. (4 and 15) not (16 or 17)<BR/>19. (randomised controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.<BR/>20. clinical trial.mp. or clinical trial.pt. or random$.mp. or tu.xs.<BR/>21. Cross-over Studies/ or exp Double-blind method/ or exp Single-blind method/ or exp Control groups/ or exp Random Allocation/ or exp Evaluation studies/ or exp Comparative study/<BR/>22. 18 and (19 or 20 or 21)<BR/>23. limit 22 to yr="2004 -Current"</P>
<P/>
<P>
<B>EMBASE</B>
</P>
<P>1. ((ketoresist$ or keto$ resist$ or nonketo$ or non keto$) adj diabet$).ti,ab.<BR/>2. ((adult$ or matur$ or late or slow or stabl$) adj diabet$).ti,ab.<BR/>3. (insulin$ defic$ adj relativ$).ti,ab.<BR/>4. ((plurimetabolic$ or metabolic) adj syndrom$).ti,ab.<BR/>5. ((typ$ 2 or typ$ II) adj diabet$).ti,ab.<BR/>6. (diabet$ and (non insulin$ depend$ or noninsulin$ depend$ or noninsulindepend$ or non  insulindepend$ or noninsulin?depend$ or non insulin?depend$)).ti,ab.<BR/>7. (mody or niddm).ti,ab.<BR/>8. (obes$ adj2 diabet$).ti,ab.<BR/>9. (impaired glucose toleran$ or glucose intoleran$ or insulin resistan$).ti,ab.<BR/>10. exp Non insulin dependent diabetes mellitus/ or exp Insulin resistance/ or exp Diabetic obesity/<BR/>11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10<BR/>12. exp Blood glucose monitoring/<BR/>13. self monitor$.ti,ab.<BR/>14. exp Glucose blood level/ or (blood adj glucos$).ti,ab. or (blood adj sugar$).ti,ab.<BR/>15. 13 and 14<BR/>16. 12 or 15<BR/>17. 11 and 16<BR/>18. 17 not exp Diabetes insipidus/<BR/>19. exp Randomized controlled trial/ or exp Controlled clinical trial/ or exp Crossover-procedure/ or exp Double-blind procedure/ or exp Single-blind procedure/ or exp Control group/ or exp Randomization/ or exp Evaluation/ or exp Comparative study/<BR/>20. (random$ or factorial$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).ti,ab.<BR/>21. limit 18 to (human and yr="2004 - 2010")<BR/>22. 21 not (exp Child/ not exp adult/)<BR/>23. limit 22 to "treatment (1 term high sensitivity)"<BR/>24. 23 or (22 and (19 or 20))</P>
<P/>
<P>
<B>
<I>The Cochrane Library</I>
</B>
</P>
<P>
<B>(CENTRAL)</B>
</P>
<P>1. (impaired NEXT glucose NEXT toleran* OR glucose NEXT intoleran* OR insulin* NEXT resistan* OR obes* NEAR diabet* OR MODY OR NIDDM) in Clinical Trials<BR/>2. (diabet* AND (non NEXT insulin* NEXT depend* OR noninsulin* NEXT depend* OR noninsulindepend* OR non NEXT insulindepend* OR noninsulinsdepend* OR non NEXT insulinsdepend*)) in Clinical Trials<BR/>3. (typ* NEXT 2 OR typ* NEXT II) NEAR/2 diabet* in Clinical Trials<BR/>4. ((keto* NEXT resist*) OR nonketo*) NEAR/2 diabet* in Clinical Trials<BR/>5. (adult* OR matur* OR late OR slow or stabl*) NEAR/2 diabet* in Clinical Trials<BR/>6. (insulin* NEXT defic* NEAR relativ*) in Clinical Trials<BR/>7. (plurimetabolic NEXT syndrom*) in Clinical Trials<BR/>8. (blood NEAR/2 glucos* OR blood NEAR/2 sugar*) AND (self NEXT monitor* OR selfmonitor*) in Clinical Trials<BR/>9. (( #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 ) AND #8), from 2004 to 2010</P>
<P>
<B>(NHSEED, CDSR, DARE, HTA)</B>
</P>
<P>1. (glucos* OR sugar* OR insulin* OR diabet*) and (selfmonitor* OR self-monitor*), from 2004 to 2010</P>
<P/>
<P>
<B>PsycINFO</B>
</P>
<P>1     (glucose or sugar).mp. or Blood sugar/ (7319)<BR/>2     Self monitor*.mp. or Self monitoring/ (3801)<BR/>3     1 and 2 (98)<BR/>4     limit 3 to yr="2004 -Current" (54)</P>
<P/>
<P>
<B>Current Controlled Trials </B>
</P>
<P>1. (monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)<BR/>2. (self) AND (monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)<BR/>3. (self-monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic) <BR/>4. (self monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-11-29 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-10-29 15:57:57 +0200" MODIFIED_BY="[Empty name]">Baseline characteristics of included studies</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-29 14:57:59 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="10" ROWS="28">
<TR>
<TH>
<P>Characteristic &#9658;</P>
<P>Study ID &#9660;</P>
</TH>
<TH>
<P>Participating population</P>
</TH>
<TH>
<P>Male (%)</P>
</TH>
<TH>
<P>Female (%)</P>
</TH>
<TH>
<P>Age (years)</P>
</TH>
<TH>
<P>HbA1c (%)</P>
</TH>
<TH>
<P>Body mass index (kg/m<SUP>2</SUP>)</P>
</TH>
<TH>
<P>Diabetes duration (years)</P>
</TH>
<TH>
<P>Duration of intervention (weeks)</P>
</TH>
<TH>
<P>Duration of follow-up (weeks)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
</P>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>57.9 ± 10.7</P>
</TD>
<TD ALIGN="CENTER">
<P>11.7 ± 3.0</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>9.0 ± 10.3</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>58.2 ± 9.7</P>
</TD>
<TD ALIGN="CENTER">
<P>12.4 ± 3.3</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>6.8 ± 6.5</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>51.8</P>
</TD>
<TD ALIGN="CENTER">
<P>47.8</P>
</TD>
<TD ALIGN="CENTER">
<P>55.9 ± 9.3</P>
</TD>
<TD ALIGN="CENTER">
<P>8.1 ± 0.84</P>
</TD>
<TD ALIGN="CENTER">
<P>30.3 ± 5.0</P>
</TD>
<TD ALIGN="CENTER">
<P>2.8 ± 4.5</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>48.2</P>
</TD>
<TD ALIGN="CENTER">
<P>50.5</P>
</TD>
<TD ALIGN="CENTER">
<P>56.1 ± 9.1</P>
</TD>
<TD ALIGN="CENTER">
<P>8.1 ± 0.89</P>
</TD>
<TD ALIGN="CENTER">
<P>30.5 ± 5.3</P>
</TD>
<TD ALIGN="CENTER">
<P>2.8 ± 3.7</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>31.1</P>
</TD>
<TD ALIGN="CENTER">
<P>68.9</P>
</TD>
<TD ALIGN="CENTER">
<P>50.9 ± 11.0</P>
</TD>
<TD ALIGN="CENTER">
<P>8.5 ± 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P>33.4 ± 7.0</P>
</TD>
<TD ALIGN="CENTER">
<P>5.8 ± 5.8</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>20.9</P>
</TD>
<TD ALIGN="CENTER">
<P>79.1</P>
</TD>
<TD ALIGN="CENTER">
<P>49.8 ± 11.2</P>
</TD>
<TD ALIGN="CENTER">
<P>8.4 ± 2.12</P>
</TD>
<TD ALIGN="CENTER">
<P>31.7 ± 6.7</P>
</TD>
<TD ALIGN="CENTER">
<P>5.5 ± 4.7</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>55.9</P>
</TD>
<TD ALIGN="CENTER">
<P>44.1</P>
</TD>
<TD ALIGN="CENTER">
<P>66.3 ± 10.2</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 1.09</P>
</TD>
<TD ALIGN="CENTER">
<P>30.9 ± 6.1</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (2 to 6)</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>SMBG less intensive</P>
</TD>
<TD ALIGN="CENTER">
<P>58.7</P>
</TD>
<TD ALIGN="CENTER">
<P>41.3</P>
</TD>
<TD ALIGN="CENTER">
<P>65.2 ± 10.6</P>
</TD>
<TD ALIGN="CENTER">
<P>7.4 ± 1.02</P>
</TD>
<TD ALIGN="CENTER">
<P>31.9 ± 6.2</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (2 to 7)</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG more intensive</P>
</TD>
<TD ALIGN="CENTER">
<P>57.6</P>
</TD>
<TD ALIGN="CENTER">
<P>42.4</P>
</TD>
<TD ALIGN="CENTER">
<P>65.6 ± 9.9</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 1.12</P>
</TD>
<TD ALIGN="CENTER">
<P>31.0 ± 5.3</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (2 to 6)</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>46.8</P>
</TD>
<TD ALIGN="CENTER">
<P>53.2</P>
</TD>
<TD ALIGN="CENTER">
<P>64.7 ± 9.6</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 0.54</P>
</TD>
<TD ALIGN="CENTER">
<P>29.8 ± 5.1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>45.5</P>
</TD>
<TD ALIGN="CENTER">
<P>54.5</P>
</TD>
<TD ALIGN="CENTER">
<P>62.5 ± 10.4</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 0.17</P>
</TD>
<TD ALIGN="CENTER">
<P>30.1 ± 5.2</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>87.5</P>
</TD>
<TD ALIGN="CENTER">
<P>12.5</P>
</TD>
<TD ALIGN="CENTER">
<P>48.7± 0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>7.9 ± 0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>30.2 ± 3.9</P>
</TD>
<TD ALIGN="CENTER">
<P>3.2 ± 4.4</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>69.6</P>
</TD>
<TD ALIGN="CENTER">
<P>30.4</P>
</TD>
<TD ALIGN="CENTER">
<P>48.9 ± 0.5</P>
</TD>
<TD ALIGN="CENTER">
<P>7.9 ± 0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>31.8 ±4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>3.4 ± 3.5</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>58.8</P>
</TD>
<TD ALIGN="CENTER">
<P>41.2</P>
</TD>
<TD ALIGN="CENTER">
<P>56.3 ± 9.1</P>
</TD>
<TD ALIGN="CENTER">
<P>8.2 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>27.0 ± 4.1</P>
</TD>
<TD ALIGN="CENTER">
<P>12.7 ± 0.8</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ALIGN="CENTER">
<P>72.2</P>
</TD>
<TD ALIGN="CENTER">
<P>27.8</P>
</TD>
<TD ALIGN="CENTER">
<P>54.9 ± 10.2</P>
</TD>
<TD ALIGN="CENTER">
<P>8.6 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>26.0 ± 3.4</P>
</TD>
<TD ALIGN="CENTER">
<P>13.3 ± 6.8</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>52.9</P>
</TD>
<TD ALIGN="CENTER">
<P>47.1</P>
</TD>
<TD ALIGN="CENTER">
<P>54.5 ± 10.7</P>
</TD>
<TD ALIGN="CENTER">
<P>8.2 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>27.1 ± 4.1</P>
</TD>
<TD ALIGN="CENTER">
<P>12.2 ± 6.6</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>56.6</P>
</TD>
<TD ALIGN="CENTER">
<P>43.4</P>
</TD>
<TD ALIGN="CENTER">
<P>62.2 ± 9.1</P>
</TD>
<TD ALIGN="CENTER">
<P>8.9 ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P>29.7 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>8.4 ± 6.6</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>53.7</P>
</TD>
<TD ALIGN="CENTER">
<P>46.3</P>
</TD>
<TD ALIGN="CENTER">
<P>60.9 ± 9.4</P>
</TD>
<TD ALIGN="CENTER">
<P>9.0 ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P>30.4 ± 6.1</P>
</TD>
<TD ALIGN="CENTER">
<P>7.7 ± 6.3</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK> </P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>72.2</P>
</TD>
<TD ALIGN="CENTER">
<P>27.8</P>
</TD>
<TD ALIGN="CENTER">
<P>58.7 ± 7.8</P>
</TD>
<TD ALIGN="CENTER">
<P>7.7 ± 0.4</P>
</TD>
<TD ALIGN="CENTER">
<P>32.7 ± 5.8</P>
</TD>
<TD ALIGN="CENTER">
<P>8.0 (3.8 to 11.3)</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>54.5</P>
</TD>
<TD ALIGN="CENTER">
<P>45.5</P>
</TD>
<TD ALIGN="CENTER">
<P>59.5 ± 8.0</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6 ± 0.5</P>
</TD>
<TD ALIGN="CENTER">
<P>29.0 ± 4.6</P>
</TD>
<TD ALIGN="CENTER">
<P>5.0 (4.0 to 7.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>45.5</P>
</TD>
<TD ALIGN="CENTER">
<P>54.5</P>
</TD>
<TD ALIGN="CENTER">
<P>60.1 ± 7.3</P>
</TD>
<TD ALIGN="CENTER">
<P>10.5 ± 1.5</P>
</TD>
<TD ALIGN="CENTER">
<P>33.3 ± 4.3</P>
</TD>
<TD ALIGN="CENTER">
<P>5.2 ± 4.6</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
</TD>
<TD ALIGN="CENTER">
<P>44</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>33.3</P>
</TD>
<TD ALIGN="CENTER">
<P>66.7</P>
</TD>
<TD ALIGN="CENTER">
<P>57.3 ± 8.0</P>
</TD>
<TD ALIGN="CENTER">
<P>10.3 ± 1.1</P>
</TD>
<TD ALIGN="CENTER">
<P>35.1 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>5.7 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
</TD>
<TD ALIGN="CENTER">
<P>44</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>63.6</P>
</TD>
<TD ALIGN="CENTER">
<P>36.4</P>
</TD>
<TD ALIGN="CENTER">
<P>60.9 ± 11.5</P>
</TD>
<TD ALIGN="CENTER">
<P>8.6 ± 2.3</P>
</TD>
<TD ALIGN="CENTER">
<P>32.0 ± 6.2</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>57.3</P>
</TD>
<TD ALIGN="CENTER">
<P>42.7</P>
</TD>
<TD ALIGN="CENTER">
<P>57.7 ± 11.0</P>
</TD>
<TD ALIGN="CENTER">
<P>8.8 ± 2.1</P>
</TD>
<TD ALIGN="CENTER">
<P>34.0 ± 7.0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>51.8</P>
</TD>
<TD ALIGN="CENTER">
<P>48.2</P>
</TD>
<TD ALIGN="CENTER">
<P>60.5 ± 6.6</P>
</TD>
<TD ALIGN="CENTER">
<P>8.4 ± 0.75</P>
</TD>
<TD ALIGN="CENTER">
<P>31.9 ± 5.5</P>
</TD>
<TD ALIGN="CENTER">
<P>5.2 ± 3.9</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>52.2</P>
</TD>
<TD ALIGN="CENTER">
<P>47.8</P>
</TD>
<TD ALIGN="CENTER">
<P>58.7 ± 7.6</P>
</TD>
<TD ALIGN="CENTER">
<P>8.5 ± 0.86</P>
</TD>
<TD ALIGN="CENTER">
<P>31.0 ± 4.6</P>
</TD>
<TD ALIGN="CENTER">
<P>5.5 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<I>Footnotes</I>
</P>
<P>values are displayed as mean (SD), median (q1 to q3) or proportion of patients</P>
<P>"-" denotes not reported</P>
<P>SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-11-29 14:58:15 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-10-29 15:54:26 +0200" MODIFIED_BY="[Empty name]">Overview of trial SMBG education programmes</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-29 14:58:15 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="28">
<TR>
<TH>
<P>Characteristic &#9658;</P>
<P>Study ID &#9660;</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>(SMBG) instructions</P>
</TH>
<TH>
<P>SMBG frequency</P>
</TH>
<TH>
<P>Feedback on SMBG</P>
</TH>
<TH>
<P>Education</P>
</TH>
<TH>
<P>Diaries</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
</P>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ROWSPAN="2">
<P>Patients were individually instructed in the prescribed testing technique, which they practised for 7 to 10 days</P>
</TD>
<TD ROWSPAN="2">
<P>A measurement before each meal every other day</P>
</TD>
<TD ROWSPAN="2">
<P>Ongoing feedback by physician</P>
</TD>
<TD ROWSPAN="2">
<P>Dietary instructions based on weight and activity level and focused on increasing fiber intake by a dietician; Instruction booklet including ADA's exchange list for food fiber classification</P>
<P/>
</TD>
<TD ROWSPAN="2">
<P>Food and exercise diaries</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>All randomised patients received diet and lifestyle advice, reinforced at each clinic visit;</P>
</TD>
<TD>
<P> None</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Instructions included information on how to use, check the glucose metre, when to take measurements and what to do in the event of hypoglycaemia.</P>
</TD>
<TD>
<P>5 measurements a day (before every meal, 2h after the main meal and before bedtime) on 2 days a week (one working day, one non-working day). Once a month 3 postprandial measurements are asked.</P>
</TD>
<TD>
<P> No information available</P>
</TD>
<TD>
<P>All randomised patients received diet and lifestyle advice, reinforced at each clinic visit; Written Information on the management of hypoglycaemia; blood glucose</P>
</TD>
<TD>
<P>Hypoglycaemia and food diary</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="2">
<P>5 dietician visits and nutritional counselling using glucose values and meal descriptions on the effects of meal components and portion sizes on rise in postprandial glucose levels.</P>
</TD>
<TD ROWSPAN="2">
<P>Food diary</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>No information available</P>
</TD>
<TD>
<P>6 measurements a day around meals (pre- and 2h post prandial) for 6 days a week</P>
</TD>
<TD>
<P>The nurse used SMBG values to make therapeutic decisions following detailed algorithms</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="3">
<P>Behaviour change techniques based applied using a goal setting and review approach and discussed within the framework of the commonsense model of illness representation. Continued at follow-up visits.</P>
</TD>
<TD>
<P>Self-care goals and strategies; activity;</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Less intensive SMBG</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2 days a week, 3 tests daily (1 after fasting, 2 before meal or 2 hours after meal)</P>
</TD>
<TD>
<P>Instruction to aim for 4-6mmol/l fasting and 6-8 mmol/l after meals. Results were interpreted by the study nurse at follow-up</P>
</TD>
<TD ROWSPAN="2">
<P>Self-care goals and strategies; activity; blood glucose results;</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>More intensive SMBG</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2 days a week, 3 tests daily (1 after fasting, 2 before meal or 2 hours after meal)</P>
</TD>
<TD>
<P>Training and ongoing support in interpreting and applying the results of blood glucose readings to enhance motivation and maintain adherence to diet physical activity and medication regimens.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="2">
<P>Lifestyle interventions based on a 2h individual session, reinforced at each follow-up visit.</P>
</TD>
<TD ROWSPAN="2">
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>1h session with information how to perform measurements and how to collect data</P>
</TD>
<TD>
<P>6 measurements a day around meals (pre- and 2h post prandial) and after change in medication, every 3 days</P>
</TD>
<TD>
<P>Reviewing of know-how  and evaluation of possible  confounding factors on recorded glucose values</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>No self-monitoring</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Standard counselling with focus on diet and lifestyle, every 3 months</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Specific education how to perform SMBG</P>
</TD>
<TD>
<P>2 weekly, pre-and 2h post prandial measurements around one main meal (1st day breakfast, 3rd day lunch, 5th day dinner) .</P>
</TD>
<TD>
<P>Structured telephone interviews every month discussing relations for elevated glucose values and quality/quantity of foods and exercise.</P>
</TD>
<TD>
<P>Standardized specific education addressing how to perform SMBG, ho to modify diet an level of physical activity according to blood glucose levels and the actions to undertake in case of abnormal values. Povided by diabetes nurses</P>
</TD>
<TD>
<P>Food, blood glucose and physical activity diary</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="3">
<P>No education, except for (renewal of) personalized dietary recommendations</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD>
<P>Instructions how to perform SMUG</P>
</TD>
<TD>
<P>Twice every other day, fasting and 2 hours after the evening meal, with an extra test 2 hours after lunch on Sundays.</P>
</TD>
<TD ROWSPAN="2">
<P>Ongoing feedback by physician</P>
</TD>
<TD ROWSPAN="2">
<P>Glucose diaries</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Instructions how to perform SMBG </P>
</TD>
<TD>
<P>Twice every other day, on the first urine voided in the morning and the first urine voided after the evening meal, with an extra test after lunch on Sundays.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="2">
<P>Education on weight loss and physical activity</P>
</TD>
<TD ROWSPAN="2">
<P> </P>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Patients received specific initial training in SMBG given by their general practitioner</P>
</TD>
<TD>
<P>At least 6 measurements a week on 3 different days of the week, including weekends.</P>
</TD>
<TD>
<P>Ongoing feedback at each consultation</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Explicit request not to self-monitor during the study</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="2">
<P>No education</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Information on how to handle the device and target glucose values were provided.</P>
</TD>
<TD>
<P>4 measurements a day (1 fasting, 3post-prandial), twice a week on a weekday and a weekend day.</P>
</TD>
<TD>
<P>No information available</P>
</TD>
<TD>
<P>Glucose diaries;</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>8-weeks behavioral weight control program before onset of the intervention; individual counselling by diabetes nurse educator and individual sessions with a dietician at baseline and at follow-up. From baseline, sessions on general principles of diabetes nutrition according to ADA guidelines.</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>SMBG training by diabetes nurse educator given in individual and group sessions</P>
</TD>
<TD>
<P>6 measurements a day (pre- and 2h postprandially) for 4 weeks. Subsequently, 2 measurements a day (pre- and 2h postprandially) for 16 weeks</P>
</TD>
<TD>
<P>No information available</P>
</TD>
<TD>
<P>8-weeks behavioral weight control program before onset of the intervention; individual counselling by diabetes nurse educator and individual sessions with a dietician at baseline and at follow-up. From baseline individual and group teaching on carbohydrate counting.</P>
</TD>
<TD>
<P>Food, carbohydrate and blood glucose diary</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD ROWSPAN="2">
<P>Structured education programme involving diabetes nurse practitioners, dieticians, podiatrists and medical staff.</P>
</TD>
<TD ROWSPAN="2">
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Instructions in the use of a glucose monitor</P>
</TD>
<TD>
<P>Four fasting and 4 postprandial measurements per week</P>
</TD>
<TD>
<P>Ongoing advice and support in interpretation of and response to glucose measurements</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P> No self-monitoring</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Non-standardized counselling focused on diet and lifestyle</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>Instructions in self-monitoring and a request to continue of using the glucose meter during the follow-up period.</P>
</TD>
<TD>
<P>6 measurements a day around meals (pre- and 2h post prandial) for 2 days a week (one weekday and a Sunday)</P>
</TD>
<TD>
<P>No information available</P>
</TD>
<TD>
<P>SMBG education and predefined counselling algorithm on self-perception, self-reflection and self regulation.</P>
</TD>
<TD>
<P>Combined food, well-being and glucose diary</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<I>Footnotes</I>
</P>
<P>SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-11-29 15:01:50 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-10-29 15:58:18 +0200" MODIFIED_BY="[Empty name]">Effects of SMBG in patients with type 2 diabetes who are not using insulin (biochemical outcomes)</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-29 15:01:50 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="12" ROWS="28">
<TR>
<TH>
<P>Characteristic &#9658;</P>
<P>Study ID &#9660;</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Included patients (n)</P>
</TH>
<TH>
<P>Baseline HbA1c (%)</P>
</TH>
<TH>
<P>6 months HbA1c (%)</P>
</TH>
<TH>
<P>12 months HbA1c (%)</P>
</TH>
<TH>
<P>6 months change in HbA1c (%)</P>
</TH>
<TH>
<P>12 months change in HbA1c (%)</P>
</TH>
<TH>
<P>Baseline FPG (mmol/L)</P>
</TH>
<TH>
<P>6 months FPG (mmol/L)</P>
</TH>
<TH>
<P>6 months change in FPG (mmol/L)</P>
</TH>
<TH>
<P>Patients reporting hypoglycaemic events (%)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
</P>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P> 11.7 ± 3.0</P>
</TD>
<TD ALIGN="CENTER">
<P> 9.7  ± 2.6</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> -2.0 ± 2.4</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>12.0 ± 2.6</P>
</TD>
<TD ALIGN="CENTER">
<P>10.5 ± 3.0</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.5 ± 2.8</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>12.4 ± 3.3</P>
</TD>
<TD ALIGN="CENTER">
<P> 10.4  ± 2.9</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -2.0 ± 3.4</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>12.0 ± 2.4</P>
</TD>
<TD ALIGN="CENTER">
<P>10.6 ± 3.6</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.4 ± 3.2</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>299</P>
</TD>
<TD ALIGN="CENTER">
<P>8.1 ± 0.84</P>
</TD>
<TD ALIGN="CENTER">
<P>7.2 ± 1.22</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> -0.9 ± 1.29</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>9.0 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>8.0</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.0 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>311</P>
</TD>
<TD ALIGN="CENTER">
<P>8.1 ± 0.89</P>
</TD>
<TD ALIGN="CENTER">
<P>7.0 ± 0.97</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -1.2 ± 1.14 <SUP>*</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>8.9 ± 2.3</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.3 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>8.7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.5 ± 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P> 7.9  ± 1.5</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -0.6 ± 2.1</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.4 ± 2.12</P>
</TD>
<TD ALIGN="CENTER">
<P> 7.5  ± 1.55</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -0.8 ± 1.6</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>152</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 1.09</P>
</TD>
<TD ALIGN="CENTER">
<P>7.4 ± 1.00</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 1.20</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.1 ± 0.73</P>
</TD>
<TD ALIGN="CENTER">
<P>0.0 ± 1.02</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>9.2</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>less intensive SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>150</P>
</TD>
<TD ALIGN="CENTER">
<P>7.4 ± 1.02</P>
</TD>
<TD ALIGN="CENTER">
<P>7.3 ± 1.02</P>
</TD>
<TD ALIGN="CENTER">
<P>7.3 ± 0.88</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.1 ± 0.84</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.1 ± 0.82</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>more intensive SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>151</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 1.12</P>
</TD>
<TD ALIGN="CENTER">
<P>7.3 ± 1.0</P>
</TD>
<TD ALIGN="CENTER">
<P>7.4 ± 1.05</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.2 ± 0.79</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.2 ± 0.73</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>28.5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>62</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 0.54</P>
</TD>
<TD ALIGN="CENTER">
<P>6.8 ± 0.84</P>
</TD>
<TD ALIGN="CENTER">
<P>6.8 ± 0.52</P>
</TD>
<TD ALIGN="CENTER">
<P> 0.1 ± 0.37</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.1 ± 0.60</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 0.17</P>
</TD>
<TD ALIGN="CENTER">
<P>6.1 ± 0.43</P>
</TD>
<TD ALIGN="CENTER">
<P>6.1 ± 0.52</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.7 ± 0.45 <SUP>*</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.6 ± 0.52 <SUP>*</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>7.9 ± 0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>7.2 ± 0.8</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>0.7 ± 0.2</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
</TD>
<TD ALIGN="CENTER">
<P>7.9 ± 0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 0.7</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>1.2 ± 0.1 <SUP>*</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.2  ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P> 7.7 </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-0.5 ± 1.5</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMUG</P>
</TD>
<TD ALIGN="CENTER">
<P>72</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.6  ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.5 </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>-0.1 ± 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.2  ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P> 7.8 </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> -0.4 ± 3.1</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>344</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.9  ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.4  ± 1.4</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> -0.5 ± 1.5</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>6.9 ± 4.6</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>5.2</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>345</P>
</TD>
<TD ALIGN="CENTER">
<P>9.0  ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.1  ± 1.6</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -0.9 ± 1.5 *</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>7.2 ± 5.1</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.5</P>
</TD>
<TD ALIGN="CENTER">
<P>10.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD ALIGN="CENTER">
<P>7.7 ± 0.4</P>
</TD>
<TD ALIGN="CENTER">
<P>7.7 ± 0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 0.5</P>
</TD>
<TD ALIGN="CENTER">
<P> 0.07 ± 0.75</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.1 ± 0.8</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6 ± 0.5</P>
</TD>
<TD ALIGN="CENTER">
<P>7.4 ± 0.7</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 ± 0.8</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.2 ± 0.67</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.1 ± 0.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P> 10.5  ± 1.5</P>
</TD>
<TD ALIGN="CENTER">
<P> 9.6  ± 2.09</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -0.9 ± 1.87</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P> 10.3  ± 1.1</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.8  ± 1.7</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -1.5 ± 1.46</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>8.6 ± 2.3</P>
</TD>
<TD ALIGN="CENTER">
<P>7.0 ± 1.1</P>
</TD>
<TD ALIGN="CENTER">
<P>6.9 ± 1.2</P>
</TD>
<TD ALIGN="CENTER">
<P> -1.6 ± 2.08</P>
</TD>
<TD ALIGN="CENTER">
<P> -1.7 ± 2.11</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>96</P>
</TD>
<TD ALIGN="CENTER">
<P>8.8 ± 2.1</P>
</TD>
<TD ALIGN="CENTER">
<P>7.0 ± 0.9</P>
</TD>
<TD ALIGN="CENTER">
<P>6.9 ± 0.8</P>
</TD>
<TD ALIGN="CENTER">
<P> -1.8 ± 2.1</P>
</TD>
<TD ALIGN="CENTER">
<P> -1.9 ± 2.06</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>110</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.4  ± 0.75</P>
</TD>
<TD ALIGN="CENTER">
<P> 7.8  ± 1.52</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -0.5 ± 1.4</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD ALIGN="CENTER">
<P>113</P>
</TD>
<TD ALIGN="CENTER">
<P> 8.5  ± 0.86</P>
</TD>
<TD ALIGN="CENTER">
<P> 7.5  ± 1.27</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> -1.0 ± 1.1*</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="12">
<P>
<I>Footnotes</I>
</P>
<P>
<SUP>*</SUP> statistically significant difference between groups (P &lt; 0.05)</P>
<P>"-" denotes not reported</P>
<P>FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; SMBG: self-monitoring of blood glucose; SMUG: self-monitoring of urine glucose<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-11-30 12:11:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-11-29 15:02:33 +0100" MODIFIED_BY="[Empty name]">Effects of SMBG in patients with type 2 diabetes who are not using insulin (other outcomes)</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-30 12:11:24 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="13" ROWS="71">
<TR>
<TH COLSPAN="9">
<P/>
</TH>
<TH COLSPAN="2">
<P>Within group differences</P>
</TH>
<TH COLSPAN="2">
<P>Between group differences<SUP>3</SUP>
</P>
</TH>
</TR>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Subscales</P>
</TH>
<TH>
<P>Range</P>
</TH>
<TH>
<P>Baseline<SUP>1</SUP>
</P>
</TH>
<TH>
<P>End of study<SUP>1</SUP>
</P>
</TH>
<TH>
<P>Difference<SUP>2</SUP>
</P>
</TH>
<TH>
<P>P value</P>
</TH>
<TH>
<P>Intervention vs control</P>
</TH>
<TH>
<P>P value between groups<SUP>4</SUP>
</P>
</TH>
</TR>
<TR>
<TH>
<P>Quality of life</P>
</TH>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>152</P>
</TD>
<TD>
<P>EQ5D</P>
</TD>
<TD>
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 1</P>
</TD>
<TD ALIGN="CENTER">
<P>0.799 ± 0.023</P>
</TD>
<TD ALIGN="CENTER">
<P>0.798 ± 0.034</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.001 (-0.060 to 0.059)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>Less intensive SMBG</P>
</TD>
<TD>
<P>150</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0 to 1</P>
</TD>
<TD ALIGN="CENTER">
<P>0.781 ± 0.022</P>
</TD>
<TD ALIGN="CENTER">
<P>0.755 ± 0.024</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.027 (-0.069 to 0.015)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-0.029 (-0.084 to 0.025)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>More intensive SMBG</P>
</TD>
<TD>
<P>151</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0 to 1</P>
</TD>
<TD ALIGN="CENTER">
<P>0.807 ± 0.024</P>
</TD>
<TD ALIGN="CENTER">
<P>0.733 ± 0.024</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.075 (-0.119 to -0.031)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-0.072 (-0.127 to 0.017)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>SF-36</P>
</TD>
<TD>
<P>Physical component</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>48.5 ± 10.6</P>
</TD>
<TD ALIGN="CENTER">
<P>47.9 ± 7.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mental component</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>50.6 ± 10.6</P>
</TD>
<TD ALIGN="CENTER">
<P>51.6 ± 7.7</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Health change</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>46.9 ± 18.0</P>
</TD>
<TD ALIGN="CENTER">
<P>56.3 ± 11.2</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-12.0 (-20.9 to -3.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 0.01</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Physical component</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>42.2 ± 10.4</P>
</TD>
<TD ALIGN="CENTER">
<P>44.3 ± 9.8</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-0.0 (-5.2  to 5.1)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mental component</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>55.5 ± 7.4</P>
</TD>
<TD ALIGN="CENTER">
<P>53.1 ± 9.5</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-1.4 (-6.6 to 3.7)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Health change</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>48.6 ± 10.4</P>
</TD>
<TD ALIGN="CENTER">
<P>44.4 ± 13.7</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>DQOL</P>
</TD>
<TD>
<P>Satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>3.0</P>
</TD>
<TD ALIGN="CENTER">
<P>2.7</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.05</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Impact</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>3.9</P>
</TD>
<TD ALIGN="CENTER">
<P>3.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Worry-social/vocational</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4.3</P>
</TD>
<TD ALIGN="CENTER">
<P>4.6</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Worry diabetes related</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4.1</P>
</TD>
<TD ALIGN="CENTER">
<P>4.5</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>3.1</P>
</TD>
<TD ALIGN="CENTER">
<P>2.7</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.05</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Impact</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4.0</P>
</TD>
<TD ALIGN="CENTER">
<P>4.1</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Worry-social/vocational</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4.6</P>
</TD>
<TD ALIGN="CENTER">
<P>4.6</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Worry diabetes related</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4.0</P>
</TD>
<TD ALIGN="CENTER">
<P>4.6</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P>Well-being</P>
</TH>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>WBQ-12</P>
</TD>
<TD>
<P>Total well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>25.1 ± 6.3</P>
</TD>
<TD ALIGN="CENTER">
<P>25.9 ± 5.8</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Negative well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>1.5 ± 2.1</P>
</TD>
<TD ALIGN="CENTER">
<P>1.3 ± 2.0</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>6.5 ± 2.9</P>
</TD>
<TD ALIGN="CENTER">
<P>6.8 ± 2.6</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6 ± 3.2</P>
</TD>
<TD ALIGN="CENTER">
<P>8.3 ± 2.8</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>Less intensive SMBG</P>
</TD>
<TD>
<P>121</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>24.3 ± 6.8</P>
</TD>
<TD ALIGN="CENTER">
<P>24.5 ± 7.0</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.38</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Negative well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>1.6 ± 2.3</P>
</TD>
<TD ALIGN="CENTER">
<P>1.4 ± 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.92</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>6.3 ± 2.9</P>
</TD>
<TD ALIGN="CENTER">
<P>6.4 ± 2.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.73</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6 ± 3.2</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6 ± 3.4</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.20</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>More intensive SMBG</P>
</TD>
<TD>
<P>105</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>25.2 ± 6.3</P>
</TD>
<TD ALIGN="CENTER">
<P>24.9 ± 6.4</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.38</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Negative well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>1.4 ± 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P>1.4 ± 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.92</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>6.6 ± 2.8</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7 ± 2.7</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.73</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>7.9 ± 3.0</P>
</TD>
<TD ALIGN="CENTER">
<P>7.6 ± 3.0</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.20</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>WHO-5</P>
</TD>
<TD>
<P>Total score</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>71.0 ± 17.9</P>
</TD>
<TD ALIGN="CENTER">
<P>76.3 ± 11.4</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total score</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>68.0 ± 20.7</P>
</TD>
<TD ALIGN="CENTER">
<P>74.4 ± 14.5</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-0.6 (-8.2 to 7.0)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>WBQ-22</P>
</TD>
<TD>
<P>Depression</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Anxiety</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Depression</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>6.05 (2.37)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.01</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Anxiety</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>5.86 (3.19)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.07</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4.16 (2.88)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.15</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 100</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-0.84 (2.83)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.77</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>110</P>
</TD>
<TD>
<P>WBQ-22</P>
</TD>
<TD>
<P>Total well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 66</P>
</TD>
<TD ALIGN="CENTER">
<P>50.66 ± 9.46</P>
</TD>
<TD ALIGN="CENTER">
<P>52.55 ± 10.47</P>
</TD>
<TD ALIGN="CENTER">
<P>1.75 ± 7.33</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Depression</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 18</P>
</TD>
<TD ALIGN="CENTER">
<P>3.33 ± 2.73</P>
</TD>
<TD ALIGN="CENTER">
<P>3.01 ± 2.61</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.26 ± 2.23</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Anxiety</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 18</P>
</TD>
<TD ALIGN="CENTER">
<P>4.88 ± 3.37</P>
</TD>
<TD ALIGN="CENTER">
<P>4.34 ± 3.66</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.51 ± 3.26</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>8.17 ± 2.42</P>
</TD>
<TD ALIGN="CENTER">
<P>9.0 ± 2.45</P>
</TD>
<TD ALIGN="CENTER">
<P>0.81 ± 2.61</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>14.6 ± 3.14</P>
</TD>
<TD ALIGN="CENTER">
<P>14.91 ± 3.38</P>
</TD>
<TD ALIGN="CENTER">
<P>0.27 ± 2.85</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 66</P>
</TD>
<TD ALIGN="CENTER">
<P>50.52 ± 8.47</P>
</TD>
<TD ALIGN="CENTER">
<P>54.03 ± 8.24</P>
</TD>
<TD ALIGN="CENTER">
<P>3.58 ± 7.01</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Depression</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 18</P>
</TD>
<TD ALIGN="CENTER">
<P>3.18 ± 2.69</P>
</TD>
<TD ALIGN="CENTER">
<P>2.38 ± 2.26</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.83 ± 2.66</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.03</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Anxiety</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 18</P>
</TD>
<TD ALIGN="CENTER">
<P>5.24 ± 3.24</P>
</TD>
<TD ALIGN="CENTER">
<P>3.91 ± 3.0</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.35 ± 3.34</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 0.05</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Energy</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>7.91 ± 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>9.04 ± 2.19</P>
</TD>
<TD ALIGN="CENTER">
<P>1.13 ± 2.29</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 0.05</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Positive well-being</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>1481 ± 2.83</P>
</TD>
<TD ALIGN="CENTER">
<P>15.27 ± 2.8</P>
</TD>
<TD ALIGN="CENTER">
<P>0.49 ± 2.37</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 0.05</P>
</TD>
</TR>
<TR>
<TH>
<P>Patient satisfaction</P>
</TH>
<TD>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>DTSQ</P>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>29.3 ± 6.8</P>
</TD>
<TD ALIGN="CENTER">
<P>30.0 ± 5.3</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hyperglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>1.7 ± 1.7</P>
</TD>
<TD ALIGN="CENTER">
<P>1.9 ± 1.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hypoglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>0.6 ± 1.2</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7 ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>Less intensive SMBG</P>
</TD>
<TD>
<P>121</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>29.4 ± 6.5</P>
</TD>
<TD ALIGN="CENTER">
<P>29.7 ± 5.6</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.93</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hyperglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>1.5 ± 1.6</P>
</TD>
<TD ALIGN="CENTER">
<P>2.3 ± 1.5</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hypoglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7 ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7 ± 1.2</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.97</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>More intensive SMBG</P>
</TD>
<TD>
<P>105</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>29.7 ± 5.4</P>
</TD>
<TD ALIGN="CENTER">
<P>30.1 ± 5.5</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.93</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hyperglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>2.0 ± 1.7</P>
</TD>
<TD ALIGN="CENTER">
<P>2.4 ± 1.7</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hypoglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>0.8 ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P>0.8 ± 1.3</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.97</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>DTSQ</P>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>30.7 ± 4.2</P>
</TD>
<TD ALIGN="CENTER">
<P>30.7 ± 4.0</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hyperglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>2.6 ± 1.7</P>
</TD>
<TD ALIGN="CENTER">
<P>1.9 ± 1.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hypoglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>0.0 (0.0, 1.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.0 (0.0, 2.0)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>29.3 ± 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>32.1 ± 3.8</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>1.2 (-1.6 to 4.1)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hyperglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>2.2 ± 1.6</P>
</TD>
<TD ALIGN="CENTER">
<P>2.3 ± 1.9</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.5 (-0.8 to 1.8)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Perceived hypoglycaemia frequency</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>1.0 (0.0, 2.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.0 (0.0, 2.0)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.3 (-0.5 to 1.1)</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>DTSQ</P>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 0.05</P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>110</P>
</TD>
<TD>
<P>DTSQ</P>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>26.95 ± 6.61</P>
</TD>
<TD ALIGN="CENTER">
<P>30.57 ± 5.54</P>
</TD>
<TD ALIGN="CENTER">
<P>3.6 ± 7.63</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TD>
<P> </P>
</TD>
<TD>
<P>SMBG</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Total satisfaction</P>
</TD>
<TD ALIGN="CENTER">
<P>0 to 36</P>
</TD>
<TD ALIGN="CENTER">
<P>27.58 ± 7.13</P>
</TD>
<TD ALIGN="CENTER">
<P>31.1 ± 4.78</P>
</TD>
<TD ALIGN="CENTER">
<P>3.52 ± 7.19</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P>0.9</P>
</TD>
</TR>
<TR>
<TD COLSPAN="13">
<P>
<I>Footnotes</I>
</P>
<P>
<SUP>1 </SUP>numbers are mean difference ± SD or median (Q25, Q75)</P>
<P>
<SUP>2 </SUP>numbers are mean difference (95% CI) or mean difference (SD)</P>
<P>
<SUP>3 </SUP>numbers are mean difference (95% CI) or b coefficient (SE)</P>
<P>
<SUP>4 </SUP>P value represents a three-group comparison for DiGEM trial</P>
<P>"-" denotes not reported</P>
<P/>
<P>DTSQ: diabetes treatment satisfaction questionnaire; EQ5D: EuroQol-5D; DQOL: diabetes quality of life inventory; SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose; SF-36: Short-Form 36; WBQ-12/22: well-being questionnaire-12/22; WHO-5: World Health Organization-5</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-11-30 13:01:46 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-10-29 15:59:15 +0200" MODIFIED_BY="[Empty name]">Adverse events</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-30 13:01:46 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="13" ROWS="16">
<TR>
<TH>
<P>Study ID &#9658;</P>
<P>Characteristic<SUP>1</SUP> &#9660;</P>
</TH>
<TH>
<P>
<LINK REF="STD-Allen-1990" TYPE="STUDY">Allen 1990</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Barnett-2008" TYPE="STUDY">Barnett 2008</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Davidson-2005" TYPE="STUDY">Davidson 2005</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-DiGEM-trial-2007" TYPE="STUDY">DiGEM trial 2007</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Dur_x00e1_n-2010" TYPE="STUDY">Durán 2010</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Franciosi-2011" TYPE="STUDY">Franciosi 2011</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Fontbonne-1989" TYPE="STUDY">Fontbonne 1989</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Guerci-2003" TYPE="STUDY">Guerci 2003</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Kleefstra-2010" TYPE="STUDY">Kleefstra 2010</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-Muchmore-1994" TYPE="STUDY">Muchmore 1994</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-O_x0027_Kane-2008" TYPE="STUDY">O'Kane 2008</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="STD-SMBG-study-group-2002" TYPE="STUDY">SMBG study group 2002</LINK>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Intervention (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>311</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P>301</P>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
</TD>
<TD ALIGN="CENTER">
<P>140</P>
</TD>
<TD ALIGN="CENTER">
<P>345</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>96</P>
</TD>
<TD ALIGN="CENTER">
<P>113</P>
</TD>
</TR>
<TR>
<TD>
<P>Control (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>299</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
<TD ALIGN="CENTER">
<P>152</P>
</TD>
<TD ALIGN="CENTER">
<P>62</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>344</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>110</P>
</TD>
</TR>
<TR>
<TD>
<P>Deaths (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>86</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>167</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events (n / %)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Drop-outs due to adverse events (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Definitions of recorded hypoglycaemic episodes</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<UL>
<LI>Grade 1: suspected mild hypo</LI>
<LI>Grade 2: suspected moderate hypo</LI>
<LI>Grade 3: suspected severe hypo with need of third party assistance</LI>
<LI>Grade 4: suspected severe hypo with need of medical assistance</LI>
</UL>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<UL>
<LI>Grade 1: self-reported hypo with no accompanying symptoms</LI>
<LI>Grade 2: mild symptoms requiring minor intervention</LI>
<LI>Grade 3: moderate symptoms requiring immediate third party intervention</LI>
<LI>Grade 4: unconscious</LI>
</UL>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<UL>
<LI>Severe hypoglycaemia: requiring assistance from a third person</LI>
</UL>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<UL>
<LI>(any) Hypoglycaemic episode</LI>
</UL>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<UL>
<LI>Asymptomatic hypo: no definition available</LI>
<LI>Symptomatic hypo: no definition available</LI>
</UL>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cut-off point for hypoglycaemic episode</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Capillary blood glucose &lt; 3mM/L</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Capillary blood glucose &lt; 4mM/L</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>Capillary blood glucose &lt; 3.3 mM/L</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Capillary blood glucose &lt; 3mM/L</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hypoglycaemic episodes (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>117</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>90</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>78</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>67</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Hypoglycaemic episodes (%)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Severe hypoglycaemic episodes (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Severe hypoglycaemic episodes (%)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Nocturnal hypoglycaemic episodes (n)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>Nocturnal hypoglycaemic episodes (%)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="13">
<P>Footnotes</P>
<P>"-" denotes not reported</P>
<P>
<SUP>1 </SUP>Data for adverse events could not be extracted separately for intervention and control groups.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="295">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies (16 publications) included in qualitative synthesis&lt;/p&gt;" WIDTH="259">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Welschen 2005a&quot; protected=&quot;true&quot;&gt;Welschen 2005a&lt;/a&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;36 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="204">
<FLOWCHARTBOX TEXT="&lt;p&gt;1153 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1138 records identified through database searching&lt;/p&gt;" WIDTH="224"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;15 additional records identified through other sources&lt;/p&gt;" WIDTH="280"/>
<OUT TEXT="&lt;p&gt;1117 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="258"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_C2902AEB82E26AA2008044A2B52EB3E3_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="C2902AEB82E26AA2008044A2B52EB3E3"><ADDRESS><DEPARTMENT>Departments of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>EMGO Institute for Health and Care Research, VU University Medical Center</ORGANISATION><CITY>Amsterdam</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>